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Dr Shelley Dua 
Peanut allergy is a public health concern which affects a significant proportion of the population. 
Accidental exposure to peanut can cause severe and fatal reactions in peanut allergic individuals and 
currently their only safeguard is to practise careful avoidance. Identification and protection of at-risk 
members of the allergic population is critical in managing this life-threatening condition. This thesis 
produces key data to enable this. 
A prospective study was performed on 60 peanut allergic participants to determine thresholds of 
reactivity to peanut using oral challenges with incrementally increasing amounts of peanut protein. 
Following a double-blind placebo-controlled peanut challenge, participants received three further 
peanut challenges, two with co-factors: sleep deprivation and exercise, and one without. Severity was 
measured using a numerical scale derived from symptoms and serum tryptase was measured at each 
challenge. A total of 187 challenges were performed. 
Findings were that the median amount of peanut protein which induces a reaction in 10% of the 
population (ED10) was 12.3mg (95% CI 7.3,20.4) equivalently this suggests that 90% of the allergic 
population will not react to doses below this level. Both sleep deprivation and exercise have a 
significant effect on lowering reaction threshold (ED10), by 5 times and 2.5 times respectively. 
Separately there is a reduction in threshold with successive challenges. 
Co-factors also significantly increased symptom severity during challenge reactions. In particular 
sleep deprivation significantly increased the severity of gastrointestinal symptoms suggesting that a 
stressful stimulus may affect intestinal permeability. Evidence was provided for the importance of 
asthma as a risk factor which increased the severity of respiratory symptoms during reaction.  Using a 
novel visual analogue scale for measuring the participant’s perception of severity, a poor correlation 
was observed between the participant’s perception of the reaction and the overall numerical severity 
score, suggesting that participants misperceive severe symptoms. This thesis provides the first data 
showing that symptom patterns in repeated challenges show a high degree of homogeneity within 
individuals, but importantly that this symptom homogeneity is also observed across individuals. 
Lastly the utility of serum tryptase in identifying food allergic reactions has been disputed previously. 
This thesis provides evidence of its value and identifies a rise cut-off of 30% as being diagnostic of a 
food allergic reaction, but cautions that acute levels must be compared with baseline as this rise may 
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Peanut allergy is a significant public health concern as peanut has the propensity to cause 
severe and fatal reactions following inadvertent consumption by peanut allergic individuals. 
Currently there is no licensed, disease-modifying therapy for peanut allergy and the mainstay 
of treatment is to advise careful avoidance, and provide emergency medication. 
Unfortunately, this approach is not watertight and accidental exposures still occur. Quality of 
life is adversely affected, and is related to fear of reactions, and limitations in food choices, 
made worse by ambiguous precautionary food labelling. 
To engage with this issue and whilst we wait for new therapies to emerge, a few strategies 
may be considered. Firstly precautionary food labels, which are currently not fit for purpose, 
can be improved to assist food allergic consumers to broaden food choice and practise safe 
allergen avoidance. Secondly attempts can be made to more accurately stratify patients at 
high risk of a severe reaction, so that they can be better advised to avoid high-risk situations. 
Lastly, laboratory tests to help emergency clinicians diagnose patients undergoing acute 
allergic reactions can be improved ensuring that allergic patients are correctly identified and 
referred for specialist care. 
A prospective study of experimentally induced systemic allergic reactions in peanut allergic 
participants forms the basis of this thesis. As one of the lead investigators on the study, I 
personally performed 187 peanut challenges and witnessed first-hand the ensuing allergic 
reactions, and treated them. Using the experience of performing these challenges, I have 
explored the three areas described above. The first theme is a study on thresholds in peanut 
allergy and seeks to establish a population reactivity threshold for allergic individuals, with 
the ultimate aim of informing reference doses for allergens. These can be used by food 
regulators and the industry to improve precautionary labelling accuracy. The second theme 
examines in great detail the severity of peanut allergic reactions and symptom patterns within 
and across participants to elucidate whether there are common and predictable features of 
severe reactions.  Incorporated into these sub-studies, in an attempt to replicate real life 
exposures, is an examination of the effect of two co-factors: exercise and sleep deprivation on 
the threshold and severity of allergic reactions. The final theme focuses on the utility of 
measurement of serum tryptase, a mast cell mediator, in the diagnosis of acute peanut allergic 





Part 1: General Overview 
An allergy is a hypersensitivity reaction which the immune system launches against a 
substance. Allergy can lead to a variety of diseases which manifest in different organ 
systems. These conditions include life threatening anaphylaxis, food allergy, urticaria, certain 
forms of asthma, eczema, rhinitis, drug and venom allergy.   The global burden of allergic 
disease is considerable and it is estimated that at least 20% of the population will suffer from 
an allergic disease at some point in their lives.1 There are suggestions that the prevalence of 
allergic disease is increasing. Two studies which used similar methodologies and the same 
population performed in the late 1990s and in the early 2000s demonstrated a 2.5 fold 
increase in the incidence of anaphylaxis (21 cases per 100,000 person-years and 49.8 cases 
per 100,000 person-years respectively).2,3 Studies in the United Kingdom which have 
examined databases of hospital discharges over time have shown a sevenfold increase in 
patients who had been hospitalised due to allergic disease.4 This upsurge in patients suffering 
from allergic disease is being referred to as the ‘Allergy Epidemic’.   
 Reasons behind the ‘Allergy Epidemic’ have yet to be properly elucidated. In the late 
eighties the ‘Hygiene Hypothesis’ was proposed by the British physician, Strachan. Quite 
simply this stated that early life infections are needed for normal immune system 
development and a reduced number of these infections provided a predisposition to allergic 
diseases.5 However in recent times this has been redefined as the ‘Biodiversity Hypothesis’ 
which claims that the excessive Western hygienic lifestyle reduces microbial exposure and 
alters the early colonisation of the infant gut, disturbing the normal tolerance development of 
the immune system.6 This theory has been supported by several epidemiological studies. One 
study showed lower diversity of gut microbiota in the first week of life is associated with 
atopic eczema at 18 months.7  A further study showed that the probability of developing 
asthma in farming children is inversely related to the range of exposure to environmental 
bacteria and fungi. It has also been postulated that an infant’s diet early in life can potentially 
influence atopic sensitisation later on. In a Finnish birth cohort it was observed that less food 
diversity in the first year of life might increase the risk of allergies and asthma in childhood.8  
Thus a reduction in ‘antigenic burden’ can potentially reduce the stimulation of the immune 
system in genetically predisposed individuals which in turn may lead to a dysregulated 
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immune response and allergy. Food allergies in particular are noticeably increasing in 
prevalence in westernised populations. 
Allergy mechanism 
The term allergy first appeared in the medical literature in 1906 when the Paediatrician 
Clemens von Pirquet noted that the response to some antigens resulted in damage to the host 
rather than a protective response.9  
The allergic response occurs in 3 phases: sensitisation phase, effector phase and the late 
phase response. In the sensitisation phase the allergen is encountered for the first time and 
presented by an antigen presenting cell (APC) to a naïve CD4+ T helper lymphocyte. These 
cells are instrumental in orchestrating the immune system. These effector Th2 cells produce 
cytokines IL3, IL4 and IL13 and stimulate B cells to induce class switching of 
immunoglobulin heavy chain to the ε type. This stimulates the production of allergen-specific 
IgE antibodies. Secreted IgE then circulates in the blood and binds to high affinity IgE 
receptors (FcεRI) on the surface of mast cells and basophils. In the effector phase, a new 
encounter with the allergen causes cross-linking of the IgE bound to FcεRI surface receptor. 
IgE cross linking induces aggregation and migration of receptors into membrane lipid rafts, 
followed by phosphorylation of ITAM motifs by associated tyrosine kinases. Adapter 
molecules then latch onto phosphorylated tyrosine residues and initiate signalling cascades 
culminating in enzyme and/or transcription factor activation.  FcεRI signalling leads to mast 
cell and basophil (1) degranulation of vesicles containing inflammatory mediators, (2) 
expression of inflammatory cytokines and 3) conversion of arachidonic acid into leukotrienes 
and prostaglandins. The mediators released by mast cells are preformed and granule 
associated. They include histamine, proteases and heparin. These act on different cell types 
producing rapid inflammatory responses including vasodilatation, increase in vascular 
permeability and smooth muscle contraction. These produce the symptoms typical of an 
allergic reaction including urticaria, angioedema, bronchospasm, vomiting, diarrhoea and 
hypotension. Hours after the immediate phase of an IgE-mediated response, mediators 
released during the course of the reaction induce localised inflammation called the late phase 
reaction. Cytokines released from mast cells particularly TNFα and IL1 increase the 
expression of cell adhesion molecules on venular endothelial cells thus facilitating the influx 
of neutrophils, eosinophils and Th2 cells. Eosinophils play a critical role in this late phase 
response. Eosinophil chemotactic factor released by mast cells in the initial reaction attract 
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large numbers of eosinophils to the affected site. Cytokines released at the site including IL3, 
IL5 and GM-CSF contribute to the growth, differentiation, activation and increased survival 
of these cells. On being activated, eosinophils release inflammatory mediators such as 
eosinophilic cationic protein (ECP), major basic protein (MBP), leukotrienes and 
prostaglandins that contribute to the extensive tissue damage typical of the late phase 
reaction. Clinically this manifests as prolonged mucus secretion, oedema formation and 
persistent bronchial hyper reactivity. Neutrophils similarly involved in the late phase reaction 
are attracted by neutrophil chemotactic factor released from degranulating mast cells. Granule 
contents of neutrophils include lytic enzymes, platelet activating factor and leukotrienes.   
Food allergy 
Food allergy encompasses a spectrum of conditions characterised by abnormal 
immunological responses to food. IgE mediated reactions to food are the most common and 
include a number of symptoms which are rapid in onset including oropharyngeal pruritus, 
flushing, urticarial or angioedema, nausea, vomiting, abdominal pain, bronchospasm, 
cardiovascular collapse and rarely death. Diagnosing IgE mediated food allergy relies on a 
careful history to elicit the allergen in question, skin prick testing, serological confirmation of 
10the presence of IgE and where appropriate oral food challenge to the allergen.  
Food allergy is a significant public health concern for numerous reasons including increasing 
hospital utilisation, increasing associated medical costs1 and an increasing burden of care on 
immediate families. Moreover, a food allergy can place a significant burden on an individual 
by restricting their daily food choices and travel plans.11 Indeed several studies have shown 
that having a food allergy impairs an individual’s quality of life.12    
How widespread is the problem? Globally around 200-250 million people suffer from food 
allergies.13 Unfortunately, estimating the prevalence of food allergy is a challenge because 
most of the data on prevalence is based on simple questionnaires, some unvalidated, which 
use self-reporting and not objective tests to document true allergic reactions.  The gold 
standard of diagnosing allergy is through a double bind placebo controlled food challenge. In 
this test, a third party prepares two foods for testing: one placebo food and one active 
challenge food which should be indistinguishable. These are then given to the patient 
separated by an interval. This procedure, however, is expensive and time-consuming and has 
the potential to trigger adverse reactions. Furthermore, variations in food allergy definitions 
and markers (skin prick test positivity or serum IgE positivity) and study methodology leads 
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to inconsistent prevalence estimations. Food allergy prevalence based on self-reporting is 
approximately 12-13% compared with studies using oral food challenge, 3%.14,15,16 Most 
studies, however, are in agreement that the prevalence of food allergy has increased in recent 
years.17,18 Recent hospitalisation data of food induced anaphylaxis has suggested that the 
incidence rate has been rising especially in children under 4 years of age. A recent review of 
the literature indicated a prevalence of 2-10% of the population19 with the prevalence being 
more common in children compared to adults (8% versus 5% in the USA).14,20 The 
development of IgE and sensitisation to food proteins is usually the first manifestation of 
allergic disease i.e. the commencement of the Allergic March.  Risk factors for the 
development of food allergy include the presence of eczema and a positive atopic family 
history. Other potential risk factors which have been suggested include ethnicity (increased in 
Asian and black compared to white children), geographical factors, genetics (familial 
associations with HLA and specific genes), Vitamin D insufficiency, the timing and route of 
allergen exposure, obesity (being an inflammatory state) and increased use of antacids 
(reducing breakdown of allergen in the gut).14   
Peanut allergy 
Peanut (Arachis hypogea) allergen attracts a lot of attention as it is widely consumed and has 
the propensity to cause severe and even fatal reactions.  
Peanut allergy is no exception with regard to the general rising trend in food allergy 
prevalence.  Studies from the United States, U.K, Canada and Australia place prevalence 
rates of peanut allergy at 1-2% for children and 0.6% for adults.  The prevalence does seem 
to vary in different regions worldwide, for example in France (0.3-0.7%), Denmark (0.2-
0.6%) and Israel (0.04-0.17%) and in Asian countries where peanut allergy is exceedingly 
rare.21,22,23,24 Reasons for this variation are not fully understood but possible explanations 
include differences in the timing of introduction of peanut into the diet, peanut preparation 
practices (roasted versus boiled), differences in exposure to sunlight with regard vitamin D 
levels or variation in the prevalence rates of atopy in general.  Anaphylaxis fatality registers 
are indicative of the severity of peanut allergy. In the United States peanut was implicated as 
a trigger in 59% of 63 deaths,25,26 however in a U.K report, peanut was less frequently 
implicated with peanut being a cause in 19% of 48 fatalities.26 Currently the standard of care 
for management of peanut allergy is allergen avoidance and a well primed emergency 
treatment plan. This provides great impetus for research in this field to develop better 
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strategies for treatment and prevention.  
 
Risk factors for the development of peanut allergy 
The fact that a family history of peanut allergy for example, in a parent or sibling, renders a 
child with a 7 fold increase in the risk of peanut allergy suggests that there may be a genetic 
component to the development this disease.27    
Race and migration may also play a role. Panjari et al showed that children who were born in 
Australia to Asian-born mothers were more likely to have a nut allergy that non-Asian 
children. However children who were born in Asia and subsequently migrated to Australia 
were at a decreased risk of nut allergy.28  These finding raise the possibility of gene-
environment interactions.  
It has been established that sensitisation to peanut allergen can occur transcutaneously and 
therefore it follows that eczema is a risk factor for peanut allergy. In a mouse mode, mice 
which were subjected to tape stripping, a surrogate for excoriations in atopic dermatitis, 
developed inflammation and subsequent sensitisation to topically applied allergens.29 The 
Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort study found that 
children who developed peanut allergy by the age of 5 were more likely to have had severe 
eczema in the first 6 months of life and to have been treated with Arachis oil for dry skin.30 
Furthermore mutations in filaggrin, a protein important in regulating transepidermal water 
loss across the skin barrier, have been shown to be associated with peanut allergy and 
sensitisation.31 Also mice with filaggrin mutations are more susceptible to becoming 
sensitised to an allergen when it is applied topically.32    
Environmental allergen exposure may also play a role. In a case-control study by Fox, peanut 
consumption in the home was used as a marker for environmental exposure. They showed a 
clear dose response relationship between household peanut consumption (using a validated 
questionnaire) and the risk of peanut allergy development in young children.33 In a further 
study Brough et al actually measured the presence of peanut allergen in household dust and 
found that high levels of peanut in household dust were associated with an increased risk of 
sensitisation and likely peanut allergy in children with atopic dermatitis particularly in 
children with severe atopic dermatitis.34  
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Since peanut allergy presents in infancy, the influence of maternal and infant diet has been 
examined with regards to the development of allergy. Sicherer et al examined an atopic 
cohort of 503 infants with no previous diagnosis of peanut allergy and demonstrated that 
maternal ingestion of peanut during pregnancy was associated with high levels of peanut 
sensitisation, however when this was later adjusted for household exposure, the effect on 
peanut allergy was no longer significant.35,36  There is debate around the role of breast 
feeding and studies have failed to show a consistent protective effect.37,38 
The timing of introduction of food allergens and the development of food allergy could also 
potentially be important and there are studies to support this. A cross sectional study by Du 
Toit found that the prevalence of peanut allergy was 10 fold higher in UK Jewish children 
(1.85%) compared to Israeli Jewish children (0.17% p<0.001) Possible explanations for this 
include differences in the median monthly consumption of peanut in Israeli infants aged 8-14 
months (7.1g) compared to 0g in the UK.  Furthermore, peanut is introduced earlier in Israel. 
Therefore early introduction of food allergens with more frequent consumption in the early 
stages of infancy may have a protective role and be instrumental in inducing oral tolerance to 
food allergens.36 These theories have recently be tested in two landmark studies. Du Toit et al 
performed a randomised controlled interventional study to test the timing of peanut 
introduction on the rate of peanut allergy development. The authors found that 17.2% of 
subjects in the avoidance group developed peanut allergy compared to 3.2% of the early 
introduction group.39 
Therefore although environmental exposure to peanut does seem to be associated with an 
increased risk of peanut sensitisation and peanut allergy in high risk groups exposure via the 
oral route has a more important role in the individual developing peanut tolerance, possibly 
as a result of increased allergen dose via the oral route and an increased regularity of 
exposure versus the environmental and transcutaneous route.  
The acquisition of natural tolerance is complex and requires further understanding. However 
immunological changes during immunotherapy have been well defined. These involve the 
development of peripheral tolerance by the promotion of regulatory Treg and Tr1 cells. These 
directly or indirectly suppress pro-inflammatory cells such as mast cells, eosinophils or 





Natural history of peanut allergy 
Peanut allergy usually presents early in life. Several studies performed in the US over the last 
15 years have shown that it frequently presents by the second year of life. Usually the first 
exposure to peanut occurs between the ages of 12 and 22 months and the onset of the first 
reaction is usually at 14-24 months. The first reaction usually occurs on the first known 
exposure in 75-80% patients. 40,41,42 43 
Twenty percent of children with peanut allergy and 10% with tree nut allergy outgrow these 
allergies.44,45 Recent studies examining the natural history of peanut allergy continue to 
support this. Arshad et al observed natural resolution of peanut allergy in 17% subjects ages 4 
to 10 and 26% ages 10 to18 in a birth cohort observed through to age 18.46 A longitudinal 
study of children diagnosed with peanut allergy at 1 year of age showed that peanut allergy 
resolved by age 4 in 22% of children and also found that decreasing SPT wheal size predicted 
tolerance to peanut and an increasing SPT wheal was associated with persistence of allergy.47  
Low rates of natural resolution means that the majority of peanut allergic patients remain 
peanut allergic through adulthood. 
There are few studies of peanut allergic adults. Savage et al reported that adults with late 
onset disease (age >10 years) tended to have milder symptoms, smaller skin prick tests and 
lower levels of serum specific IgE to peanut than adults with early childhood onset. It has 
been proposed that that late onset adult disease is associated with sensitisation to cross 
reactive pollen allergens rather than primary allergens.48 
Peanut allergens 
An allergenic protein is a molecule that has the ability to induce sensitisation and to trigger a 
reaction. There are multiple peanut varieties however the allergenic proteins are conserved 
among them and are found in the cotyledon (seed leaf). Peanut allergy can either be caused 
by primary sensitisation to the disease eliciting food allergen or it can occur as a result of 
primary sensitisation to inhalant allergens and subsequent IgE cross-reaction to homologous 
proteins in food (minor allergens). Allergens are considered major if they are recognised by 
the serum IgE of greater than 50% of the allergic population.   
Seed storage proteins, which form the major allergens within peanut, are present as one or 
more groups of proteins in large amounts in seeds to provide a store of amino acids for use 
during germination and seed growth. They are extremely stable against denaturation from 
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heat, acidity and proteolytic activity. As a result, these allergens are presented to immune 
cells in the gut in an almost intact form and therefore usually induce severe reactions. Several 
allergens have been identified in peanut including the cupin superfamily members which 
form the major seed storage proteins of peanut known as the 7s and 11s seed storage 
globulins (Arah1 and Arah3 respectively).  The function of these proteins within the peanut 
plant is to inhibit fungal growth and deter insect predators. Arah1 belongs to the vicilin (7s) 
family of seed storage proteins. It is a glycoprotein and contains 23 independent Ig-E binding 
epitopes.49 Burks et al performed 3-dimensional modelling and demonstrated that Ara h 1 
forms stable homotrimers with allergenic sites clustered into two main regions.50 The internal 
location of the IgE binding regions explains the relative weak activity of native Ara h 1 in 
cross linking IgE and the strong binding of IgE to denatured monomers.51,52  Ara h 2, 6 and 7 
belong to the prolamin superfamily and include the 2S albumin fraction. These are considered 
to be plant defence-related proteins. The biological plant protective functions of many of 
these proteins contribute to their resistance to degradation as well as to their overall 
allergenicity.53 Arah2 contains 10 independent IgE-binding epitopes stretching throughout a 
linear structure.54 There are two isoforms Ara h 2:01 and Ara h 2:02. The larger isoform, 
Arah 2:02 contains 12 extra amino acids including duplication of a strong IgE sequence and 
hence binds more IgE.55 Ara h 6 is 59% homologous to Arah2 but is 2-4 kD smaller. It is heat 
and digestion stable protein with an allergenic potency similar to Ara h 2.56 Ara h 7 is 35% 
homologous to Ara h 2, however its allergenic properties have not been further 
characterised.56 Ara h 3 is a peanut glycinin and belongs to the legumin (11s) family of seed 
storage proteins.57 The non-specific lipid transfer protein (LTP) allergen (Arah9) form 
another family of the prolamin superfamily. They are involved in stabilisation of membranes, 
cell wall organisation, signal transduction and resistance to biotic and abiotic stress.58 They 
are associated often with primary sensitisation to the major peach allergen Prup3. Arah9 has 
been associated with more severe symptoms and affects patients in the Mediterranean 
basin.59,60   Other minor allergens in peanut include those associated with pollen sensitisation 
such as the Betv1 homologue of peanut (Arah8), profilin (Arah5) and the oil-body associated 
allergens (Arah 10 and 11). In contrast, these, more minor food allergens, including Betv1 
homologues and profilins are relatively unstable when exposed to digestive enzymes and 
thermal processing.  
Importance of peanut proteins in peanut allergy 
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The pattern of binding to peanut proteins varies geographically probably due to different 
environmental exposures. In the US and UK populations more than 90% have specific IgE to 
Arah1 and Arah2 and 45-95% have specific IgE to Arah3. 61   In one study comparing peanut 
allergic patients from Spain, the US and Sweden, differences were found in peanut allergen-
binding patterns, the severity of symptoms and the timing of onset of peanut allergy.62 Ara h 
1, 2 and 3 were found to be the main elicitors of allergic reactions in the USA and often 
associated with severe symptoms. These allergens were less frequently recognised by the 
Spanish population who were more often sensitised to the lipid transfer protein. Swedish 
patients detected Arah1 and Arah3 more frequently than Spanish patients but had the highest 
sensitisation rate to Arah8, a major cross-reactive homologue of the major birch pollen 
Betv1. In a study examining peanut allergic subjects from across 11 European countries who 
were sensitised to Ara h 1, Ara h 2 and Ara h 3 since childhood Ara h 2 was identified as the 
sole major allergen. Arah8 and Arah9 were identified as the major allergens for 
Central/Western and Southern Europeans respectively.63 In a study of peanut allergic patients 
from the Netherlands the most frequently recognised allergen was Ara h 2.64  Kukkonen et al 
demonstrated that co-sensitisation to Ara h 2 and Ara h 6 was associated with severe 
reactions distinguishing severe allergy from mild symptoms.65 In a study of children from the 
Swedish BAMSE birth cohort children sensitised to both peanut and birch pollen were less 
likely to report symptoms to peanut than children sensitised to peanut to peanut but not to 
birch pollen at aged 8. 66 Sensitisation to peanut oleosins has been associated with severe 
systemic reactions. 67 
Purification of natural peanut allergens 
Purification of natural allergens from peanut may be difficult. Food allergens undergo 
modification during food processing which are not present in recombinant allergens. Peanuts 
are consumed after they have been modified through cooking methods such as boiling 
roasting or frying which can alter the physiochemical properties of the allergens by changing 
their allergenicity or IgE binding capacity. Peanut allergens make up 22-30% of the total 
protein in peanut seeds.68 Sixteen proteins belonging to 7 protein families are at present 
classified as allergens. The peanut seed storage allergens Ara h 1 and Ara h 2 make up 12-
16% and 5.9-9.2% of the total peanut protein content respectively.64   
Effects of thermal processing on peanut allergens 
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Peanuts are eaten in various cooked forms according to culinary tradition. These differing 
preparation methods seem to have an impact on peanut allergy prevalence. For example 
boiling a peanut can reduce its allergenicity by reducing the IgE binding capacity of Arah1, 
Arah2 and Arah3 compared to roasting and countries employing this cooking methods, for 
example China, seem to have lower incidences of allergy.69  The process of roasting a peanut 
was shown to increase peanut allergenicity and the IgE binding capacity of allergens possibly 
by glycosylation of protein residues also known as the Maillard reaction.70 Frying of peanuts 
but not boiling or roasting is known to alter the secondary structure of Ara h 2 by decreasing 
the molecule’s content of αhelices and increasing its βsheets thereby altering Ara h 2 epitopes 
and reducing its allergenicity.71  
Diagnosis of peanut allergy 
A key component in the diagnostic evaluation of peanut allergy is history taking. It is the role 
of the physician to correctly identify the potential allergen, timing of symptoms in relation to 
exposure to the allergen, amount ingested and any comorbid conditions. Once the history has 
been established then the physician may move to diagnostic tests.  IgE mediated food allergy 
is associated with the presence of allergen-specific IgE antibodies which can be measured in 
the serum or can be shown by a positive skin-prick test (SPT) to allergen in which a small 
amount of allergen is introduced into the epidermis using a pinprick and the ensuing wheal 
and flare response is measured. However sensitisation, the presence of antigen-specific IgE 
antibodies, does not automatically equate to clinical allergy and it is not sufficient to solely 
demonstrate the presence of allergic antibodies when diagnosing an allergy. One study which 
examined 2848 infants found the prevalence of sensitisation to peanut to be 8.9% however 
when the individuals were challenged the prevalence of challenge proven peanut allergy in 
sensitised individuals was much lower, 3%.18 Another study by Nicoloau estimated the 
prevalence of sensitisation to be 11.8%  and the prevalence of clinical peanut allergy among 
sensitised subjects as 22.4%.72  Threshold levels have been identified for levels of peanut IgE 
measured by Immunocap (>15 kU/L) that are 95% predictive of clinical reactivity73 although 
differences in 95% predictive values have been reported across different study 
populations.74,75 Peanut is composed of many proteins (components). Allergen components 
can either be produced biotechnologically in a recombinant fashion or purified from their 
original sources.  Diagnosis of allergy to peanut is enhanced by measurement of IgE to 
specific components and may potentially reduce the need for oral food challenges.75 For 
example IgE against the major component Arah2 has a greater specificity for peanut than IgE 
20 
 
against whole peanut.76 It has been shown that sIgE to Ara h 2 could be used as a good 
predictor of suspected peanut allergy for both children and adults among allergic populations 
of several geographic regions.77 Furthermore in a study by Flinterman et al IgE reactivity to 
Ara h 2 remained stable over time within an individual.78 Codreanu et al showed that a cut off 
of Arah2 > 0.23 would be optimal to separate peanut allergic patients from those who are 
tolerant.79 In contrast studies performed with the peanut allergens Ara h 1 and Ara h 3 
showed that the predictive diagnostic value of the their sIgE was low and depended on the 
geographical area of origin of the study population.63,77 In other studies sensitisation to 
multiple allergens is indicative of more severe reactions than sensitisation to only one of the 
peanut components.80 There are also significant geographical variations in the pattern of 
binding to peanut proteins.59  
Oral Food Challenges 
Oral challenge testing can be undertaken. This is when the food in question for example, 
peanut, is introduced in gradually increasing amounts in a controlled environment until either 
a specific goal dose is achieved or there are objective symptoms of a clinical reaction.  
Typically in a clinical setting this is undertaken for 3 main reasons. 
1. To establish a firm diagnosis when the diagnosis remains unproven through history, skin 
prick tests and or elimination diets. 
2. If a patient has significant eczema or gastrointestinal disease and specific IgE levels are not 
in the diagnostic range and there is an unclear response to an elimination diet.  
3. To determine if a patient with a known food allergy has developed a tolerance to food.  
In a research setting food challenges are undertaken for 3 main reasons: 
1. To evaluate the accuracy of existing diagnostic methods such as SPT/ allergen specific 
serum IgE/patch tests.  
2. To establish threshold doses for specific allergens such as peanut 
3. To clarify the effect of food processing on allergenicity.  
Methods of performing challenges include open challenges, single blind challenges and the 
double-blind placebo-controlled food challenges (DBPCFC). In an open challenge the food is 
administered without blinding or use of a placebo. However this may introduce bias on the 
part of the clinician administering the challenge and the observer. This can result in false 
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positive challenge results with even up to 30% false positives being reported in some studies. 
81 This challenge is of use when there is high probability that the outcome will be negative. In 
a single blind challenge the patient is blinded to the challenge material whereas the observer 
is not. In a double-blind placebo-controlled challenge there are two separate visits to the 
procedure. On one day the patient receives the food containing the active challenge and on 
the other day the patient will receive the placebo. Both the investigator and patient are 
blinded to the order. Although regarded as the ‘gold standard’ the DBPCFC is not perfect and 
false positive and false negative rates have been estimated to be between 1 and 3%.82  
Nonetheless a food challenge is a very useful tool and one study which examined the impact 
of food challenges on the quality of life of peanut and tree nut allergy individuals and their 
caregivers found that food challenges are associated with an improved food-related quality of 
life in the months following a challenge in patients regardless of whether the challenge 
outcome was a positive or negative reaction.83 It is therefore clear that having a food allergy 
has a major impact on the quality of life of an individual. Due care, however must be taken 
when performing a food challenge as they carry inherent risk. In one study 28% of OFC 
resulted in systemic and potentially life threatening reactions.84  
Basophil Activation Test 
Basophil activation test is a flow-cytometry based assay that assesses changes in the 
expression of activation markers on the surface of basophils following antigen stimulation.85 
As it is a functional assay it uses live basophils in whole bloods to detect the ability of IgE to 
mediate activation of basophils after stimulation with allergen. It may potentially more 
closely resemble the clinical phenotype of patients rather than methods which merely detect 
specific IgE binding to allergen as it tests IgE function which depends not only on the 
allergen-sIgE levels but also on IgE epitope specificity, affinity and clonality.86 The basophils 
of allergic patients display a dose-dependent expression of activation markers on response to 
allergen challenge whereas sensitised-tolerant patients do not express or have a much lower 
expression of activation markers after stimulation with allergen.87 Compared to SPT and 
serum specific IgE it has enhanced specificity with conserved sensitivity. For example in the 
case of peanut the BAT showed 98% sensitivity and 96% specificity to diagnose peanut 
allergy.  Its utility appears best in cases where conventional allergy tests have failed to 
diagnose allergy and provocation tests are to be considered.88 
Quality of life and peanut allergy 
22 
 
Quality of life (QOL) refers to an individual’s subjective perception of his or her position in 
life. 89 Quality of life is most often assessed by patient report in the form of questionnaires. A 
food allergy can impact on someone’s quality of life in a variety of ways. The need for 
continuous allergen avoidance and the constant threat of anaphylaxis can cause significant 
stress and anxiety. Early work which used general health related QOL scales (HQOL) to 
examine QOL in food allergic patients found that QOL in children was significantly impaired 
relative to both healthy children11 and children with chronic diseases.90,91 Food restriction can 
also place a significant burden on an individual. A study of peanut and tree nut allergic 
children found that quality of life was better amongst children who reported eating foods with 
the ‘may contain’ label versus patients who reportedly avoided foods with the ‘may contain’ 
label.11 Food allergies also have a wider effect for example on the sufferer’s caregivers. A 
study performed by Bollinger et al asked the caregivers of children what kind of impact their 
child’s allergy had on their family. Half of the sample reported that their child’s allergy 
significantly affected their family’s social activities including their child playing at a friend’s 
house, attending birthday parties and sleepovers, going out to eat and parental relationships.92  
Furthermore travel is another social activity which poses risk to a food allergic individual and 
restrictions on travel undoubtedly impacts a food allergic individual’s life. Work performed 
by Barnett et al examining food allergic patients’ experiences of travel abroad found that 
foreign travel was considered difficult with inherent risk particularly with regard to airlines or 
restaurants.93  
Although studies on health related quality of life in food allergic children and their caregivers 





Part 2: Thresholds  
The Scope of the Problem 
As mentioned, presently there is no therapy available in clinical practice for the treatment of 
peanut allergy. Thus the current strategy in managing this condition is careful avoidance of 
the allergen and rescue therapy in the event of accidental exposure. Allergens in foods 
present a risk to allergic individuals. To help food allergic consumers practice safe allergen 
avoidance, European Legislation mandated that the presence of 14 allergens, deliberately 
added as ingredients, must be declared on prepacked foods. In December 2014 this was 
extended to non-prepacked foods and foods eaten outside the home. There were also changes 
to the way in which the allergenic foods were labelled. Allergens now have to be highlighted 
in bold and located in a single place i.e. in the ingredients list. However an additional type of 
labelling exists: precautionary allergen labelling (PAL). This type of labelling is aimed at 
notifying allergic consumers about allergens which are not deliberately added as ingredients 
but may be there by chance, for example by contamination during processing methods. With 
an increasingly complex food manufacturing process, often equipment is shared and several 
different types of food are processed using the same production line. This PAL often takes 
the form of warnings such as ‘May contain peanut’, ‘Contains nuts’, ‘Made in factory where 
nuts are processed’ etc. Unfortunately there is no legislation that governs the use of these 
advisory labels and furthermore these advisory labels are voluntary.  As a result, these labels 
often send mixed messages to consumers making it difficult for them to make rational 
decisions about food choices.  
The problem with Precautionary Allergen Labelling 
PALs are present to try and convey the risk of reaction that a certain food poses. Labels 
however are very inconsistent making risk assessment difficult. Currently, due to fears over 
litigation with regards to accidental exposure to food allergens, advisory labels seem to be 
becoming increasingly common. Food manufacturers take a very risk averse approach to 
PALs. Patients mistakenly believe that a food with a label which reads ‘May contain nuts’ 
poses a greater risk than one which is labelled ‘May contain traces’.94 However studies have 
demonstrated that there is often no relationship between the wording that is used on food 
labels and the amount of allergen that that food actually contains.12 This inconsistent labelling 
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practice leads allergic consumers to become distrustful of labels leading them to act in one of 
two ways: either ignoring these advisory statements completely thereby placing themselves at 
risk or by avoiding these foods and thus narrowing their food choices considerably. The latter 
approach may have significant adverse consequences on their nutritional status.95 Food 
allergic consumers need to be able to trust the food label. There should be stricter regulation 
and legislation in place which governs when to use PAL and some standardisation of these 
labels.  Regulation on when to use PAL could be based on, for example, reference doses for 
allergens such as peanut which have been derived from the distribution of individual 
threshold doses in the allergic population. These can be used to determine action levels below 
which PAL will not be required as ideally PAL should only be used when food manufacturers 
cannot provide a guarantee, to a defined degree, the absence of unintended allergens to a 
level that would be likely to be harmful to food allergic consumers.96 The absence of the PAL 
should imply a clear level of agreed safety. Consumers need to be well educated about the 
process of allergen risk assessment to enable them to trust in food manufacturing and 
labelling practices.  How can this problem therefore be addressed? 
Establishing thresholds: The theory 
Food policy makers are tasked with assessing the hazard posed by allergenic foods. To do 
this, risk assessors need information about the response characteristics of the at-risk 
population and the size of the population at risk. In an ideal scenario it should be possible for 
risk assessors to calculate the number of reactions that would occur for any given level of 
residual allergen in a food product if allergic individuals consumed that food. Thus data are 
required on the levels of allergen which may potentially pose a small risk to most members of 
the allergic population. There is cause to believe that there is a level of peanut allergen that 
exists below which no member of the allergic population would react. Indeed in a review on 
existing threshold data for peanut, Taylor et al concluded that ‘thresholds for common 
allergenic foods are finite, measurable and above zero.97  Indeed a ‘threshold’ is defined as ‘a 
limit below which a stimulus causes no reaction’. In the field of toxicology scientists use 
thresholds to determine the harmful effects of chemicals and pollutants. In this area, a 
threshold is defined as a dose at or below which a response is not seen in an experimental 
setting. Techniques on modelling thresholds in toxicology studies have been transposed to 
modelling thresholds in food allergy. In food allergy a threshold is defined as the amount of 
protein which evokes an allergic reaction. An individual’s elicitation threshold to an allergen 
is thought to lie between the No Observed Adverse Effect Level (NOAEL), the highest dose 
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that will not produce an adverse effect in that person and the Lowest Observed Adverse 
Effect Level (LOAEL).  Data on individuals’ thresholds can be obtained through various 
types of clinical study including diagnostic challenges, threshold finding trials and 
immunotherapy studies.  Data from these studies show that the eliciting dose or LOAEL for 
peanut allergic individuals can range from a tenth of a milligram to many grams.98 
Thresholds exist at both an individual and population level. It would be logical to believe that 
in an allergic population the lower the dose, the milder the symptoms and the lower the 
proportion of reactive individuals. However there is little data on the proportion of allergic 
individuals reacting to a given dose as well as limited information on how severity relates to 
the dose threshold for any given individual. Furthermore it has also been reported in some 
very sensitive individuals that systemic reactions have resulted from exposure to micrograms 
of food.99  
Therefore risk managers can utilise the data on NOAELs and LOAELs gleaned from these 
studies to examine the distribution of clinical minimum eliciting doses. This useful statistical 
approach allows inferences to be made about reaction rates to doses out with the experimental 
range; an advantageous approach given the restriction on being able to test all individuals in 
the allergic population.  From a public health perspective, the optimal outcome would be to 
define a population threshold where all members of the allergic population are protected. 
However this ‘zero risk’ approach unfortunately is not practicable and it is not possible to test 
the reaction threshold of every member of an allergic population.  A more realistic and 
achievable aim, therefore, is to try and uncover an amount of protein that is unlikely to cause 
serious adverse effects in the majority of the population at risk. Thus the population threshold 
can be redefined as the largest amount of allergenic food which will not cause a reaction 
when tested in a defined proportion of allergic individuals. The Eliciting Dosex approach is 
often used and is pragmatic. It refers to the amount of allergen that is predicted to produce a 
reaction in a defined proportion of the allergic population. For example the ED10, which is 
commonly referred to in threshold studies, is the dose which will elicit a dose in 10% of the 
population. Eliciting doses are used to model reference doses which are essentially an index 
of safe exposure. The United States Environmental Protection Agency defines a reference 
dose as an estimate of a daily exposure to the human population (including sensitive 
subgroups) that is likely to be without an appreciable risk of deleterious effects during a 
lifetime. 
Types of study 
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The eliciting dose of peanut varies by several orders of magnitude in the allergic population 
(0.5mg to 8000-10000mg of whole peanut) 98 and this is possibly due to the diversity of 
studies that the data are derived from. These studies vary in their study entry criteria, dosing 
regime, dosing interval and food matrix (discussed below). 
There have been reports of patients severely reacting to trace amounts of allergen or reacting 
to peanut via the inhaled route. These often take the form of case reports or case series and do 
not provide quantitative information. Diagnostic double blind placebo are also a source of 
threshold data. However it should be noted that these studies were not designed specifically 
for the purpose of ascertaining allergen thresholds. Data from these studies are often obtained 
retrospectively and from studies which vary widely in their protocols. In the late 1990s, 
studies designed specifically to establish allergen thresholds came into fruition. In these 
studies, investigators aim to establish thresholds by starting at low enough doses of allergen 
to capture low dose reactors, allow a sufficient dosage interval to allow symptoms to evolve 
and have strict criteria for stopping the challenge when the reactive threshold is established. 
These provide the most reliable data on threshold. Lastly immunotherapy studies can give 
data on thresholds.100 These studies typically measure reactive threshold before and after 
therapy and thus provide information on no adverse effect levels (NOAELS) and lowest-
observed adverse effect levels (LOAELS).  
How design affects the outcome of threshold studies 
Procedure 
It is critical that threshold finding studies have a low enough starting dose to establish 
NOAELs and LOAELs. Not having a low enough starting dose runs the risk of having first 
dose reactors which then renders it impossible to establish a NOAEL in these individuals. 
Additionally it is important that top dose is high enough to capture high dose reactors. A top 
dose which is too low runs the risk of false negative results by failure of reaching that 
subject’s high dose threshold and hence a LOAEL. This runs the risk of providing false 
reassurance to that individual following a non-reactive challenge. In threshold studies 
placebos play an important role. They enable to symptoms to be better interpreted and help to 
confirm that during active challenges, symptoms are attributable to the allergen itself rather 
than anxiety or psychosomatisation. In some studies, placebo doses are interspersed with 
active doses while other studies have placebo and active arms on separate days. Lastly, a 
carefully thought out dosing interval is essential. Doses are often administered at 30 minute 
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intervals to allow assimilation of the peanut protein. However it is likely that the speed of 
absorption by the gastrointestinal tract will vary across individuals and therefore it is difficult 
to fully ascertain whether an individual is reacting to a previous cumulative dose or the one 
recently administered. Thus threshold doses should be reported both as cumulative and 
discrete entities. Solely using a discrete dose may also result in a more conservative estimate 
of threshold at a population level. Although it is preferable to leave a fairly long interval to 
enable symptoms to fully evolve at each dose it is also important to ensure that the interval is 
short enough to allow top doses to be reached in patients who tolerate greater amounts. There 
have been recent calls however by Blumchen et al check to extend the dosing interval 
possible to 2 hours as reactions have been reported at up to 58 minutes post dose.101  
Scoring of reactions and stopping criteria can affect any threshold estimate. Some studies 
have used subjective symptoms such as itch or abdominal pain to stop challenges whereas 
others use objective criteria. It has been reported that the eliciting dose for subjective 
symptoms lies below the eliciting dose for objective symptoms sometimes by several 
doses.102 This can of course have implications when threshold data from different studies is 
collated to obtain a common threshold.  
Participant inclusion 
In statistical modelling, the aim is to extrapolate from the tested population to the allergic 
population as a whole in order that predictions may be made about the numbers of subjects 
who may potentially react to doses outside the experimental range.  Participants taking part in 
threshold studies need to reflect the allergic population at large.  Volunteers for clinical 
studies are often highly motivated individuals who are often very cognizant of their allergy 
and its management. They represent only a subgroup of the at risk population. Some studies 
select patients from a clinic environment on the basis of their history and results of serum and 
skin prick IgE tests. This can lead to a highly selected population. Selection from clinic also 
has the potential to miss patients who are potentially less sensitive, have milder forms of 
allergy and do not feel the need to seek out specialist help. Failure to include this section of 
the population may result in more conservative estimates of threshold.  Further, some studies 
for safety reasons actively exclude patients with histories of anaphylaxis or life threatening 
symptoms. There is a worry that these individuals represent the more sensitive end of the 
spectrum however clinicians have presented data suggesting that low dose reactivity is not 
synonymous with the ability to experience a reaction at a low dose.103 Care must be taken 
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therefore when designing a study to recruit patients from as unselected a population as is 
possible.    
Challenge materials  
The method of delivery of the allergen is important when considering threshold with respect 
to both the nature of the allergen (preparation) under investigation and the vehicle in which it 
is delivered (matrix).  Peanut can be processed and eaten in many forms including raw, fried, 
boiled or roasted and is often eaten as a compound, for example, in chocolate or in a sauce 
such as satay. For safety reasons, challenges should use most allergenic form of the food. In 
the case of peanut this is often the roasted form. Work on peanut has shown that roasting 
increases their allergenicity compared with other cooking methods such as boiling or frying. 
The roasting process results in the Maillard reaction which results in the glycosylation of 
amino groups to form more stable compounds.104 This process results in higher extractable 
levels of Arah1105 and demonstrated that the glycosylated form of Arah1 but not the 
deglycosylated form can act as a Th2 adjuvant by activating dendritic cells to drive the 
maturation of Th2 cells demonstrated by the increased T cell production of IL4 and IL13.  
Other ways that cooking may influence allergenicity include alteration of epitope availability 
or configuration.69  
Other food compounds delivered in conjunction with peanut protein can also influence the 
allergen effect. In a study by Grimshaw et al, it was observed that participants suffered more 
severe reactions and higher eliciting doses than expected when challenged with a high fat 
recipe compared to a lower fat recipe.40 Possible explanations for this include a delay in onset 
of taste perception induced by high fat food, delays in stomach emptying induced by fat and 
concealment of allergenic epitopes by a high fat food matrix. Experimentally, chocolate 
specifically impairs protein detection in vitro106 which may account for the relatively 
increased frequency of fatal outcome after compound foods are consumed compared to foods 
containing unadulterated allergen.25,107  
Also the form of peanut used in clinical studies can vary, for example, peanut flour versus 
roasted whole peanut. However this may be less significant when allergens are heat stable, as 
is the case with peanut. Indeed Allen et al, when reviewing data from multiple challenge 
protocols, noted no differences in ED5 roasted peanut versus peanut flour.108 Differences in 
allergen content among peanut cultivars has been noted although these are only minor and 
remain undetermined in vitro.109   
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In order to try and reduce bias in double-blind placebo controlled food challenges the allergen 
must be masked. The active and placebo materials must be indistinguishable. Often this is 
achieved by masking the taste of the allergen with a stronger taste or smell.  To mask the 
granularity of peanut, foods of a similar texture such as oatmeal can mask the grainy texture 
of peanut flour.  
Interpretation of an adverse reaction 
Allergic reactions may be subjective meaning that they are experienced only by the 
challenged individual or objective meaning that they are identifiable and verifiable by outside 
observers. Studies have reported that subjective symptoms occur before objective symptoms 
and often represent early warning signs of an allergic reaction.110 However data are limited 
on the temporality and importance of these early warning signs. Moreover, a study by Van 
Erp et al reported that subjective symptoms (oral symptoms and abdominal complaints) were 
significantly associated with disagreement among clinical observers.111 Therefore there is 
debate over whether eliciting doses based on subjective symptoms are comparable to eliciting 
doses based on objective symptoms. Objective symptoms are often perceived as more a 
reliable indication of an allergic reaction to food.  
Statistical dose-distribution  
As previously mentioned data on thresholds are derived from 3 main sources: diagnostic 
challenge studies, threshold studies and immunotherapy trials. Often it is possible to derive 
individuals’ NOAELS and LOAELS from these studies.  
In the past, data from published clinical studies have been pooled to increase the sample size 
when estimating population threshold. Data can be reported in terms of grams of peanut flour, 
whole peanut or peanut protein. One of the preliminary steps therefore is to standardise the 
allergen amount from the source such as calculating the mg peanut protein in the challenge 
material. In the following discussion on existing threshold data in the literature statistical 
models used include LOAELs, NOAELs and Eliciting Dose (discussed before). Endpoints 
include both subjective and objective symptoms and eliciting doses are reported both as 
cumulative and discrete doses. It is generally considered that an individual’s elicitation 
threshold actually lies between the NOAEL and the LOAEL. In statistics when the 
observation is known to lie within an interval rather than the exact value being known, 
interval censored survival analysis is used112 to model a dose distribution curve. The data 
were fitted to parametric models using log normal, log logistic and Weibull to select the 
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apparent best fits. There is no biological rationale for using one parametric model over 
another.  The output of the dose distribution modelling is a reference dose in mg of total 
protein from the allergenic food.    
Existing population threshold data 
As previously mentioned the population threshold is defined as the largest amount of peanut 
that would not cause an adverse reaction in any individual within the total population of 
peanut allergic individuals. As it is impossible to test and perform challenges on every 
member of the entire peanut allergic population, estimates of the population threshold are 
derived from data on individuals’ thresholds which have been obtained from clinical food 
challenge studies. Data from clinical studies which have examined the same allergenic food 
can be combined. This is advantageous in that a wider range of study participants of 
potentially varying sensitivities are included. In addition by merging studies, differences in 
the food matrix as well as in dose regimes are averaged out.  
Two studies by Taylor et al98,113 have attempted to establish population thresholds for peanut 
allergy and contain some of the largest data sets for eliciting doses for individuals. Although 
several studies prior to these had given a wealth of information on the lowest doses of peanut 
allergen required to elicit a reaction in peanut allergic individuals namely the LOAEL, many 
of these studies gave little information on the NOAEL (the highest dose which elicits no 
reaction in peanut allergic individuals).  This made it difficult to estimate population 
thresholds from these studies.  
In 2009, Taylor analysed 12 publications for information on peanut thresholds. These 
publications were based on a spectrum of clinical studies including diagnostic oral food 
challenges, immunotherapy studies and threshold studies. From these publications 
information was available on the NOAELs and LOAELs of 185 peanut allergic subjects. 
These data were analysed using interval censored survival analysis and probability 
distribution modelling to obtain a population threshold estimate. In this case the ED10 (the 
amount of protein required to provoke a reaction in 10% allergic population) was found to be 
17.6 mg whole peanut using the log-normal distribution. On further analysis of the data from 
the three different types of study it was found that the ED10 estimates varied significantly 
between them (11.9mg for threshold studies, 18mg for diagnostic series and 65.5mg for 
immunotherapy trials). It was thought that this was possibly due to patient selection biases for 
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example investigators of immunotherapy studies enrolling less sensitive patients with higher 
NOAELs and LOAELs.  
Because of this discrepancy between different challenge studies, Taylor attempted a further 
analysis in 2010 examining data on a large clinical dataset from Nancy in France where a 
consistent challenge protocol was used over 10 years. Clinical records of 286 consecutive 
patients (adults and children) undergoing oral challenges to peanuts were examined. In this 
study the ED10 and ED5 were 14.4mg and 7.3mg respectively. Furthermore there had always 
been concern that previous studies had omitted patients with histories of severe reactions and 
whether these individuals represented a more sensitive section of the population. However it 
was found that minimum eliciting dose distributions for patients with histories of more severe 
reactions did not differ significantly from those patients with histories of milder reactions.  
More recently Ballmer-Weber looked at threshold distributions for peanut in the Europrevall 
birth cohort and found an ED10 value of 11.2mg of whole peanut.114  Zhu et al performed a 
retrospective analysis of published data from OFC with peanut to assess eliciting doses. From 
their data they proposed an ED10 of 2.8 mg determined by a log normal distribution which is 
a much lower ED10 than other studies.115 This is possibly explained by the fact that they 
included data on LOAELs based subjective symptoms which have not been included in other 
studies. NOAELs based on subjective symptoms have been shown to be much lower than 
LOAELs based on objective symptoms. A similarly low ED10 and ED5 was reported by 
Blom et al 2012 who also took subjective symptoms into account (4.4mg and 1.6mg peanut 
protein respectively).102 The opposite was true of a study by Eller et al whose population 
threshold estimates were much higher than any others reported. Based on their data most of 
which, comprised peanut thresholds from children, they reported ED10 and ED5 of 133.8mg 
and 77.0mg whole peanut.116 These high threshold estimates are possibly attributable to the 
fact that this study used a combination of open challenges and DBPCFC with a relatively 
high starting dose of peanut.  In one of the most recent studies by Allen et al, attempts have 
been made to derive the ED1. A reference dose based on the ED01 would be expected to 
protect at least 99% of people allergic to the particular food from any objective reaction. 
They combined data from 55 studies of clinical oral food challenges and have estimated the 
ED1 to be 0.2 mg of peanut protein (0.8mg whole peanut).108  In the remaining 1% patients, 
the hope is that only mild reactions would occur on exposure to these doses, further work is 
currently being undertaken using single dose challenges to examine this concept and validate 
these dose levels.117  Going forward, ED1 and ED5 estimates are be preferred by regulatory 
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authorities as they confer a greater level of protection to patients with food allergy however 
these estimations require larger dose distribution sets. A summary of threshold estimates to 
date are shown in Table 1. 
Table 1: Summary of threshold estimates derived from studies. All values are shown in 
mg peanut protein (equivalent to 25% of whole peanut). 
Group Study Type ED10 ED5 ED1 
Allen (2014) Mixed   0.29 
Ballmer-Weber (2015) Threshold 2.80   
Blom (2012) Threshold 4.42 1.56 0.15 
Blumchen (2014) Threshold 4.10 1.95  
Eller (2011) Threshold 32.90 18.90  
Klemans (2015) Threshold 10.80 5.08  
Taylor (2009) Mixed 4.40   
Taylor (2010) Diagnostic 3.60 1.83  
Zhu (2015) Mixed 0.70   
 
Eliciting doses in relation to severity 
When food policy makers are designing reference doses it is useful to them to determine the 
relationship of reaction severity to the threshold dose. So far data is limited in this regard. 
Several studies have failed to find a correlation between eliciting dose and severity during 
challenge.101,118 In one study, however, it was observed that peanut allergic adults with 
moderate to severe reactions during DBPCFC had significantly lower threshold doses 
compared with those who had mild reactions. It was also shown that a low ED in challenge 
was correlated to severity of previous reactions.119 However this observation could not be 
reproduced in other studies involving children.120,121 Interestingly a recent study showed that 
patients with severe reactions to peanut had statistically significantly higher MEDs than 
patients with mild or moderate reactions.115 
Other factors relating to threshold 
There has been a great deal of interest recently looking into whether an individual’s reaction 
threshold can be predicted using biochemical or immunological markers or factors related to 
an individual’s history. Blumchen et al found that there was an inverse correlation with the 
eliciting dose at challenge and the number of accidental reactions and the worst accidental 
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reaction in the patient’s history. Furthermore they found that increasing levels of specific IgE 
levels to peanut and Arah2, increasing SPT responses and basophil activation and Th2 
cytokine production by PMBC (peripheral blood mononuclear cells) were significantly 
associated with eliciting dose.101  Conversely another study found that there was no 
correlation between SPT reactivity and level of specific IgE to eliciting dose.118 It was 
observed in the same study, however, that the DBPCFC seemed to be representative of real 
life with individuals who had reacted to hidden traces in their history having a lower ED.  In 
terms of associated atopic conditions and their bearing on threshold of reaction, studies have 
generally agreed that the presence of asthma does not affect the eliciting dose.122 One study 
did find that the presence of atopic dermatitis was associated with higher eliciting doses in 
children. This is possibly because the presence of atopic dermatitis may mask early 
symptoms such as itch or urticarial which may occur with lower doses of peanut.120 Recent 
work by Santos et al found that patients with a higher cumulative peanut threshold dose had a 
higher ratio of peanut-specific IgG4 (a blocking antibody) to IgE. This suggests that IgG4 
may be competing with IgE for binding with allergen and blocking its effect.123  
Threshold differences between adults and children 
Many previous threshold and diagnostic food challenge studies involve children rather than 
adults. Indeed a large retrospective analysis by Zhu of several published threshold studies 
found that 67% studies worldwide were based on children.115 It is disputed whether age has 
an effect on eliciting dose with some studies claiming that increasing age is inversely 
correlated with eliciting doses120 while others have found no effect of age on eliciting 
dose.101,108,122 In recent work by Klemans et al the differences between peanut threshold 
distribution curves for adults and children were studied. The threshold distribution curves for 
both objective and subjective symptoms were significantly different between adults and 
children. In this sample they observed that given a certain dose increase a lower proportion of 
the adult population reacts to the following dose with objective symptoms compared to the 
paediatric population suggesting that children react to lower doses with objective symptoms. 
However overall ED5 and ED10 for objective symptoms were comparable between adults 
and children.  Subjective ED5 and ED10 for adults were significantly lower compared to 
children.124 This may be related to the fact that it may be more difficult for children to note or 




How threshold doses can be translated into clinical practice 
The establishment of population thresholds and reference doses would permit public health 
agencies and the food industry to set limits on the use of precautionary labelling. The 
establishment of a definite level of peanut allergen which is known to be harmful to a 
proportion of the population would allow food manufacturers to aim to ensure that their foods 
remain free of this level of contaminant. Furthermore improvements to labelling can be made. 
Partly this may involve removing precautionary labels where they are not needed which 
instilling confidence in peanut allergic consumers. Also establishment of a reliable labelling 
system free of conflicting advice, informed by evidence would improve safety and reduce 
overuse. The VITAL initiative, developed in Australia in 2007, was the first formal attempt 
to establish an evidence based labelling system. The VITAL program developed a grid in 
which action levels (in parts per million) were defined for major allergenic foods.125 It also 
took into account consumption levels of the food and whether a food contained a dose of the 
allergenic food above the reference dose, for example, foods typically consumed in large 
amounts will contain large amounts of allergen compared to foods which are eaten in small 
amounts such as a condiment or garnish. At the time that this system was instituted limited 
data existed on minimal eliciting doses and therefore a 10 fold uncertainty factor was applied 
by VITAL to ensure that sufficiently conservative action levels were promoted. In light of 
updated data and new knowledge on thresholds this guidance was updated to VITAL 2.0.108  
More recently the ED05 has been established for peanut (1.5mg peanut protein, 6mg whole 
peanut). Hourihane sought to validate this predicted ED05 by challenging peanut allergic 
patients with a single dose challenge.  Three hundred and seventy eight children were given a 
dose of 1.5mg peanut protein. Most children experienced no reaction following this dose 
(65%). Only 2.1% met the criteria for an objective reaction and no child experienced more 
than a mild reaction.117 In practice this single dose challenge protocol may be used to identify 
the most dose sensitive members of the allergic population not otherwise identifiable by 
using standard skin prick tests or specific IgE levels.     
Threshold levels across different foods 
A few studies have attempted to compare threshold dose distributions across different 
allergenic foods. Blom et al compared egg, milk, hazelnut and peanut thresholds in a 
retrospective study of children who underwent DBPCFC.102 They found that the dose 
response within the allergic population for the different foods was not equally distributed. 
35 
 
Hazelnut allergic patients reacted to the lowest doses of allergen. They also observed that the 
dose range to which the peanut allergic population was reacting was smaller and at higher 
doses the population with peanut allergy was more likely to respond. They found that at a 
dose of 67mg peanut protein 50% of the allergic population had reacted whereas at the same 
dose of other allergens such as egg and milk only 35% of the equivalent allergic populations 
had responded.      
This contrasts with Eller et al who found the threshold distributions to be broadly similar 
amongst hazelnut, milk and peanut.116 Again this different finding may be due to differences 





Part 3: Co-factors 
It appears that in an allergic reaction there is not a simple linear relationship between allergen 
exposure and reaction in a sensitised individual. One study of children who underwent two 
peanut challenges at an interval showed that almost all children reacted at a different severity 
score or another dose at the repeat challenge.126 Anecdotally, patients report in clinic that 
their allergic reaction seems to change in different situations. Therefore it seems that there 
perhaps may be other factors responsible for modulating an allergic reaction. When 
considering these ‘other’ factors, two groups are thought to exist: host (intrinsic factors) 
factors and event (extrinsic) factors. Host factors are factors which specifically pertain to an 
individual such as atopic disease, age, previous reactions, comorbidities, physiological 
compensatory capability and gastrointestinal absorption. Event factors are external factors 
which can vary with time or certain situations and include such things as exercise, 
psychological stress, alcohol, intercurrent infections and use of medications such as non 
steroidals. It has been suggested that co-factors may in some way be responsible for 
augmenting allergic reactions. Indeed in peanut immunotherapy studies it has been reported 
that patients seemed to lose tolerance to peanut doses during both the updosing and 
maintenance periods when they took the doses close to periods of exercise or when they were 
tired.127 Co-factors have been identified in up to 30% of anaphylactic reactions in adults128 
with a variety of co-factors being implicated (Table 2). In the presence of these factors, 
allergic reactions may be elicited at lower doses or may be more severe or life threatening. 
However, underlying mechanisms have so far yet to be elucidated. 
Table 2: Prevalence estimates of co-factor involvement in anaphylactic reactions. 
Adapted from Wolbing et al.128 





Mental stress 8% 
Other e.g. menstruation 12.1% 
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Exercise as a co-factor 
 Physical exercise is the best known and best studied co-factor in anaphylaxis. There 
are few data in existence on how physical exercise modifies an allergic reaction to peanut in 
an individual who is known to be peanut allergic. Instead the clinically distinct condition, 
Food Dependent Exercise-Induced Anaphylaxis, serves as a model condition for 
understanding how exercise may play a role. In this disorder, the triggering food is tolerated 
under normal conditions but when the food is consumed in association with physical exercise, 
it is no longer tolerated and an allergic reaction usually ensues.129 The intensity of exercise 
required to induce an allergic reaction is variable with reports of this condition occurring with 
both strenuous exercise and even very light physical activity such as walking or gardening. 
Food Dependent Exercise Induced Anaphylaxis 
The most common form of this condition is ‘Wheat-Dependent Exercise-Induced 
Anaphylaxis’ (WDEIA). Two possible mechanisms for the underlying pathophysiology have 
been proposed: 
1. The bioavailability and distribution of certain allergens may be increased by exercise 
2. The threshold for activation of mast cells and basophils may be decreased by exercise 
Matsuo and colleagues investigated individuals with WDEIA. They observed significantly 
increased levels of immunoreactive gliadin in the sera of individuals after consumption of 
wheat combined with physical exercise compared with consumption of wheat without the 
application of physical exercise. This change was also observed in healthy volunteers.130 
However it should be noted in this condition that exercise is not always the essential co-
factor. Recently, Brockow et al were able to reproduce symptoms in 4 patients with a history 
of WDEIA by challenging them with gluten, acetylsalicylic acid (ASA) and alcohol without 
the involvement of exercise. 131 
Indeed in the aforementioned study by Matsuo et al it was demonstrated that acetylsalicylic 
acid (ASA) increased the amount of serum gliadin by five times after wheat consumption.132 
The exact mechanism of how aspirin exerts its effect is yet to be fully elucidated however 
various theories have been suggested. Firstly it has been suggested that aspirin disrupts the 
integrity of cellular tight junctions thereby increasing gastric permeability.133 Secondly ASA 
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inhibits cyclooxygenase function resulting in decreased prostaglandin and increased 
leukotriene synthesis. In a study by Inoue et al they found after administering a synthetic 
analogue of prostaglandin E1 (Misoprostol) which compensated the ASA-induced inhibition 
of prostaglandin synthesis, that allergen absorption and the outbreak of allergic symptoms 
induced by ASS in patients with WDEIA may be suppressed. 134 Lastly ASA has been 
reported to directly augment the degranulation of mast cells and accelerate histamine release 
via increased Syk kinase activation.132   
Physiological changes during exercise 
Increases in gastric permeability 
Intestinal uptake of food proteins occurs via two routes across the epithelium: transcellular or 
paracellular. Diffusion, active transport or endocytosis utilise the transcellular route whereas 
paracellular transport is characterised by the transport of larger molecules through tight 
junctions into the interstitial space. These molecules then enter the systemic circulation from 
the interstitial fluid between the enterocyctes.  
 Physiologically, exercise induces changes conducive to enabling the above reactions 
to take place. Much work previously has focussed on alterations to intestinal absorption 
through alterations in blood flow during exercise. These changes were demonstrated 
elegantly in a study by Van Wijck et al who examined healthy men undertaking 60 minutes 
of cycling at 70% of maximum work load capacity. They assessed splanchnic hypoperfusion 
through gastric tonometry, enterocyte damage parameters through serum markers (intestinal 
fatty acid binding protein (I-FABP) and ileal bile acid binding protein (I-BABP) and 
intestinal permeability through sugar probes. They found that splanchnic perfusion fell during 
exercise and that hypoperfusion increased plasma I-FABP, I-BABP and hypoperfusion 
correlated significantly with small intestinal damage. An increase in small intestinal 
permeability after exercise was seen which correlated with intestinal injury.135 Therefore 
should allergen absorption be combined with exercise, intuitively it follows that the 
absorption of large molecules such as intact allergens would be facilitated through a more 
permeable gastric mucosa, therefore having access to the gut-associated immune system. Pals 
et al also demonstrated in a group of healthy participants that running at 80% VO2 max 
(maximum exercise capacity) increased small intestinal permeability measured through 
urinary excretion rates of the lactulose to rhamnose ratio compared with rest and lower 
exercise intensities (40 and 60%).136  
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Blood flow redistribution and mast cell heterogeneity 
During exercise blood is redistributed away from visceral organs (kidneys, gastrointestinal 
system) towards working muscles and organs (skeletal muscle, lungs, heart and skin). 
Robson-Ansley et al hypothesised that the sudden redistribution of blood transports the 
allergen away from the gut to the skin or skeletal muscle where phenotypically different mast 
cells reside resulting in altered mediator release and an altered disposition for developing 
anaphylaxis.137 Currently however there is no experimental evidence to support or refute this 
theory.  
Changes to plasma osmolality inducing basophil histamine release. 
It has been suggested that plasma osmolality may increase marginally during prolonged 
physical activity. In vitro studies have indicated that alterations in plasma osmolality can 
increase basophil activation and histamine release.138,139  By performing histamine release 
assays using a range of buffers with increasing osmolality, Barg et al demonstrated on 
basophils from patients with FDEIA, food allergy and healthy controls that histamine release 
and basophil activation increased in the patient with FDEIA at 340 nOsm and not in the food 
allergic or control subjects.138 It is possible to hypothesise that physical activity may induce a 
transient serum hyperosmolarity which may trigger increased basophil reactivity and 
histamine release on exposure to a food allergen. 
Other possible proposed mechanisms include the increased release of mediators during 
exercise which sensitise the calcium channel through which histamine works (TRPV1 
receptor) and also local and systemic changes in acid-base balance during acute exercise 
whereby a cellular-reduced pH promotes mast cell degranulation heightening a propensity 
towards anaphylaxis.140  
Stress and sleep deprivation as cofactors 
Stress has also been described as an augmenting cofactor in allergic reactions. Generalised 
stress or malaise has been described as a contributory factor in fatal allergic reactions.141 A 
well-established clinical observation is that stress can exacerbate urticaria and angioedema, 
particularly non-IgE mediated forms. The mechanism is unknown, but a reduced threshold 
for mast cell activation is likely.142 In a recent immunotherapy study it was shown that 
acquired tolerance to peanut was reversed under the influence of co-factors. Six out of 20 
individuals were unable to tolerate a dose that they had previously been able to tolerate if 
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they had suffered restricted sleep (<6 hours).143 Acute sleep loss is a potent stimulus of stress 
hormones in animals.144 Rather than subjecting patients to psychological stress, in this study 
we decided to use sleep restriction as a proxy for stress. Moreover sleep restriction has the 
benefit of being easily reproducible, measurable and the ensuing tiredness relatively long 
lasting. 
Clinical and experimental studies in human and animal models have shown that sleep loss 
can lead to impaired immune function. It has been suggested that cellular immune responses 
can be disrupted by shifting T helper cell activity towards a Th2 cytokine profile. This was 
demonstrated by Axelsson et al who investigated partial sleep deprivation for five days and 
the production of inflammatory cytokines and the Th1/Th2 balance in healthy subjects. They 
noted a shift towards Th2 activity determined by a decrease in IL-2/IL4 ratio.145 Sleep loss 
exerts a significant regulatory influence on peripheral levels of inflammatory mediators of the 
immune response. Sakami et al also noted this shift in insomniacs. In their study they noted a 
significantly lower IFN-gamma and ratio of IFNgamma/IL4 than non-insomniac men again 
suggesting a Th2 dominant profile.146 In anaphylaxis clinical manifestations arise as a result 
of mast cell and basophil inflammatory mediators acting on a variety of target organs. In 
addition to these mediators, several cytokines are released into the milieu including IL4, IL5, 
IL13, IL16 TNFα and various chemokines. These act on various effector cells propagating 
the allergic response by cell activation, chemoattraction, IgE production and increased FceR1 
expression. Changes in cytokine levels have been observed in various studies subjecting 
individuals to sleep deprivation protocols. In particular, a study of partial sleep deprivation (4 
hours) found increased production of TNFα and IL1β following stimulation of peripheral 
blood mononuclear cells with Lipopolysaccharide and Polyhydroxyalkanoate respectively.147  
Alcohol as a cofactor 
Ethanol, like exercise, can also activate the TRPV1 channel. This can lower the threshold to 
activation by products of allergic inflammation which act via this ion channel. TRPV1 
activation causes neuromediator release including calcitonin neve related peptide which can 
result in vasodilatation.148  The vasodilatory response may exacerbate shock in anaphylaxis. 
Alcohol may also cause gastritis, permitting greater allergen absorption. and augment 





Literature review  
Part 4: 
Symptoms and severity of peanut allergic reactions 
Allergic reactions vary in severity. This variation occurs across individuals in a population 
but in addition, a patient’s own reaction severity can change from one allergen exposure to 
the next. It seems intuitive that the dose of allergen that a person is exposed to determines the 
severity of reaction implying that a greater dose of allergen leads to an increase in severity. 
However severe laryngeal symptoms requiring adrenaline administration have been reported 
for doses as low as 0.3-1mg of peanut protein.119,143 A good understanding of a patient’s 
reaction severity is crucial for clinicians as it can guide them on both acute and long term 
management of that individual. Furthermore knowledge about reaction severity and symptom 
progression can enhance safety in oral food challenges by instructing physicians on when to 
stop a challenge and administer treatment. Unfortunately limited data exist on the evolution 
of allergic symptoms during challenge. Further the classification of allergic reaction severity 
is problematic as various grading systems are used to report systemic reactions but none are 
globally accepted: venom150, food 80,151–153 , drugs154 and adverse reactions to allergen 
immunotherapy.155  Furthermore each system has usually been developed based on 
observations of patients with different types of allergy which may differ in symptom pattern 
and thus different weights are attributed to different symptoms across the scores. An 
implication of contrasting classification systems is that comparison of clinical practice 
becomes problematic. From a research point of view there may be difficulties in assessing the 
efficacy of treatments (e.g. immunotherapy), interventions (e.g. adrenaline administration) or 
patient outcomes. Thus further fine grain detail on symptom severity will inevitably lead to 
the development of a more universal classification system. 
Symptoms associated with peanut allergic reactions 
In general, symptoms of an allergic reaction usually reflect the route of allergic exposure. 
Thus in reactions triggered by parenterally administered agents such as intravenous drugs or 
venom, cardiovascular manifestations such as hypotension usually predominate. In contrast 
with food allergic reactions, the skin and mucous membranes are involved as these represent 
the first point of contact between the individual and their environment. In an IgE-mediated 
reaction to peanut cutaneous manifestations are usually the most common occurring in about 
74% patients with an immediate reaction to food.156 In a series by Perry et al, 253 failed food 
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challenge reactions were examined and the investigators found that gastrointestinal symptoms 
also were common occurring in 43% of failed challenges. Oral, upper respiratory and lower 
respiratory symptoms were less common and occurred in approximately 25% of failed 
challenges.84 Distinct behavioural changes are also very common especially in young 
children. It is common to see children change suddenly from happy and playful to quiet and 
frightened with the onset of a reaction. In Food Dependent Exercise Induced Anaphylaxis, 
symptom patterns may be different often starting with pruritus of the scalp which then 
becomes generalised followed by respiratory obstruction and occasionally cardiovascular 
collapse. 153  Severe and life threatening reactions are rare. Symptoms of food anaphylaxis 
may develop as soon as 3 minutes after exposure to usually up to 2 hours after the ingestion 
of a food allergen.101 However the vast majority of food allergic reactions happen within 30 
minutes. Biphasic reactions occur when symptoms recur after apparent initial resolution. In a 
systematic review and meta-analysis of 27 observational studies biphasic episodes occurred 
in 192/4114 (4.7%) patients with anaphylaxis with the range varying between 0.4-23.3%. 
Patients with hypotension and unknown triggers were at greater risk.157   
Fatal anaphylaxis  
Peanut has the propensity to cause fatal allergic reactions. However the exact incidence of 
fatal anaphylaxis for food allergic people is unknown. In general, the majority of studies 
suggest that although the overall incidence of anaphylaxis is increasing, there does not seem 
to be an increase in fatalities from this condition. 158,159 However there is one recent 
Australian study which did report a rise in fatal cases.160 Umasunthar et al estimated the 
incidence rate of fatal food anaphylaxis based on 10 studies in a food-allergic person as 1.81 
(95% CI 0.94, 3,45 range 0.63, 6.68) per million person years.161  In a recent study examining 
databases from the Office of National Statistics between 1992 and 2012, 124 fatalities were 
attributed to food-induced anaphylaxis.  The triggering food was identified in 95/124 cases 
(77%). Peanut was responsible in 22% adult cases (>16 years old) and in 16% paediatric 
cases (<16 years old). The percentage of fatalities caused by peanut and tree nut is higher in 
US registries compared to UK but this may be due to the data being based on voluntary 
registries in the US.25,26  
The mode of death in anaphylaxis has previously been reviewed.41,162,163 The major causes 
are asphyxia from upper and lower airway (45%), shock (41%), unknown (9%), 
Disseminated Intravascular Coagulation (3%) and epinephrine overdose (2%).162  
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Risk factors for fatal anaphylaxis have been identified. Delayed or lack of administration of 
adrenaline has unequivocally been found to be a major contributor to mortality.164 Pumphrey 
et al found in a fatal anaphylaxis registry that adrenaline was only administered in 62% of 
fatal reactions and before arrest in only 14%. However, timely administration of adrenaline 
was not sufficient in some cases to avert a fatal outcome. In the series of 48 cases reviewed 
by Pumphrey, 3 patients died despite receiving adrenaline from their own kit at the onset of 
reaction.165 Asthma is present as a co-morbid condition in more than 90% of fatal 
reactions.166–168 In particular poor asthma control is linked to fatalities. This may be a feature 
in younger age groups where medication compliance is potentially an issue. A preponderance 
for younger age has been shown. Young adults or adolescents are particularly at risk.4,25 This 
may possibly be due to an increased risk-taking behaviour in this age group leading to an 
increase in co-factor exposure for example sleep deprivation or alcohol.  Other contributory 
factors include a failure to carry their adrenaline autoinjector or even disease denial. 
Yunginger et al evaluated 13 cases of fatal and near fatal anaphylaxis and also reported that 
failure to identify the responsible food allergen in the meal was a significant risk factor.169  In 
instances such as these there may be concealment of the allergen and increased dose 
exposure.  
Risk multipliers in anaphylaxis 
The presence of a known risk factor for anaphylaxis can enable clinicians to instigate 
strategies to reduce the risk of this potentially fatal condition. The role of co-factors in 
amplifying allergic reactions has been discussed in the previous chapter. However intrinsic 
host-level factors have also been proposed which may modify allergic reactions. At an 
immunological level, Nowak-Wegrzyn170 reported that individuals who have IgE to specific 
allergenic epitopes which are more heat stable may have a predisposition to more severe 
reactions. El-Khouly et al showed in 40 peanut allergic patients that both IgE and IgG avidity 
to Arah2 showed a weak positive correlation to severity challenge score.171 Underlying 
cardiovascular disease and cardiovascular medications may influence reaction severity. 
Nassiri et al showed in human and mouse models that singly beta-blockers and ACE 
inhibitors can increase the severity of anaphylaxis and this effect was more pronounced if the 
two drugs were combined. The proposed mechanism is that these drugs can act 
synergistically to decrease the threshold of mast cell activation.172 However in a study by 
Brown at al, although cardiovascular risk and medications had a significant association with 
age, there was a lack of a correlation with symptom severity.173 Possible factors associated 
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with the absence of significant reactions to peanut in allergic individuals include isolated 
specific IgE to Arah8, the PR-10 related component and suggests Pollen Food Syndrome 
rather than primary peanut allergy. These individuals usually demonstrate clinical tolerance 







Diagnosis of an acute allergic reaction: mast cell tryptase  
Diagnosing anaphylaxis acutely can sometimes be problematic for acute physicians. This is 
because the symptoms of anaphylaxis: wheeze, flushing, hypotension and angioedema for 
example can be presenting features of other, more common conditions. Furthermore an 
allergic trigger may not always be immediately obvious.  As a consequence of this, 
anaphylaxis is under-diagnosed and under-reported.175,176 Diagnosing anaphylaxis is 
imperative as correct diagnosis allows secondary prevention strategies to be implemented 
such as allergen avoidance, immunotherapy and provision of adrenaline auto injectors.  
When anaphylaxis occurs, numerous mediators and pathways may be activated. However not 
all are measurable in routine clinical practice. Mast cell tryptase has been reported, in 
national guidelines, to be the most useful blood test to confirm a diagnosis of anaphylaxis if 
correctly performed.177 Tryptase measurement, however, has the potential to be useless if 
samples are incorrectly timed. Tryptase is released from mast cells, crucial cells which 
belong to the innate arm of the immune system. Mast cells are present at interfaces between 
the organism and environment for example skin, bronchi and gut and have many 
immunoregulatory functions including pathogen clearance to inflammation resolution. 
Tryptase belongs to the family of trypsin-like serine proteases and is the most abundant 
mediator in mast cell granules. Tryptase is highly specific for mast cells as only trace 
amounts <1% are detected in basophils and none in other human cells.178  During IgE 
mediated degranulation mast cell granules fuse with the plasma membrane and release dozens 
of preformed mediators including mature tryptase into the extracellular space.179,180 The 
release of secretory granule contents into the extracellular environment occurs in a matter of 
minutes. A rise in histamine may be detected in the first 5 minutes, however levels only 
remain elevated for 30-60 minutes and thus capturing peak levels is difficult as there may be 
a delay in the patient presenting to hospital. Tryptase, on the other hand, is released from 
mast cells in a complex protease-proteoglycan complex which diffuses slowly. As a result of 
this, elevation of serum tryptase concentrations may not be detectable in the first 15 or 30 
minutes181 however once in the bloodstream the half-life of serum tryptase is about 2 hours. 
Thus levels will remain elevated between 30 minutes and 2 hours after the onset of 
anaphylaxis making this the optimal time to sample.182 This allows enough time for 
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degranulated tryptase to reach peripheral blood and short enough to avoid missing elevated 
serum tryptase due to plasma clearance. This lowers the risk of obtaining a false negative by 
too early or too late measurements. Therefore due to its relatively long biological half-life 
and stability in serum stored at -20oC tryptase is a convenient surrogate marker for other 
pharmacologically active mediators which are released at the same time. Baseline or 
‘constitutive’ mast cell tryptase levels are the result of continuous release of immature 
inactive alpha and beta tryptase monomers (pro-tryptases) and reflect the number of mast 
cells. Mature beta tryptase is contained in secretory granules and released only when mast 
cells degranulate.183 Currently there is only one commercially available tryptase test which 
detects both immature and mature forms of alpha and beta tryptase in body fluids 
(ImmunoCAP  Tryptase, Thermofisher Scientific Diagnostics, Phadia, Sweden).184 With this 
current method, according to data obtained from 126 healthy donors, 95% individuals 
displayed tryptase values of less than 11.4 µg/L and a median value of 3.8 µg/L. It is 
generally thought that tryptase values are stable in a given individual over time. 
The usefulness of mast cell tryptase has been demonstrated widely in studies of venom and 
general anaesthetic induced anaphylaxis. It is often raised in reactions which are severe and 
feature hypotension. Other studies however are reticent about its utility. Sala-Cunill studied 
patients presenting with acute anaphylaxis and found that mast cell tryptase was not raised in 
36.3% of cases. In a study by Stone et al, tryptase was elevated in 55% of moderate reactions 
an in 75% severe reactions.185 Lin et al prospectively sampled β and total tryptase in 97 adults 
presenting to A&E and found raised tryptase in only 20/97 (20%) patients.186 However the 
sampling time points are not clear from this study nor whether serial samples were taken 
which could, in part, explain the few elevated readings. However a few of these studies 
attributed the lack of a rise in tryptase to the fact that they contained a large proportion of 
food allergic reactions. Previously it has been reported that tryptase levels fail to rise in food 
allergic reactions. This is largely based on an analysis of 5 samples (1 postmortem, 1 near 
fatal and 3 with severe food anaphylaxis).  Tryptase failed to significantly rise in all cases. 
Proposed reasons for this include a predominantly basophil mediated rather than mast cell 
mediated response or in the fatal case that death intervened before a rise could occur. Post 
mortem samples in general have been reported to be less sensitive and specific as a non-
specific tryptase release may occur after death.187 It is believed that tryptase levels peak at 1-2 
hours and therefore a single measurement of tryptase has a low sensitivity as a peak may be 
missed or may occur within the normal range for the assay. Borer-Reinhold et al used a 
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relative increase in tryptase compared to the baseline value when investigating patients who 
developed systemic reaction to stings. They found that a relative tryptase increase to ≥135% 
above the baseline value (relative delta bound) indicated mast cell activation in these patients 
even below the upper limit of the tryptase assay (11.4ng/l).188 There are limited data on the 
application of this principle to food allergic reactions with one study examining tryptase 
changes in acute allergic reactions to shrimp in shellfish allergic patients. Thirty two patients 
suffered allergic reactions during challenge, 38% anaphylaxis. They reported that delta-
tryptase (peak minus baseline) levels were higher in the anaphylaxis group compared to non-
reactive and milder reactions. They identified a cut-off using ROC analysis of ≥0.8µg/L (83% 
sensitivity and 93% specificity).189 Thus use of a ratio (peak related to baseline) is thought to 
improve sensitivity, specificity and positive and negative likelihood ratios.  
Many mediators are generated during anaphylaxis by numerous cell types. Tryptase is only 
one of these mediators, may not be the predominant one and may only be released in very 
small amounts. More recently platelet activating factor (PAF) has been identified as an 
important mediator in anaphylaxis and in an animal model interventions which block PAF 
prevent fatal anaphylaxis.190 Vadas et al measured PAF and PAF acetylhydrolase activity in 
41 patients with anaphylaxis and 23 control patients and found that serum PAF levels were 
directly correlated and serum PAF acetylhydrolase activity was inversely correlated with the 
severity of anaphylaxis.191 In a further study when comparing PAF with histamine and 
tryptase neither histamine nor tryptase showed as good correlation with severity scores during 
reaction as did PAF.192 Prostaglandin determinations are available commercially and can be 
of value in the diagnosis of anaphylactic events. In a study of patients with systemic 
mastocytosis who experienced anaphylaxis it was found that anaphylaxis cold be diagnosed 
by a selective excessive release of prostaglandin D2.193 With regard to basophil activation it 
has been demonstrated that BAT may correlate with symptom severity for peanut allergy.194 
However basal basophil responsiveness is known to vary from day to day within an 
individual and so may not predict reaction severity on a different day.195   Therefore using a 
multiple mediator approach i.e. using numerous markers simultaneously may improve the 








The Thresholds Reactivity and Clinical Evaluation (TRACE) Study upon which this thesis is 
based was a 52 week multicentre randomised cross over study. One hundred participants 
were recruited across two centres carrying out the food challenges: Addenbrooke’s Hospital, 
Cambridge and the Royal Brompton Hospital, London, United Kingdom. For this 
dissertation, only the results from the Cambridge cohort, whom I personally administered 
peanut challenges to, will be reported. Pilot work was used to determine the feasibility of the 
study method. This will be described in ‘Pilot Work’ following description of the main study 
method.  
Setting 
All clinical procedures were carried out in the Wellcome Trust/NIHR Clinical Research 
Facility, Cambridge. 
Recruitment and population 
Participants were recruited from the general adult peanut-allergic population. A media agency 
(MWI) was employed to generate a study identity for a website and advertising materials. 
Participants were recruited through advertisements on London and Cambridge-based 
Newspapers (Metro and Evening Standard), Facebook, Google Words and Twitter 
advertising campaigns. Interested participants were directed to a dedicated study website 
where further information about the trial was available. Through this website, potential 
participants registered their interest and answered some simple screening questions including: 
‘Has your worst reaction to peanut only been mouth or lip swelling?’, ‘Has your allergy been 
diagnosed by a doctor?’, ‘Are you able to run on a treadmill for 10 minutes?’ and ‘Are you 
available to take part in the study for the next 12 months?’. Registered participants were 
added automatically to a database including the responses to screening questions. Following 
this registered eligible participants underwent a brief telephone consultation as a further 
screening stage.  
Study inclusion and exclusion criteria 
Inclusion criteria  
 Male and female subjects who are 18-45 years of age at the time of study entry 
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 A diagnosis of peanut allergy as manifested by urticaria, angioedema or 
respiratory/gastrointestinal tract symptoms, with acute onset of symptoms after 
ingestion (up to 2h). 
 A positive peanut DBPCFC at baseline (Visit 1). This outcome was defined as the 
onset of objective or significant subjective allergic events after ingestion of peanut 
protein but not to the placebo.  
 Sensitisation to peanut demonstrated by skin prick test, or serum specific IgE 
Exclusion criteria 
 Oral allergy syndrome to peanut (defined as a clinical history of only oral allergy 
symptoms on exposure to peanut and principal sensitization to only PR10 homologues 
of peanut (Ara h 8) 
  Monosensitisation to Ara h 9 
 History of hypersensitivity to the matrix components used within the challenge 
material. 
 Poorly controlled asthma. 
 History of significant and repeated exercise –induced asthma attacks requiring 
treatment, independent of food ingestion or a drop in FEV1 of >15% during screening 
Vo2max exercise session 
 History of any of the following: 
o Severe anaphylaxis to peanut as defined by hypoxia (SpO2 < 92%) or 
hypotension (>30% drop in systolic blood pressure), with or without 
neurological compromise 
o A previous reaction to peanut that in the opinion of the investigator was life-
threatening  
o Mastocytosis 
Other exclusion criteria include conditions which would directly impair the participant’s 
ability to undertake the study protocol such as musculoskeletal disorders impairing exercise 
and shift working impairing the sleep deprivation challenge. 
Screening visit 
Suitable participants were invited for a screening visit which involved a detailed history, skin 
prick and blood tests (specific IgE to peanut and Arah1, 2, 3, 8 and 9) to determine their 
allergic status. Each participant underwent a VO2 max test to ascertain their maximum 
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exercise capacity which was used to determine the exercise intensity for their exercise 
challenge. Lung function was assessed through spirometry and participants with asthma 
undertook the Asthma Control Test to determine their asthma control. Pre and post exercise 
lung function was used to exclude any participants with exercise induced asthma.  A fall in 
FEV1 of greater than 10% following exercise excluded participants from the study. 
Informed consent 
Each participant received a Participant Information Leaflet and a detailed verbal explanation 
of the study protocol including the risks and benefits of participation. Potential participants 
were given the opportunity to ask questions and were provided with sufficient time to make a 
decision. No clinical procedures were undertaken until informed consent had been obtained. 
Participants could withdraw at any time without the need for explanation. 
Data collection and management 
Participant demographic data, details of symptoms during challenge including timing of onset 
and resolution, threshold reached and treatment administered during challenge was collected 
on a paper case record form. Data from these forms were then entered by the study team onto 
a centralised computerised database managed by the University of Manchester.  
Quality control of the data and data checking was carried out by an independent person at 
each site who checked 100% of the primary outcome data (cumulative peanut dose reached) 
and symptoms at the time of onset of reaction.  
Study design 
Each participant underwent a baseline challenge (to determine their allergic status and initial 
threshold) followed by a further 3 interventional challenges (exercise, sleep and no 
intervention) spaced 3 months apart to reduce the possibility of a desensitisation effect 
produced by repeated peanut challenges (Figure1). The initial baseline challenge was double 
blind and placebo controlled and took place on 2 separate days: one day active and one day 
placebo. The order of the two days was randomly assigned and determined by randomisation 
lists produced by the study statisticians. Both participants and investigators were blinded to 
the ordering of the challenge days. Following this there was a further randomisation step. 
There were six allocation arms which varied by the order of the final 3 challenges 
(exercise/sleep/no intervention). The order of challenges between the six groups was 
balanced by employing a Latin square design. Participants were randomly assigned to one of 
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the six arms using a secure online tool with audit trail. The six possible sequences were, 
ABC/BCA/CAB/ACB/BAC/CBA with each letter representing a different co-factor: A for 
exercise, B for sleep deprivation and C for no intervention. The strong degree of balance 
allowed for natural variations in intra-individual threshold over time.  Randomisation was 
stratified by age, centre and the presence of asthma. (Figure 1). The final three challenges 
were not placebo controlled and participants received the active arm only. 
Figure 1: Study design 
 
Oral food challenge procedure 
Baseline challenge 
A series of eight doses of peanut in the form of peanut flour were prepared. This was 
incorporated into a masked dessert food carrier developed for a European epidemiological 
project (Europrevall)196 and manufactured at the University of Manchester and then 
distributed to the study centres for reconstitution at the point of use. Microbiological safety 
and allergen content were confirmed before materials sent out to the clinical centres. The 
dosing regimen is shown in Table 3. Numerous dosing schedules are currently in use for 
performing food challenges. Incremental scales vary from 10 fold increases, semi-
logarithmic, doubling dose or even smaller increases with the latter associated with schedules 
aiming to deliver cumulative doses with shorter time intervals between doses (15 minutes). 
With schedules aimed at delivering discrete doses, intervals are typically longer (30 minutes). 
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Using lower starting doses and prolonged intervals can increase the likelihood or partial 
desensitisation and false-negative results.197   Data from the literature suggests that a starting 
dose of 3 micrograms should be low enough to provide No Observed Adverse Effect levels 
(NOAELS, the highest dose known to not induce an objective allergic reaction). However 
starting at very low doses can make it more difficult to achieve meaningful top doses with 
acceptable increments in an acceptable period of time. Thus a combination of logarithmic 
increments (from 3 micrograms to 30mg) followed by semi-logarithmic increments thereafter 
was used. Usually dosing regimens escalate to high cumulative dose of allergen protein to 
reduce the risk of a false negative challenge. Sicherer et al reported approximately 5% false-
negative challenge results with a top dose of 876mg of protein.198 In this study, doses were 
delivered at 30 minute intervals which has been proposed as a suitable interval for the 
investigation of IgE associated reactions.82  However if significant symptoms evolved during 
the interval, the clinical investigator could increase the interval to 60 minutes. Longer time 
intervals however lengthen the challenge procedure and decrease the chance of accumulating 
high doses which may result in more severe reactions.199  The doses were given until the 
participant was judged to have developed objective signs of an allergic reaction and thus have 
reached their clinical threshold. Allergic reactions were treated appropriately and all 
treatments and their effect were recorded. On a separate day the participant underwent a 
further challenge where all doses administered were placebo. The placebo dessert matrix 
matched the active dessert having previously been subjected to blinding tests at the 
University of Manchester. Placebo challenges were carried out under similar conditions. Both 
active and placebo challenges occurred in a random order for each participant and were 
spaced a week apart.  
Table 3: Dose regimen  




3µg 30µg 300µg 3mg 30mg 100mg 300mg 1g 
 
Criteria for scoring symptoms and stopping food challenge 
In this study the PRACTALL criteria proposed by Sampson et al82 were adapted following 
our pilot challenge experience (described in ‘Pilot Work’) (Appendix 1). Participants were 
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deemed to have reached their threshold, and the challenge stopped if they developed three 
concurrent yellow symptoms within one organ system or across different organ systems or 1 
red symptom in any organ system. If the participant was almost at their threshold (e.g. 2 
yellow symptoms) and the investigator was concerned about escalating to the next dose level 
for fear of inducing severe symptoms then the dose could be repeated.  
The colour coded symptom grading system was used as follows: 
Green (mild) symptoms were not an indication to alter dosing. 
Yellow (moderate) symptoms if present singly would be an indication for the investigator to 
proceed with caution. If three yellow symptoms were present concurrently within the same 
organ or across different organ systems then this was an indication to stop.  
Red (severe) symptoms if present singly was an immediate indication to stop. 
The challenge could also be stopped at the investigator’s discretion if they believed that 
continuing the challenge would place the participant at risk or also if the participant did not 
wish to continue.   
Any extra symptoms which did not form part of the stopping criteria were recorded on the 
case record form as ‘Free text symptoms’.  
Exercise challenge  
On the challenge day the participant was admitted to the ward on the day of the exercise 
challenge. Participants were given each dose followed 5 minutes later by a 10 minute bout of 
exercise at 85% VO2 max on a static bike. Heart rate was measured throughout the challenge 
using an Actiheart monitor to ensure that they achieved their target heart rate. The participant 
was allowed to drink water but not able to eat any food apart from the challenge meal.  
Sleep challenge 
Participants received a peanut challenge after being sleep deprived. Participants were 
admitted to the research ward on the night before the food challenge. They were allowed to 
sleep for a maximum of 2 hours during the night. All participants were woken by 3am 
regardless of whether they have slept and were kept awake by nursing staff who kept a log of 
the participant’s activities every 15 minutes until the morning peanut challenge. Dosing was 
conducted in the same manner as the baseline challenge. Tiredness was assessed objectively 
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using the Psychomotor Vigilance Task200 and subjectively using the Karolinska Sleepiness 
Scale.201  (Appendix 2) 
No intervention challenge 
This was conducted under the same conditions as the baseline challenge.  
Ethics committee approval 
This study was approved by the NRES committee East of England. Informed, written consent 
was obtained from all participants prior to participation in the study. An Independent Data 
Monitoring Committee consisting of a team of experienced allergists oversaw safety data and 
assessed severe reactions.  RD approval at each site and CRF permissions were obtained.  
Study oversight 
There was a Trial Management Group (TMG) comprising principal investigators from each 
site, clinical fellows, nursing staff and a trial statistician who met on a fortnightly basis 
during study set up and then monthly thereafter to review project progress and safety.    
An Independent Data Monitoring Committee (IDMC) consisting of clinicians and 
statisticians not directly involved in the study reviewed safety data and severe events reported 
by the Principal Investigators.  
The Trial Steering Committee (TSC) consisted of an independent chair, representatives from 
patient organisations, a clinician with experience of undertaking oral food challenges and the 
Food Standards Agency. The TSC had overall responsibility for the scientific strategy and 
direction of the study as well as ensuring the study achieved its aims in a timely manner. 
Funding 





PILOT STUDY AND ALTERATION TO INITIAL STUDY DESIGN 
The pilot process which led to the finalisation of the above study protocols is detailed below. 
Pilot Baseline Challenges 
Double blind placebo-controlled food challenge (DBPCFC) is the gold standard investigation 
for diagnosing food allergy and for establishing the allergen threshold of reactivity. Assessing 
symptoms elicited during challenge and deciding whether or not they are objective is a 
critical part of a threshold finding study and variability in interpretation can adversely affect 
threshold estimation. Adopting a standard way of assessing symptoms including how to 
classify subjective or objective symptoms, allows comparison of outcome during DBPCFC.  
Moreover the scoring and stopping criteria designed for conducting food challenges can 
affect the threshold estimate of a study. Therefore the parameters for stopping and declaring a 
challenge should be prespecified in challenge protocols. The only published practice 
parameter on oral food challenge in existence at the commencement of the study was the 
PRACTALL consensus report for food challenge which had received broad consensus from 
US and European allergists hence the decision to follow these criteria.82 
Aims of the pilot baseline challenge study 
 To determine whether the PRACTALL challenge stopping criteria which had been 
designed for use in other studies could be safely applied to the TRACE study 
Methods 
4 peanut-allergic participants underwent a pilot baseline challenge to peanut (active arm only) 
using the method described above (Main Study Method: Baseline Challenge). Challenges 
were scored using the PRACTALL consensus criteria. This scoring system indicates 
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symptoms and signs that may merit caution and aims to inform the investigator whether a 
dose should be delayed, repeated or that the challenge should be stopped. Symptoms and 
signs are scored using a traffic light warning system. 
Results 
4 peanut allergic participants, 3 female and 1 male, age range 18-41 underwent challenges. 3 
participants developed objective symptoms based on the challenge stopping criteria which 
allowed their reaction threshold to be defined (Table 4). One participant developed subjective 
symptoms only but we took the decision to stop the challenge as this was the first one we had 
conducted. It was decided for safety reasons that further refinement of the criteria was 
needed. We felt that many of the original criteria were based on symptoms experienced by 
children during oral food challenge and required alteration to make them applicable to adults. 
Furthermore, some participants, during the pilot baseline challenges were experiencing a 
rapid evolution of respiratory symptoms. By adding further refinement to airway symptoms 
we felt that we could detect warning signs, prevent rapid progression to severe symptoms and 
thus enhance safety. In addition we incorporated the peak expiratory flow rate as a functional 
measurement. Gastrointestinal symptoms were also further defined in terms of their 
persistence. Based on the pilot challenge reactions the weighting of various symptoms was 
changed. In the original PRACTALL consensus criteria it was suggested that challenges 
could be stopped on the basis of green (mild) symptoms present for greater than 120 minutes. 
We regarded these as subjective symptoms and stopping a challenge for subjective symptoms 
increased the risk of a false positive test. Therefore we decided to base a threshold estimate 
on objective symptoms (yellow or red symptoms as previously described) only.   
Outcome 
The PRACTALL consensus criteria have been modified for use in this study  
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Pilot Exercise Challenges 
Background 
Anaphylaxis during exercise has been reported to occur during bouts of physical activity of 
varying intensities. This ranges from high intensity activity such as running or jogging to 
even ordinary physical activity such as gardening.137 In a study by Pals et al it was shown that 
small intestinal permeability, assessed by sugar excretion, was increased after exercising at 
80% VO2 max for 60 minutes and not at lower intensities (40 and 60% maximal oxygen 
uptake).136 However it would be impractical to exercise our participants at this intensity for 
the same duration on repeated occasions during a single challenge day. 
Aims of pilot exercise study 
 To determine an acceptable and tolerable intensity and duration of exercise for 
participants during the study 
 Aim to imitate real life exercise  
 Detect any ingestion of food ingestion on exercise capacity (healthy volunteers will 
undergo the exercise protocol with the placebo dessert matrix). 
Pilot exercise method 
8 healthy volunteers of varying levels of fitness undertook a V02 max test to determine their 
maximum exercise capacity as measured by maximum oxygen uptake. ECGs were performed 
on all volunteers prior to exercise. Participants performed varying durations of exercise at 
85% VO2 max to determine tolerability. Exercise was performed initially on a treadmill but 
then latterly on a static bike for reasons outlined in results. In 5/7 healthy volunteers, placebo 
dessert matrix was given 5 minutes prior to each bout of exercise. Following finalisation of 
the protocol, 3 peanut allergic participants underwent a pilot exercise challenge to determine 
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safety. Blood lactate was measured during exercise, an elevated lactate is indicative of a 
normal physiological response to exertion. Dramatic increases in lactate characterise a normal 
response to exercise if a patient exceeds the work rate at which lactate can be removed from 
the blood as quickly as it enters the blood. Serum lactate was measured before and after each 
exercise bout.  
Pilot exercise results 
2 healthy volunteers undertook 8 x 15 minute bouts of exercise at 85% VO2 max on a 
treadmill but this protocol was deemed to be too intense and unacceptable. 1 healthy 
volunteer undertook 8 x 5 minute bouts of exercise at 85% VO2 max (treadmill) but this was 
deemed to be too easy and subjectively did not tire the participant. 4 healthy volunteers 
undertook 8 x 10 minute bouts of exercise at 85% VO2 max (treadmill). One participant had 
to withdraw during the exercise due to a pre-existing knee injury. Otherwise this protocol was 
well tolerated and caused sufficient cardiovascular exertion. Ingestion of the challenge matrix 
did not affect exercise capacity. Due to logistical issues in obtaining a treadmill in the other 
study centre the exercise mode was switched to a static bike. The protocol of 8 x 10 minute 
bouts of 85% VO2 max was piloted on 3 further healthy participants on a static bike. The 
exercise protocol was replicated with good results and a high heart rate was achieved during 
the bouts (Fig 2). Serum lactate was measured before and after each exercise bout and 
demonstrated an increase post exercise compared to pre exercise levels (data not shown).  




Following an initial open baseline challenge with active peanut doses, 3 peanut allergic pilot 
volunteers undertook exercise challenges also with active doses. 2 performed the exercise 
challenge on a treadmill (prior to the change) and one performed the challenge on a static 
bike. 2 participants developed objective symptoms and one participant completed all 8 doses 
without reaction. For the 2 reactive participants there appeared to be an increase in reaction 
severity compared to their baseline challenge (Table 4). Both required treatment with 
adrenaline for severe symptoms which was not needed in their baseline challenges. 
Table 4:  Pilot baseline (n=4|) challenges and pilot exercise (n=3) challenges. 
OP Oropharyngeal pruritus/tingling, PruG Generalised pruritus, ECP Ear canal 
pruritus, Ch subjective chest tightness Na Nausea persistent, AP Abdominal pain 
persistent, Rh Rhinorrhoea (persistent), U Urticaria localised, EryL Erythema 
Localised, ThT throat tightness, E Emesis, ERep Repeated emesis EryG Generalised 
erythema, Co Dry cough persistent, Wh Wheeze audible Al C altered consciousness 
OAH Oral antihistamines OP Oral prednisolone IVAH IV antihistamines IVHy IV 
hydrocortisone Adr Adrenaline Salb salbutamol 
NB: Participant 0108 completed baseline challenge only and did not undergo exercise 
challenge. 
Outcome 
 It was decided that the optimal regime was for participants to undertake 8 x 10 minute 
bouts of exercise at an intensity of 85% VO2 max during the exercise challenge days. 
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Aims of pilot sleep deprivation study 
-To determine an acceptable and tolerable amount of sleep restriction for participants. 
-To aim to imitate sleep restriction in the community. 
-To pilot the use of objective and subjective measures of tiredness namely the Psychomotor 
Vigilance Task and the Karolinska Sleepiness Scale. 
Pilot sleep deprivation method 
3 peanut allergic participants underwent a peanut challenge with active doses following 
restricted sleep of 3 hours. 
Pilot sleep deprivation results 
3 peanut allergic participants, 1 male and 2 female, age range 18-28 completed the pilot sleep 
deprivation challenges. All participants developed objective symptoms during challenge and 
reaction thresholds could be established (Table 5). 
Table 5: Pilot sleep deprivation challenges 
OP Oropharyngeal pruritus/tingling, PruG Generalised pruritus, ECP Ear canal pruritus, Ch 
subjective chest tightness Na Nausea persistent, AP Abdominal pain persistent, Rh 
Rhinorrhoea (persistent), U Urticaria localised, EryL Erythema Localised, ThT throat 
tightness, E Emesis, ERep Repeated emesis EryG Generalised erythema, Co Dry cough 
persistent, Wh Wheeze audible Al C altered consciousness 
OAH Oral antihistamines OP Oral prednisolone IVAH IV antihistamines IVHy IV 












0115 5 (30mg) ECP, OP, Na, AP, E (1) IVAH, IVHy 
0121 5 (30mg) OP, Co, Al C IV AH, IV Hy, 
Salb, Adr 
0126 6 (100mg) OP, ThT, EryL, U IV AH, OPr 
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However 2/3 peanut allergic participants subjectively reported that they did not feel tired 
following the sleep restriction of 3 hours. 1 participant did subjectively report tiredness. 
Based on these pilot findings it was decided to further restrict the amount of sleep in the 
protocol to ensure adequate fatigue and to use formal objective and subjective measurements 
of tiredness (the Karolinska Sleepiness Scale (Appendix) and Psychomotor Vigilance Task).  
Therefore 3 further healthy volunteers were asked to pilot the protocol with 2 hours of sleep 
restriction. This amount achieved adequate levels of tiredness (Table 6) and was tolerated 
well. 
Table 6: Psychomotor vigilance task results for 3 pilot healthy volunteer sleep 
participants. A reaction time of greater than 300 milliseconds is classed as an impaired 
response time.   







PRE sleep deprivation 278 1 1 
POST sleep 
deprivation 
357 0 2 
Outcome 
 Sleep restriction to 2 hours was decided upon for the final protocol.  
Alteration to main study design: Placebo challenges 
The intention of the original study design was to have a placebo arm for every active arm. 
The rationale of including placebos was to eliminate investigator or participant influence on 
the challenge outcome at every stage and also to validate the symptoms and signs which 
occur on active days.  
However there were delays in starting the baseline challenges due to appointment of staff, 
obtaining local site permissions and additional piloting work, described above, for protocol 
refinement. It became clear that keeping to the original study design would result in challenge 
burden exceeding site capacity and the study not being completed by the funder deadline. 
Therefore as a study team we had to propose a study redesign to reduce the challenge burden 
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whilst maintaining scientific validity and participant safety. Various proposals were explored 
including eliminating an intervention (either sleep or exercise), removing placebos from some 
challenges, interspersing placebo doses within the active doses, removing ‘predictable’ 
placebos i.e. ones occurring on day 2 of the challenge pair or removing placebos from 
interventional challenges. We performed a sensitivity analysis looking at data from 29 
baseline challenge pairs (placebo and active day) and 9 interventional challenge pairs 
(placebo and active) and found that there was no difference in threshold with the challenge 
method applied. The prediction of the researcher as to whether each day was placebo or 
active, based on the symptoms encountered was correct in every case. We also examined the 
symptoms and signs that occurred on placebo days. In every case these were minor and 
would not have triggered the challenge to be stopped or scored positive. Furthermore we 
observed that participants who received the active challenge on Day 1 of the challenge pair 
were essentially unblinded and were expecting to have an allergic reaction on Day 2 reducing 
the validity of the placebo arm. 
It was decided that a placebo must be retained for the initial baseline challenge as this is 
essential for correct diagnosis in peanut allergy. However the decision was taken to remove 
placebos from the intervention arms. This also meant that each participant only had to attend 
5 instead of 8 challenge appointments which also helped to improve booking challenges, 
study retention and reducing drop outs. 
With no placebos, the participants would attend each interventional challenge knowing they 
would receive peanut. It could be argued that this would change their expectation and 
somehow alter their reporting of symptoms, compared to the original design. This might be 
true if subjective symptoms were being used to determine challenge outcome (e.g. itching or 
discomfort), however the stopping criteria used on active days required three concurrent 
‘yellow’ symptoms or signs to be present. It is unrealistic to believe that such objective 
symptoms could be induced by a placebo effect, and our analysis indicated it is very unlikely 
to occur. A further criticism might be that comparing the original DBPCFC with later non-
placebo interventional challenges would not be comparing ‘like with like’. However, this is 
controlled for in the study design as the main outcome is the difference between (baseline-
repeat baseline) and (baseline-intervention). Both the repeat baseline and intervention 





How do reaction thresholds vary as a result of sleep deprivation and 
exercise?  
Introduction 
Currently there are efforts by scientists, clinicians and food policy makers to model and 
manage allergen thresholds to help the food industry, and ultimately allow patients to make 
better informed and safe food choices. There is a lack of standardised international guidance 
on managing levels of unintentional contamination of food with allergens. Partly, this is due 
to a lack of knowledge about the exact level of allergen contamination which poses a problem 
to the food-allergic population. Several clinical studies have examined thresholds of reaction 
to allergen in food-allergic participants. From these, attempts have been made to model a 
population threshold. Peanut, probably due to its ubiquity and also its propensity to cause 
severe and fatal allergic reactions, has been the most widely studied. Taylor et al showed that 
peanut allergen elicitation thresholds can range from 0.5mg to 10000mg of whole peanut 
between peanut-allergic individuals.98 There is clearly a wide intrinsic variation in patients’ 
thresholds. However a possible factor influencing this wide apparent variation is that the 
contributory studies used to derive these estimates have varied in dosing regime, dosing 
interval, study entry criteria and food matrix.      
Although it is widely known that thresholds vary across individuals in a population, little data 
exists on the variation of thresholds within allergic individuals over time. One study by 
Moneret-Vautrin suggests up to a 10-fold change in threshold with successive challenges 
(personal communication: Professor DA Moneret Vautrin and the North American and 
European branches of International Life Sciences Institute), while another suggests a small 
negative change in threshold of 0.81 fold in a control group of participants in an 
immunotherapy study who undertook a peanut challenge pre and post intervention (personal 
communication Dr Andrew Clark, STOP 2 study).  It has been suggested that intra-individual 
variation may occur as a result of both host factors (associated atopic or comorbid conditions, 
age, medications) and co-factors (exercise, sleep deprivation, alcohol, infection and non-
steroidal anti-inflammatory drugs). Indeed extrinsic factors, also referred to as cofactors, have 
been identified in 30% of anaphylactic reactions in adults.202 Furthermore the influence of co-
factors in causing reactions during immunotherapy to previously tolerated doses of allergen 
64 
 
has been well described. In a single study of peanut immunotherapy, six out of 20 individuals 
suffered from a clinical loss of tolerance if they took their maintenance doses when sleep 
deprived (for example <6 hours sleep overnight).143  It is important that variation accounted 
for by co-factors is taken into account when undertaking statistical modelling of the 
population threshold. For this study two co-factors exercise and sleep deprivation were 
chosen as these were two, easily reproducible co-factors. Exercise has already been shown to 
have an effect in the clinically distinct condition Food Dependent Exercise Induced 
Anaphylaxis as discussed earlier and even light exercise such as walking or housework 
activities have been shown to be associated with allergic reactions. Sleep deprivation was 
chosen as there are no prospective data on how this modulates an allergic response and 
studies suggest that usual sleep duration has decreased substantially over time with an 
estimated 25-30% of the United States population sleeping 6 hours or less per night, an 
amount associated with significant health problems.203 Other factors were considered such as 
infection, alcohol and nonsteroidal anti-inflammatory drugs. Infection was rejected on the 
basis that although it would be apparent symptomatically it would be difficult to quickly 
confirm this via microbiological and virological investigation. There were also concerns that 
infection may be a very high risk co-factor given the concomitant effect of exacerbating 
asthma in asthmatics.   With regard to alcohol it would be difficult determine the amount to 
be administered to achieve the same physiological effect across individuals in respect to 
different tolerance levels amongst participants. Furthermore there was a concern that 
participants may be less compliant with the study protocol and may be less able to articulate 
their symptoms in an inebriated state hence raising a safety concern. Further the TRACE 
study is part of iFAAM, a food allergy consortium and other research groups are looking at 
other factors such as the effect of proton pump inhibitor use and the effect of the allergen 
matrix and allergen processing on allergic reactions. The aim is to eventually combine the 
data from these studies hence the rationale for not choosing these other factors to examine. 
Chapter Hypothesis 
Co-factors impact peanut allergy reactions by lowering reactivity thresholds.  
Chapter aims 
1. To establish a dose-distribution curve for peanut threshold in a UK peanut allergic 
population of adults. 
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2. Model the variability of challenge thresholds and severity over time within individuals as a 
result of repeat challenges. 
3. Examine how co-factors (exercise and stress through sleep deprivation) shift the dose 





The full method has been described in detail in Chapter 2. The following is an abbreviated 
method. 
Recruitment  
Between 2013-2016 participants were recruited to the study hosted in the NIHR/Welcome 
Trust Clinical Research Facility at Addenbrooke’s Hospital, Cambridge. Participants were 
recruited through advertisements in local media and also from general allergy clinic.  
Screening 
An initial screening visit was undertaken to elicit a history of peanut allergy (a previous 
systemic reaction following ingestion of peanut) and evidence of sensitisation to peanut 
through skin prick tests and serum specific IgE to whole peanut and its components 
Arah1,2,3, 8 and 9 (ImmunoCap Thermofisher). The presence of other comorbidities 
including atopic diseases and their control was assessed.   In preparation for the exercise 
challenge, a VO2 max test was performed to determine the participant’s maximum exercise 
capacity. Participants were provided with sufficient time to consider written and verbal 
information related to the study. Written informed consent was obtained from participants 
before any study procedures were undertaken. Full study inclusion and exclusion criteria are 
shown in detail in Chapter 2. 
Baseline challenge 
Eligible participants were invited back for an initial baseline double-blind placebo-controlled 
food challenge (DBPCFC).  On the day of the challenge a preliminary examination to assess 
fitness for the challenge was performed including spirometry, POEM score, asthma control 
test and vital signs. As per the PRACTALL consensus report, the challenge was only allowed 
to proceed if participants were considered to be stable regarding other atopic conditions. 
Treatment with antihistamines was withheld for 3-5 days prior to challenge. For safety, an 
intravenous line was inserted prior to challenge in order that treatment could be rapidly 
administered if required. 
The DBPCFCs were undertaken as previously described, ingesting increasing doses of food 
matrix either alone or containing allergen until objective symptoms of an allergic reaction 
were seen. The dosing regimen is shown in Table 7. The starting dose was 3 micrograms of 
67 
 
peanut protein corresponding to 12 micrograms of whole peanut.  Peanut allergy was 
confirmed by a positive outcome (objective symptoms) during DBPCFC. The dose at which 
the participant developed objective symptoms was recorded as their threshold. Participants 
with confirmed peanut allergy were then randomised to receive 3 further active peanut 
challenges (sleep, exercise and no intervention) in a random order. 
Table 7: Study dosing regimen 




3µg 30µg 300µg 3mg 30mg 100mg 300mg 1g 
 
Exercise challenge 
Participants were administered each dose 5 minutes after completing a 10 minute bout of 
exercise at 85% VO2 max. 
Sleep challenge 
Participants underwent a night of restricted sleep (2 hours) and received the peanut challenge 
the following morning.     
No intervention challenge 
This was carried out in the same manner as the initial baseline challenge but with the active 
arm only. 
Statistical analysis 
The primary endpoint was the cumulative peanut threshold dose in mg of protein after each 
DBPCFC.  Experimentally induced individual thresholds lie between two boundaries: the no 
observed adverse effect level (NOAEL) the highest dose observed not to produce any adverse 
effect and the lowest observed adverse effect level (LOAEL) which is the lowest dose that is 
observed to produce an adverse effect. Operationally the LOAEL is also referred to as the 
minimum eliciting dose or MED.204 In this study the LOAEL was the lowest cumulative dose 
of peanut protein which caused a reaction. 
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The primary endpoint of difference in the LOAEL was defined as the natural log of LOAEL 
at challenge minus the natural log of LOAEL at baseline.  
=Challenge log LOAEL-baseline log LOAEL 
The primary outcome was summarised by challenge type and challenge timing (median, 
IQR). The difference in threshold (logged) LOAEL between the non-intervention challenge 
and each intervention challenge (exercise and sleep deprivation) was estimated using a linear 
mixed effects model. Fixed effects included the challenge type (exercise, sleep deprivation, 
with non-intervention as reference), age, sex, timing of challenge, baseline threshold 
(logged), presence of asthma, centre and baseline Arah2. The primary analysis estimated the 
effect of type of challenge, against non-intervention, from the model along with confidence 
interval and p-value for whether the difference in log-LOAEL was significant.  
Sample size estimation 
As there were no published data on intra-individual variation in thresholds over time from 
repeat challenges different scenarios were considered with power assessed by simulation. In 
addition an example from the development of hypoallergenic infant formula in 1999 was 
used.205 It was suggested that low dose challenges should be conducted using a standardised 
protocol on a total of 29 subjects with a specific food allergy and if a level could be identified 
which did not elicit a reaction in any of the 29 subjects then statistically it could be inferred 
that there is 95% confidence that less than 10% of the allergic population would react to this 
amount of allergenic protein or less.206 Food challenges based on these numbers have become 
standard. However the sample size should also be sufficient to fit threshold distributions 
based on both the NOAEL and LOAEL. Klein Entink et al conducted a simulation study to 
evaluate the effects of sample size and dosing regimens on the accuracy of the threshold 
distribution curve (described below)207 and showed that the bias and accuracy of estimation 
improved the most with each step in sample size from n=20 to n=60. Therefore for the 
establishing a population threshold curve, a sample size of 60 was chosen. 
Population threshold curve 
A secondary objective of the study was to derive a population curve for the different 
challenge types (no intervention, exercise and sleep deprivation). 
Performing challenges in all food allergic individuals in the general population is impossible, 
thus statistical models have been developed to construct a dose distribution curve, as 
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described by Crevel et al,208 together with parametric interval censored survival analysis used 
by Taylor et al for a specific allergen for individuals in a sample population.98  From these 
curves it is possible to derive an ‘eliciting dose’ and estimate the dose likely to elicit reactions 
in a certain proportion of an allergic study population. For example, an ED10 is the dose 
which elicits a reaction in 10% of the allergic population. 
Interval censored survival analysis (ICSA) is a statistical method which is used when there is 
uncertainty as to the exact time that units ‘failed’ within an interval. This methodology is 
appropriate when considering allergen threshold doses as the exact dose that provokes a 
reaction is not known but is known to fall into a particular interval i.e. between two doses.  
Interval censored survival analysis permits the use of data points from first dose reactors 
(classed as left censored) and those failing to respond to the uppermost dose (right censored). 
If the participant had subjective symptoms only to the uppermost dose then the last dose was 
set as the NOAEL and the LOAEL was set to infinity. ICSA was carried out using the 
Survreg function in the statistical package, R.209  
Data were analysed as cumulative doses and modelled using 3 distributions log-normal, log-
logistic or Weibull as no biological or mathematical reason exists to favour one over the 
other. This model was used to find the dose predicted to provoke reactions in different 
proportions of the peanut allergic population (ED1, ED5, ED10, ED50, ED80, and ED95). 
However the reference dose is not a simple mean of the chosen EDs from each distribution 
but requires expert judgement. When selecting the recommended reference dose, weight is 
given to the best statistical fit for each parametric model (as determined by log likelihood), as 
well as visual examination of the fitted probability dose distribution curves to the actual 
individual threshold data within the low dose zone which are the most important doses with 
regards to public health protection.  
Once ED estimates were calculated, confidence intervals for these levels were calculated by 
taking the 2.5th and 97.5th percentiles of the bootstrap distribution of the EDs.   
 Dose distribution curves together with eliciting doses were modelled for each challenge type: 






Study recruitment took place between May 2013 and September 2016. There were 232 
potentially eligible website registrants and 35 potentially suitable recruits from the Allergy 
clinic at Addenbrooke’s Hospital. Ninety seven participants were screened. Out of the 97 
screened participants, 75 (77%) were eligible to attend for baseline challenge. Sixty 
participants undertook baseline challenges. Positive DBPCFC confirmed the diagnosis of 
peanut allergy in 57/60 subjects (95%), 3/60 participants reacted with only subjective 
symptoms during the entire challenge. Three further participants had to be excluded 
following baseline challenge, 2 participants suffered severe reactions at baseline and were 
therefore excluded on safety grounds and 1 participant because she disliked the taste of the 
dessert matrix. Fifty four participants were randomised to attend for the intervention 
challenges. In total 41 participants completed the full study (all 5 challenges) and are referred 
to as the per-protocol study population. Several more participants attended for at least 1 
intervention and this group is referred to as the full analysis population (No intervention 
challenge, n=44, Exercise n=43, Sleep Deprivation n=43). To maximise the data available the 
analyses in this chapter are based on the full analysis population. The per-protocol results are 
included in Appendix 3 and are reflective of the full analysis population results.   
For the second part of the analysis which involves the production of the threshold distribution 
curves and the derivation of the population thresholds (ED estimates), the extended analysis 
population was used. This refers to all participants who underwent a baseline challenge and 
includes all the participants who were excluded at baseline and also right censored 
individuals.   For comparison of the population threshold curves for the intervention 
challenges, the full analysis population was used. The characteristics of the extended analysis 





Table 8: Baseline clinical characteristics of extended analysis population (n=60). Values 
are presented as medians where shown. 
 
Establishing NOAEL and LOAEL 
Baseline challenges 
For the extended analysis population, no objective symptoms occurred on the first dose of the 
challenges thus no participants were left censored. The lowest median cumulative LOAEL of 
peanut protein for objective symptoms was 133.333mg (IQR 33.333-433.333mg). The 
median cumulative NOAEL was 33.333mg. Three participants experienced only subjective 
symptoms to the last dose. These participants were therefore right censored. One of these 
participants proceeded to open challenge with whole peanut in a food challenge clinic and 
was reactive at a dose of 16 whole peanuts, equal to 2400mg peanut protein (higher than the 
upper limit of the study dose range (1433.333 mg)). A paired T test was used to compare the 
means of the baseline challenge (230.2mg) and No Intervention challenge (202.4mg) and 
Clinical characteristic Values 
Age (y) 21 
Female sex (%) 50 
Asthma (%) 52 
Rhinitis (%) 82 
Eczema (%) 33 
Age of onset of allergy (y) 3 
Number of previous reactions 4 
Adrenaline use during most severe historical 
reaction (%) 
25 
Wheeze during most severe historical 
reaction (%) 
23 
Peanut SPT wheal diameter (mm) 10 
Peanut specific IgE (kUA/L) 11.9 
Arah2 specific IgE (kUA/L) 9.14 
72 
 
showed no statistical difference between the two means (p value 0.22). For the full analysis 
population the median cumulative LOAEL was 133.333mg (IQR 33.333-433.333mg).  
Correlation of threshold dose with participant characteristics 
There was a significant correlation of the age of onset of peanut allergy with threshold dose 
with an older age of onset being associated with a higher threshold dose. A significant 
correlation was also demonstrated with the severity grade of the most severe historical 
reaction and threshold dose. There was a significant inverse collection of the markers for 
sensitisation (peanut specific IgE and Arah2 specific IgE) with the threshold dose at baseline 
challenge (Table 9) but peanut SPT wheal size could not be correlated. The number of 
adverse reactions to peanut and age at study entry could not be correlated to threshold dose at 
baseline challenge.    
Table 9: Relationship between threshold dose and clinical characteristics (n=57, p<0.05)  
Comparison Correlation coefficient Significance 
Age at study entry   0.15 0.27 
Age of onset of peanut 
allergy 
 0.37 0.007 
Severity grade of most 
severe reaction to peanut 
 0.29 0.03 
Number of adverse reactions 
to peanut 
-0.12 0.39 
Skin prick test to peanut 
(wheal in mm) 
-0.09 0.52 
Peanut specific IgE -0.28 0.03 
Arah2 specific IgE -0.30 0.02 
 
The effect of sleep deprivation and exercise on challenge threshold 
The median cumulative threshold dose reached for the no intervention challenge was 
133.333mg (IQR 33.3-433.333). In both exercise and sleep deprivation challenges the median 
cumulative threshold dose reached was lower: exercise 63.333mg (IQR 33.333-133.333mg) 
and sleep, 33.333mg (IQR 33.333-133.333) respectively compared to the dose reached during 
the no intervention challenge. Figure Plots are provided on the dose scale (Figure 3a) and log 
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dose scale (Figure 3b). Using a linear mixed effects model, a significant effect of exercise 
and sleep deprivation on the change in log-threshold from the no intervention challenge was 
observed with a more pronounced effect with sleep deprivation (Table 10). The estimated 
changes in log-threshold for exercise and sleep (95% confidence intervals) were -0.311 (-
0.636,0.013; p=0.060) and -0.755 (-1.079,-0.43; p=0.000) respectively. Random effects for 
each participant were included in the model: challenge type (exercise, sleep-deprivation), age, 
sex, timing of the challenge, baseline log-threshold, presence of asthma and baseline Arah2. 
The only significant effect was of visit number. 
 
Table 10: Estimated effect, 95% confidence interval and p-value for each term in the 


















Variables Estimate CI pvalue 
Baseline 
LOAEL 
-0.001 (-0.001,0) 0.136 
Non-
intervention 
NA (NA,NA) NA 
Exercise -0.274 (-0.59,0.041) 0.088 
Sleep -0.703 (-1.024,-0.383) 0.000 
Visit1 NA (NA,NA) NA 
Visit2 -0.133 (-0.448,0.182) 0.403 
Visit3 -0.448 (-0.768,-0.127) 0.007 
No Asthma 
at baseline 
NA (NA,NA) NA 
Asthma at 
baseline 
-0.341 (-0.878,0.196) 0.206 
Arah2 0.005 (-0.005,0.014) 0.303 
Female NA (NA,NA) NA 
Male 0.041 (-0.516,0.598) 0.882 
Age -0.016 (-0.055,0.023) 0.419 
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Figure 3(a): Dose reached (mg peanut protein) by challenge for full analysis population 
 
 





The effect of visit number on challenge threshold 
The cumulative threshold dose reached by visit number is shown in Figure 4a and 4b. There 
is a decreasing trend in the median threshold over time with a significant decrease in 
threshold at Visit 5 (final intervention challenge) compared to Visit 3 (first intervention 
challenge), Visit 5 median 33.333mg (IQR 33.333mg-133.333mg) compared to Visit 3 
median 133mg (IQR 33.333mg-133.333mg). 
 
Figure 4(a): Plot of dose reached (mg protein) by visit for full analysis population.  The 
three intervention challenges (sleep, exercise and no intervention) are referred to as 








Figure 4(b): Log (dose reached) by visit for full analysis population. The three 
intervention challenges (sleep, exercise and no intervention) are referred to as Visit 3,4 
and 5.   
 
Population threshold curves 
Log-normal, log-logistic and Weibull probabilistic distribution models were fitted to the data 
and no significant differences were found between the three models. Using the Akaike 
information criterion (AIC), a value was calculated for each model, a lower AIC suggesting a 
relatively better fit between candidate models. The log-normal model, which fitted the data 
best was used. Curves were derived for each challenge type and are shown. Figure 5 displays 
the threshold distribution curve for the extended analysis population which consisted of all 
individuals who underwent a baseline challenge and included non-randomised individuals. 
Threshold distribution curves for the Full Analysis Population are shown in Figure 6 and 
included all individuals who underwent at least 1 baseline challenge. Cumulative EDs were 
extrapolated from the models and are listed below. In the Full-Analysis set (Table 11), the 
ED10 and ED5 for baseline challenges estimated using the log-normal distribution model for 
all peanut allergic participants was 12.2mg peanut protein (95% CI 7,20.8) and 7.5mg peanut 
protein ( CI 4.1, 13.2). The ED10 and ED5s in the extended analysis set (Table 12) which 
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includes the right censored individuals were similar, 12.3mg peanut protein (CI 7.3,20.4) and 
7.6mg peanut protein ( CI 4.3, 9.7) respectively.  
 
The effect of co-factors (exercise and sleep deprivation) on eliciting doses 
The eliciting doses are shown in Table 11. Using the ED10 as an example, compared to the 
No Intervention challenge (15.5mg 95% CI 10, 23.7) the ED10s for exercise (6.3 mg 95% CI 
3.4,11) and sleep deprivation (3.2mg 95% CI 1.7,5.8) were lower. The ED10 for exercise was 
nearly 2.5 times lower and sleep deprivation 5 times lower.  
 
Figure 5: Dose reaction curve for baseline challenge, extended full analysis set. The 








Figure 6(a): Dose reaction curve for non-intervention challenge, full analysis 
population. 
 





Figure 6(c): Dose reaction curve for exercise challenge for full analysis population. 
 
 





challenge Sleep challenge 
Exercise 
challenge 
ED1 3 (1.5,5.6) 7.4 (4.4,12.3) 0.7 (0.3,1.4) 1.5 (0.7,2.7) 
ED5 7.5 (4.1,13.2) 11.8 (7.3,18.6) 1.9 (0.9,3.5) 3.8 (2,6.8) 
ED10 12.2 (7,20.8) 15.5 (10,23.7) 3.2 (1.7,5.8) 6.3 (3.4,11) 
ED50 66.4 (44.3,99.3) 49.1 (34.5,69.6) 22.5 (13.4,37.5) 39.1 (24.5,62) 
ED80 188.6 
(123.8,286.9) 



















ED1 3.1 (1.6,5.6) 
ED5 7.6 (4.3,13) 
ED10 12.3 (7.3,20.4) 











This study provides the first systematically generated threshold data for a U.K peanut allergic 
adult population and is the first study to demonstrate that co-factors such as sleep deprivation 
and exercise lower reactivity thresholds. Furthermore, an inverse correlation between 
eliciting dose and sensitisation markers such as specific IgE to peanut and Arah2 is shown as 
well as a positive relationship between the number of previous accidental exposures and 
severity of previous reaction.  
By using a dosing regimen with a low starting dose of 3 micrograms, a NOAEL was 
confidently established as there were no first (left censored) dose reactors. In addition, by 
using modified symptom severity grading criteria true thresholds based on objective 
symptoms were identified. Previous studies have often based threshold estimates on 
subjective symptoms which could lead to an underestimation of the true threshold dose.119  
Three participants were able to tolerate the top dose (right censored) however this was a 
minority of subjects (5%). These three right censored individuals did not affect median 
cumulative threshold dose of peanut protein which was the same for the extended analysis 
population (including these individuals) as for the full analysis population (excluding these 
individuals).  The median cumulative threshold of peanut protein in our sample was 133mg 
which is approximately equivalent to the amount of protein contained in 1 whole peanut seed 
(150-200mg).   
In this study, a fall in the median cumulative threshold dose for peanut occurred when 
participants were subjected to exercise and sleep deprivation compared to receiving a peanut 
challenge with no intervention applied. These data support the hypothesis that co-factors 
augment anaphylaxis. Reports from the literature suggest that exercise as a cofactor plays a 
role in 0-15.9% of anaphylaxis cases.210–212 However this estimate is based on retrospective 
analyses of implicating factors in anaphylactic reactions. Previously it has been shown in a 
clinically distinct condition, Food Dependent Exercise Induced Anaphylaxis that exercise can 
act as an augmentation factor in patients who can otherwise tolerate wheat containing 
products when given alone.213 However the effect of exercise in patients who have 
established allergy and cannot tolerate the allergen under any circumstance has not previously 
been shown. It is possible that exercise exerts its effect through under-perfusion of the gut 
82 
 
resulting in a relative ischaemia with resultant damage to tight junction integrity. This may 
lead to increased permeability of the gut to food allergens.137  
Sleep deprivation resulted in a more pronounced lowering of the reactivity threshold 
compared to exercise. The effect of sleep deprivation, in this case used as a proxy for stress, 
has never prospectively been studied in allergic reactions. As mentioned previously, it has 
been noted in immunotherapy studies that a loss of tolerance to peanut can occur in the 
maintenance phase when subjects consume peanut doses whilst tired or stressed. The 
underlying mechanism may also due to enhanced gastrointestinal permeability.  It has been 
shown in animal models of inflammatory bowel disease that stress results in enhanced 
intestinal permeability.214 Both acute and chronic stress have been shown to increase ion and 
water secretion and intestinal permeability in the jejunum and colon of laboratory animals.215 
These changes were associated with a significant increase in the permeability of the 
epithelium to macromolecules. It is well known that under stressful circumstances such as 
acute sleep loss, corticotrophin releasing factor (CrF) is released signalling the first step in 
the activation of the HPA. This hormone has potent effects on the gut via modulation of 
inflammation, increase in gut permeability and modulation of gut motility.216 The translation 
of stress signals to gut mast cells may also play a pivotal role. Mast cells have surface 
receptors for CrF which may be an important indication of the link between stress and these 
cells. Mast cells in the GI tract serve as end effectors of the brain-gut-axis (BGA). When the 
brain gut axis is activated mast cells release a wide range of mediators including mast cell 
tryptase, histamine, heparin and PAF.217 Tryptase can activate PAR2 receptors on epithelial 
cells resulting in modulation of tight junction proteins and increases in permeability through 
paracellular pathways in the intestinal epithelium.218 PAR2 receptors have also been found on 
mast cells, thus activation of PAR2 can propagate the release of proinflammatory mediators 
from nerve endings, potentiating mast cell degranulation and creating a positive feedback 
loop.219 Stress did not affect gut permeability in MC-deficient rats216 supporting the critical 







Figure 7: The effect of stress on mucosal mast cells and intestinal permeability 
  
 
There is evidence of an effect on threshold with an increasing number of visits. A significant 
lowering of threshold in the final intervention visit compared to the first intervention visit 
was seen.   Indeed in a study by Wainstein et al where follow up oral food challenges were 
performed in peanut allergic children who had been challenged at 35.5 (mean) months earlier, 
a decrease in threshold was noted in 10/13 patients, probably reflecting a high rate of natural 
resolution in their cohort of patients.220 However we did note that there was some 
reproducibility in threshold between the baseline challenge (median cumulative threshold 
dose 133mg peanut protein) compared to the no intervention challenge (median cumulative 
threshold dose 133mg peanut protein) even accounting for the fact that the baseline challenge 
was placebo controlled and the no intervention was not. Knulst et al have also reported that 
there is reasonable inter-challenge consistency when people have a second identical challenge 
1-2 years after their first challenge.221 However Glaumann et al found no threshold 
reproducibility in children who received 2 successive peanut challenges.126 The relationship 
with reaction severity over time will be discussed in the next chapter. Although the lowering 
of threshold dose over time may be a true phenomenon it is possible that the study design 
may have exerted some effect. It is possible that the participant learns their reaction over time 
and anticipates the development of symptoms. Similarly the investigator may act in a more 
cautious way with recall of the participant’s previous reaction. However the study was 
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designed to minimise this bias by ensuring that the participant was deemed to have reached 
their reaction threshold with only the appearance of clear objective symptoms. 
The relationship between the degree of sensitisation and threshold has previously been 
studied. In our study, a higher peanut and Arah2 specific IgE level correlated with a lower 
elicitation threshold. A correlation between skin prick test wheal and threshold dose could not 
be demonstrated. This inverse correlation has been noted in paediatric studies101 and more 
recently in an adult population.222 Other studies, however, have failed to show such a 
correlation perhaps due to differences in the recruited population.121 A relationship between 
the severity grade of the most severe historical reaction and eliciting dose has also been 
identified in our study i.e. participants who had suffered more severe reactions tended to have 
a higher eliciting dose at challenge. This is directly in contrast to Blumchen et al who showed 
that patients who had more severe symptoms during their worst accidental reaction had lower 
eliciting doses at challenge.101 The present study is the first to demonstrate a correlation 
between the age of onset of peanut allergy and eliciting dose, with an older age of onset being 
associated with a higher eliciting dose at challenge. Unlike other studies, an association 
between the number of previous accidental exposures and eliciting dose at challenge could 
not be found.101  
Using the data from individual participant threshold doses we were able to estimate a 
population threshold using dose distribution modelling. Population eliciting thresholds can be 
used by governments and the food industry to help inform policy and precautionary labelling. 
We identified an ED10 of 12.3 mg of peanut protein and ED5 7.6 mg of peanut protein. 
When including the 3 right censored individuals in the analysis there was a minimal effect on 
the dose distribution curve and therefore threshold estimate. In comparison to other studies, 
our ED estimates were similar to Klemans et al who derived ED10 and ED5 threshold 
estimates 10.8mg and 5.08mg peanut protein respectively.124 However our estimates were 
much higher compared to most other studies where the ED10 estimates range from 2.8-
4.42mg.101,102,108,113,115 A possible reason for this difference could be that the majority of 
other studies are based on data from children. It has previously been reported that there are 
differences in the threshold distribution curves of children compared to adults with peanut 
allergy are different with children exhibiting a greater sensitivity than adults. However when 
the ED10 and ED5 estimates were compared for both groups little difference was found.124  
The most likely explanation for our much higher estimate, however, are stopping criteria and 
study population. In our study three definite concurrent objective symptoms were required to 
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stop the challenge and establish the threshold. Eller at al proposed an ED10 of 32.9mg for 
their population of peanut allergic children however it is possible that this was due to a high 
starting dose of 85mg of peanut protein in their DBPCFC.116  
Other studies simply use the appearance of a single objective symptom to establish a 
threshold101,102 or ‘any’ symptom including successive subjective symptoms.124 In terms of 
study population, we included only those with a history of a systemic reaction who 
demonstrated sensitisation to major components (Arah2) whilst excluding those participants 
who were predominantly sensitised to Arah8 or monosensitised to Arah9. Some studies 
included participants who have never ingested peanut and are sensitised only.124 Other studies 
have not stipulated that the history must be of a systemic reaction may therefore have 
included patients with oral allergy syndrome who display a milder phenotype.119 Thus it can 
be seen that directly comparing threshold studies is problematic.  
This study is the first to establish population eliciting doses for peanut when participants are 
subjected to co-factors: sleep deprivation and exercise. Furthermore we are able to relate 
these to an index threshold estimate when no co-factor (No intervention) is applied to 
calculate the magnitude of the effect. This calculation can be utilised by regulatory authorities 
when attempting to calculate an adequate safety net for reference dosing. Currently in 
allergen risk assessment, regulatory authorities have been guided by regulatory toxicology 
practice determining safety or uncertainty factors. Once a threshold dose has been 
established, an uncertainty factor is applied to account for variability. In toxicology studies, 
an uncertainty factor of 10 is applied when extrapolating data from animals or observations 
on human subjects to determine acceptable daily intake. In addition to this, another factor of 
10 is often applied to account for human to human variability giving an overall uncertainty 
factor of 100 providing a very conservative safety net. However by determining the 
magnitude of variability caused by co-factors, this study has enabled an uncertainty factor to 
be better tailored to allergic individuals hopefully establishing a more realistic reference dose. 
This study has also been instructive in terms of advice to patients. When patients are treated 
with peanut immunotherapy in our centre, they are advised to leave an interval of 2 hours 
between ingestion of their peanut doses and subsequent exercise. Furthermore, if the patients 
have suffered a period of sleep loss (for example due to jet lag or sleepovers) they are advised 
to omit the peanut dose. In general allergy clinic, we have also observed that cofactors may 
be implicated in reactions in patients who are allergic to lipid transfer protein. Allergy to lipid 
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transfer protein is widely reported in the Mediterranean population but less so in northern 
European countries such as the UK.63   
A limitation of this study is that our derived eliciting dose estimate is based on a controlled 
clinical study with a selected, well characterised peanut allergic population. Although 
patients were included with a history of anaphylaxis and historical adrenaline use, this study 
population may not be completely representative of the peanut allergic population at large 
and there may be selection bias in that patients who have suffered the most severe reactions 
in the community may be more reluctant to enrol in the study. However this is only a problem 
if one assumes that patients who suffered more severe reactions in the community represent 
the more sensitive (i.e. lower dose reactors) however our data demonstrate the opposite 
effect. Furthermore community exposures to peanut could be larger and more sudden than the 
gradual incrementally increasing allergen exposure in our protocol thus further data is needed 
on individual consumption patterns of high risk foods. Food matrix is known to have an 
effect on threshold dose, with higher fat matrices delaying absorption of allergen and 
ultimately resulting in higher cumulative doses of allergen.40 However an ultimate aim is to 
combine these data with data from other studies using a variety of matrices which will 
average out the differences between the challenge vehicles. In this study partially defatted 
roasted peanut flour was used and previously authorities have questioned whether this differs 
significantly from whole peanut. Allen at al had sufficient data to allow a comparison or ED5 
values for challenges using pulverised peanut and others using partially defatted peanut flour 
and found no significant difference between the two sources.108 Lastly our study population 
were predominantly students and a broader demographic would have been preferable. 
However in fatal anaphylaxis enquiries, deaths tended to be more common in this age 
group223 perhaps due to more risk taking behaviour 224 thus it may be of benefit that the 
model is based on this age group.   
In conclusion, in this study an ED estimate for a well characterised UK adult peanut allergic 
population was identified and for the first time it has been shown that co-factors such as sleep 
deprivation and exercise can lower an allergen reactivity threshold. This study has important 
public health impact through helping food policy makers and the food industry provide 




The effect of repeat challenges on reaction severity and symptoms 
Introduction 
The severity of allergic reactions is influenced by several factors which are both host and 
event specific making allergic reactions unpredictable. This changeability is of concern given 
the propensity of peanut allergy to cause severe and fatal reactions.165 This lack of stability in 
allergic reactions over time can add to anxiety for patients in managing their own allergy and 
uncertainty for clinicians in advising patients. A further practical implication is that oral food 
challenge, the current gold standard of food allergy diagnosis, carries with it inherent risk of 
invoking severe allergic reactions with one study reporting that 28% of these tests resulted in 
systemic and potentially life-threatening reactions.84 There are limited data on the variability 
of reactions from one to the next within individuals particularly with regards to severity. 
Most information comes from patient recollection of symptoms occurring during reactions 
following accidental exposures which are anxiety provoking events and may be subject to 
recall bias. Even less information is available on the change in severity with repeat food 
challenges221 as normally, food challenges are used to establish diagnosis and once an allergy 
is confirmed most patients do not undergo subsequent challenges. Therefore fine grained, 
prospectively collected detail on the evolution of symptoms during challenge has not been 
reported. Knowing this information would be useful to allergic individuals to help guide them 
about potential warning symptoms and the timely administration of treatment. Physicians will 
find the information helpful when advising patients about the potential severity of accidental 
reactions, and of ways to reduce risk. 
 Furthermore there is a lack of consensus about how to grade severity, with several 
different grading systems proposed. It has been reported that this is due to patients not 
presenting with a consistent constellation of allergic symptoms225 as well as debate about 
how much weight to attribute to certain symptoms, for example, comparing gastrointestinal to 
extensive cutaneous symptoms. Attempts have been made to determine clinical and 
laboratory predictors of severity on the basis that if higher risk allergic individuals could be 






Repeated challenges with peanut will result in a change in reaction severity with successive 
visits. 
Symptoms patterns during allergic reactions are unique to individuals but with the application 
of co-factors there may be a change in symptom pattern, severity and frequency.  
Chapter Aims: 
1. To determine whether reaction severity changes over time within an individual as a result 
of repeated challenges  
2. To assess whether co-factors influence reaction severity independently.  
3. To examine whether symptom patterns are similar within individuals at each challenge and 
analyse whether there is commonality in symptom pattern across individuals in our 
population.    
4. To determine whether there are any participant level characteristics such as asthma which 
predict severity of reaction.  
5. To examine the perception of severity from a participant and investigator point of view and 
how these correspond with each other and also with the overall challenge severity score. 
Methods 
Challenge method 
The challenge procedure including symptom stopping criteria has been described previously 
(Chapter 3). 
Challenge treatment 
In order to harmonise the management of positive reactions during challenge a treatment 
algorithm was used. This was delivered in accordance with symptom severity. The 
recommended treatment for red symptoms was with intramuscular adrenaline (0.5ml of 
1:1000 (0.5mg)) administration. If there was a failure of improvement of symptoms, a second 
dose of adrenaline could be administered after 5-10 minutes. If there was still no resolution 
the critical care outreach team was alerted. With red respiratory symptoms, nebulised 
salbutamol (5mg) was co-administered. Nebulised adrenaline (1mg in 5ml 0.9% N. saline) 
was used as an adjunct treatment with very severe respiratory symptoms failing to respond to 
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initial bronchodilators and for significant laryngeal symptoms such as hoarseness, voice 
change or stridor. If there were severe generalised cutaneous symptoms suggesting extensive 
vasodilatation, persistent emesis or diarrhoea or hypotension intravenous fluids (Normal 
saline 0.9%) was administered. 
For milder symptoms intravenous or oral antihistamines (chlorpheniramine 10mg or 
cetirizine 10mg respectively) with intravenous or oral corticosteroids (hydrocortisone 200mg 
or prednisolone 30mg respectively) were administered.  
If participants suffered extremely severe reactions it was deemed unsafe for them to continue, 
they were excluded from the study. 
If two or more doses of IM adrenaline were given to a single participant due to inadequate 
response to the first dose on 2 separate occasions, they were excluded. 
To safeguard against late reactions participants were discharged with an adrenaline auto-
injector, antihistamines, a short acting beta-agonist (asthmatics only) and a detailed plan of 
how to treat late symptoms.    
All treatments administered and the frequency of adrenaline use for all challenges was 
reported.  
Grading severity of reactions 
There are various grading systems used to report systemic reactions but none are globally 
accepted. These proposed systems typically present 4 or 5 different grades of severity and are 
limited in discriminating reactions of varying severities especially towards the moderate and 
moderate-severe end of the spectrum. In order to overcome this, a weighted numerical score, 
based on the stopping criteria, was devised to capture shifts in severity between challenges.  
Development of the severity score 
An ideal scoring system for allergic reaction severity should be based on easily and routinely 
recorded variables. The score ideally should be applicable to all types of allergic reactions 
involving all triggers and to all patient populations. A severity classification should reflect 
two concepts: i) as the severity increases the number of involved organ systems usually 
increases and ii) cardiovascular, neurological, bronchial and laryngeal involvement are 
potentially life threatening and therefore signify more severe reactions.226 Numerical 
weighting was assigned by a consensus panel comprising a committee of experts. All 
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symptoms across all organ systems in the stopping criteria were ranked from least severe to 
most severe. Each symptom was assigned a weight such that a combined total score of all 
green symptoms could not add up to a greater value than a single yellow symptom, with the 
same reasoning adopted for yellow symptoms and red symptoms. In previous fatal 
anaphylaxis enquires the mode of death has been reported to be respiratory arrest.141 In 
another fatal anaphylaxis study by Mullins et al, acute dyspnoea was noted in 64% cases.159 
Low et al reported that cardiac and peripheral vascular symptoms were the leading cause of 
death in fatal anaphylaxis cases.227  Cardiovascular and respiratory symptoms have 
previously been considered by consensus to be life-threatening features of anaphylaxis.228  
Therefore severe cardiovascular and respiratory symptoms were deemed potentially “life-
threatening red symptoms” and were assigned a considerably higher weight than all other 
symptoms reflecting their importance. The score was road tested on example cases to ensure 
that there was adequate discrimination between shifts in severity particularly at the 










1 Pruritus -Occasional scratching [Green] 
1 Rash- Few areas of faint erythema [Green] 
1 Rare bursts of sneezing occasional sniffing [green] 
1 Transient Nausea [Green] 
1 Throat tingling/altered sensation in throat [Green] 
1 Oral itching [Green] 
1 Itching in inner ear canal [Green] 
2 Pruritus- scratching continuously for >2 mins at a time [Green] 
2 Transient abdominal pain[Green] 
2 Chest tightness  without any fall in PEFR [Green] 
6 Rash- Areas of erythema [Yellow] 
6 
I Bursts < 10, intermittent rubbing of nose, and/or eyes or frequent sniffing 
[Yellow] 
6 Continuous rubbing of nose and/or eyes [Yellow] 
6 Hard continuous scratching>excoriations [Yellow] 
10 Persistent nausea[yellow] 
12 Urticaria-<3 hives or mild lip oedema [Yellow] 
12 > 3 discrete episodes of throat clearing or cough [Yellow] 
13 Chest tightness with less than or equal to  10% fall in PEFR [Yellow] 
15 Persistent abdominal pain[yellow] 
18 Emesis/diarrhoea (1 episode) [Yellow] 
20 Periocular swelling and/or long bursts of sneezing, [Yellow]  
20 Persistent rhinorrhoea [Yellow] 
20 Urticaria <10 or   >=3 hives or significant lip or face oedema [Red] 
20 Altered level of consciousness [Red] 
25 Persistent throat tightness [Yellow] 
25 Weak/dizzy or tachycardia [Yellow] 
25 Emesis /diarrhoea (more than 1 episode) [Red] 
30 Rash- Generalised marked erythema>50% [Red] 
30 Urticaria-generalised involvement [Red] 
35 Chest tightness with a10% -  20% fall in PEFR [yellow] 
40 Hoarseness or frequent dry cough [Red] 
50 Expiratory or inspiratory wheeze [Red] 
70 Chest tightness with a > 20% fall in PEFR[red] 
70 Use of accessory muscles [Red] 
100 Stridor [Red] 
150 Drop in BP of  >20% from baseline [Red] 




Assessing the change in severity within an individual as a result of repeated challenges 
and co-factors 
A threshold was called at the development of objective symptoms by the investigator and 
therefore participants’ reactions were unable to evolve fully. As a result of this there is an 
unavoidable endogeneity between threshold dose and severity in this study. In order to 
overcome this problem a consistent dose across all challenges within an individual was 
examined for severity. The chosen dose was the highest dose reached in all challenges (i.e. 
equivalently, the lowest threshold dose reached across the 4 challenges) as demonstrated in 
Table 14. 
Table 14: Method for determining comparable dose in two example participants   
Example 
participant 1 
Challenge type Threshold dose 
reached 
Dose chosen for  
Comparison 
 Baseline 6 (100mg) 5 (30mg) 
 Exercise 5 (30mg)  
 No intervention 6 (100mg)  
 Sleep 5 (30mg)  
Example 
participant 2 
Baseline 8 (1000mg) 6 (100mg) 
 Exercise 6 (100mg)  
 No intervention 7 (300mg)  
 Sleep 6 (100mg)  
To estimate the within-participant impact of repeat challenges on severity, a linear fixed 
effects model of severity was estimated on i) a linear trend representing visit number by 
participant and ii) a set of dummy variables representing visit number by participant (i.e. visit 
2, visit 3 and visit 4). The marginal impact of visit number on severity was expressed relative 
to severity on visit 1.  
Although exercise and sleep deprivation interventions were randomised for each participant 
by visit number, they were never performed on visit 1, which was used to establish a baseline 
without intervention. Therefore, it was important to control for the impact of interventions on 
the average severity of visits 2, 3 and 4 relative to visit 1 by including dummy variables for 





Frequency of symptoms 
The frequency of each symptom across all challenges was reported. The change in symptom 
frequency (arranged in systems) with sleep deprivation and exercise compared to baseline 
challenge was reported.  
Using a fixed effects regression analysis, I examined at a system level whether there was a 
change in symptom severity with sleep deprivation and exercise. 
Reproducibility of symptom patterns within and across individuals 
Participants’ symptom patterns during each challenge were compared. A comparison of 
symptom patterns across participants was also examined. A bioinformatics technique called 
pairwise sequence alignment was used. This has previously been used to align two query 
sequences of amino acids to find similarities in two proteins.229   
Using the same method as described above, for each individual, the lowest dose common to 
all challenges was taken and all symptoms up until that point in each reaction were observed. 
If a symptom occurred twice it was counted once only. 
To compare sequences, a 37 (all possible symptoms) digit binary code was produced for each 
reaction based on the presence (1) and absence (0) of each symptom. The percentage match 
for pairs of reactions was calculated based on the coincident presence or absence of each 
symptom. Percentage match was identified by identifying the number of matches in the pair 
divided by the length of sequence (i.e. 37 symptoms) and multiplying by 100. 
In order to assess across-participant symptom patterns, 1000 randomly selected pairs of 
reactions across-participants were selected and analysed for pairwise matches. 
Predictors of severity  
Using linear regression, the severity of reaction was correlated to clinical characteristics 
including: presence of asthma, presence of eczema, age of onset of peanut allergy, severity of 
worst historical reaction, number of previous adverse reactions, and the timing of last 
community reaction. Severity was also correlated to markers of sensitisation including SPT 
wheal to peanut (mm), specific IgE peanut and specific IgE to Ara h2. 
Analysis of anaphylaxis group 
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Participants who suffered from anaphylaxis during any of their challenges were analysed in a 
separate group. 
For the purposes of this study anaphylaxis was defined as two or more of the following 
rapidly occurring symptoms (minutes to up to 2 hours) following exposure to peanut: 
generalised involvement of the skin-mucosal tissue, respiratory compromise (pronounced 
dyspnoea, wheeze, bronchospasm), reduced blood pressure or associated symptoms, severe 
and persistent abdominal symptoms (cramping abdominal pain and vomiting).230 
Univariate linear regressions of the presence of anaphylaxis on the underlying characteristics 
(linear probability model) were used to compare whether the underlying characteristics were 
more predictive of developing anaphylaxis compared to not developing anaphylaxis. 
Participants who suffered life threatening anaphylaxis will be reported separately as clinical 
case summaries at the end of the results section. 
Adrenaline use 
The frequency of intramuscular and nebulised adrenaline use was reported. 
Severity of symptoms in relation to dose 
The frequency of severe symptoms grouped by organ system in relation to dose was 
examined.  
Reporting of late symptoms 
Immediate symptoms were defined as symptoms during the challenge or within 2 hours of the 
last challenge dose. Late-onset symptoms were defined as symptoms occurring more than 2 
hours after the last challenge dose. These symptoms were reported in two groups- symptoms 
which recurred after apparent resolution of the initial phase of symptoms, termed ‘separate 
resurgence’   or those which occurred as part of a protracted reaction.  
Perception of severity 
Both the investigator and participant were asked to subjectively appraise their allergic 
reactions. In order to ensure that the results were not presented in an arbitrary manner and 
that they were statistically documentable and analysable, a visual analogue scale (VAS) was 
developed. Visual analogue scales have been used in the past for a multitude of disorders 
including allergic rhinitis 231 and angioedema.232 A 10cm long horizontal line was produced 
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with verbal descriptors at each end to express the extremes of severity.  A scale of 0 to 10 
was selected. The participant was asked to place a cross on the straight line to express their 
assessment. Using this scale, symptoms in each organ system were scored. The participant 
was also asked to give an overall reaction severity score (Appendices 4 and 5). Finally the 
points from each organ system and the overall severity score were added to give an aggregate 
points score. Both the overall reaction severity score and aggregate score were analysed. Both 
the investigator and participant score were correlated with each other. For the strength of 
correlation, the Pearson correlation coefficient was computed. A correlation of greater than 







Fifty seven participants mean age 21 years (range 18-39) were included in this analysis. All 
participants received a baseline challenge. Two participants had a life-threatening reaction at 
their baseline challenge and did not proceed in the study. In total, 187 active peanut 
challenges were performed. Eleven participants did not proceed to the intervention stage 
following baseline challenge, forty-one participants completed all 4 active challenge days and 
46 participants completed at least 1 intervention challenge. A distribution of the overall 
challenge severity score is shown in Figure 8 and as a comparison in Table 15, the 
distribution of severity grades according to Sampson.153  The mean of the sample was 69.2 
and standard deviation 31.9.  





Table 15: Distribution of severity grades according to Sampson Classification 
Severity 
grade 
1 2 3 4 5 
Baseline 0 30% 44% 26% 0 
Exercise 0 32% 43% 25% 0 
No 
intervention 
0 35% 46% 19% 0 
Sleep 0 38% 43% 19% 0 
 
Assessing the change in severity within an individual as a result of repeated challenges  
Estimating within-participant using a linear fixed effects regression model based on 176 
challenges across 46 participants (the 11 participants with only one observation being 
omitted, and each included participant typically undergoing 4 challenges), a positive effect of 
visit number on severity at constant dose was observed (Figure 9). 
Figure 9: Within-participant visit effect on challenge severity (at constant dose)  
 
When examining the within-participant effect of visit number using dummy variables for 
visits 2, 3 and 4 (column 1 in Table 16) a strong monotonic increase by each progressive visit 
























Linear visit effect (with sleep & exercise controls)
Visit  effect (without controls)
Visit effect (with sleep & exercise controls)
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deprivation interventions were only ever implemented on visits 2 3 or 4, which would tend to 
bias the coefficients on the visit dummies upwards and bias the p-values downwards. 
When controlling for exercise and sleep, although the incremental impact remains monotonic, 
disentangling the impact of exercise and sleep imposed a cost to the statistical significance of 
these coefficients (column 2 in Table 16).  
Estimating the effect of each progressive visit as a linear trend rather than using visit 
dummies whilst still controlling for exercise and sleep produces a statistically significant 
effect of visit number on severity (column 3 in Table 16). Given an average severity score 




Table 16: Summary of results of three regression estimations, illustrating the within-
participant effect of visit number on severity – using visit dummies with and without 
exercise and sleep controls ( 1 and 2), and a linear visit trend with exercise and sleep 
controls (3). 
 














 (0.067) (0.836)  
    
Visit 3 15.93*** 4.971  
 (0.009) (0.510)  
    
Visit 4 22.72*** 12.39*  
 (0.002) (0.071)  
    
Exercise  12.51* 11.37* 
  (0.056) (0.062) 
    
Sleep  20.53*** 19.25*** 
  (0.002) (0.003) 
    
Linear trend   4.238* 
   (0.051) 
    














N 176 176 176 
Participants 46 46 46 
Robust standard errors, p-values in parentheses 







Assessing the change in severity within an individual as a result of interventions (sleep 
deprivation and exercise) 
Using a linear fixed effects model to estimate within-participant effect controlling for visit 
number using visit dummies a positive effect was seen, with both interventions increasing the 
severity of reaction (column 2 Table 16 ; the effect was robust to controlling for the visit 
effect using a linear trend instead of visit dummies, see column 3 of Table 16). The effect 
was larger in sleep deprivation. Sleep was associated with a 20.5 (0.67 SD) points higher 
reaction severity (p=0.002) compared to exercise which was associated with a 12.5 (0.39 SD) 
higher points severity (p=0.056).  
Frequency of symptoms experienced by participants during challenge and how these 
change with sleep deprivation and exercise. 
The frequency of the 37 symptoms during all challenges is displayed in Figure 10. Symptom 
frequency at a system level for baseline challenges and no-intervention combined is shown in 
Figure 11. Cutaneous symptoms were most common, followed by throat symptoms. Changes 
occurring in symptom frequency with sleep deprivation and exercise are shown in Figures 
12(a) and (b) respectively. Only small changes in symptom frequency were observed for 
sleep deprivation. The most noticeable effect on symptom frequency was observed in 












Figure 10: Frequency of symptoms during all 187 challenges 
Figure 11: System involvement during baseline and no intervention challenges (n=100). 




Throat clearing or cough > 3 discrete episodes [Yellow]
Altered level of consciousness [Red]
Use of accessory muscles [Red]
Stridor [Red]
Drop in BP and/or >20% from baseline [Red]
Cardiovascular collapse/signs of impaired circulation…
Urticaria-generalised involvement [Red]
Chest tightness with a > 20% fall in PEFR[red]
Expiratory or inspiratory wheeze [Red]
Periocular swelling and/or long bursts of sneezing,…
Chest tightness with a10% -  20% fall in PEFR [yellow]
Hard continuous scratching>excoriations [Yellow]
Continuous rubbing of nose and/or eyes [Yellow]
Hoarseness or frequent dry cough [Red]
Rare bursts of sneezing occasional sniffing [green]
Urticaria <10 or   >=3 hives or significant lip or face…
Emesis /diarrhoea (more than 1 episode) [Red]
Rash- Generalised marked erythema>50% [Red]
I Bursts < 10, intermittent rubbing of nose, and/or…
Chest tightness with less than or equal to  10% fall in…
Chest tightness  without any fall in PEFR [Green]
Pruritus- scratching continuously for >2 mins at a…
Weak/dizzy or tachycardia [Yellow]
Persistent rhinorrhoea [Yellow]
Emesis/diarrhoea (1 episode) [Yellow]
Pruritus -Occasional scratching [Green]
Itching in inner ear canal [Green]
Urticaria-<3 hives or mild lip oedema [Yellow]
Transient abdominal pain[Green]
Transient Nausea [Green]
Persistent throat tightness [Yellow]
Rash- Few areas of faint erythema [Green]
Persistent nausea[yellow]
Persistent abdominal pain[yellow]
Rash- Areas of erythema [Yellow]
Oral itching [Green]
Throat tingling/altered sensation in throat [Green]
% Frequency














Figure 12(a): % change of system involvement frequency with sleep deprivation (n=43). 
Cutan, Cutaneous; Gastro, Gastrointestinal; Rhin, Rhinitis; Resp, Respiratory; Cardio, 
Cardiovascular 
 
Figure 12(b): % change of system involvement frequency with exercise (n=43). Cutan, 
Cutaneous; Gastro, Gastrointestinal; Rhin, Rhinitis; Resp, Respiratory; Cardio, 
Cardiovascular 
 
How does the severity of symptoms change at a system level with exercise and sleep 
deprivation? 
A fixed effects model was used to examine within-participant changes in severity at system 
level with sleep deprivation and exercise. Significant effects were only observed in sleep 


















deprivation challenges for 2 systems. Exercise did not produce any significant effects on 
increasing symptom severity at system-level. The severity of gastrointestinal and throat 
symptoms increased under sleep deprivation conditions by 5.8 (0.55 SD) (p=0.036) severity 
points and 7.0 points (0.75 SD) (p=0.003) respectively. 
Persistence of participant symptom pattern within individuals with repeated challenges. 
There were 304 possible within-participant pairs of reactions. The average pairwise 
percentage match was 81.9% 
Persistence of symptom patterns across individuals 
1000 across-participant pairs of reactions were selected ensuring that reactions were 
compared with like for like doses. The average pairwise percentage match was 78.3%. 
Correlation of reaction severity with participant characteristics 
There was a positive correlation of SPT wheal size with severity of reaction (p=0.03). 
Presence of asthma, eczema, age of onset of peanut allergy, severity of worst historical 
reaction, number of previous adverse reactions, timing of last community reaction, specific 
IgE peanut and specific IgE to Arah 2 could not be correlated.  
The effect of asthma on severity 
Although the presence of asthma was not associated with a higher reaction severity overall, 
the presence of asthma was associated with a higher severity of respiratory symptoms only 
(p=0.02). When examining the whole sample (including challenges with no respiratory 
symptoms/zero respiratory severity) the presence of asthma was associated with an increase 
of 7 points on the respiratory severity scale (0.33SD) (p=0.02). Using only the challenges 
with respiratory symptoms the presence of asthma was associated with a 16 point increase in 
respiratory severity (0.74SD) (p=0.017).  
Anaphylaxis group 
Out of the 187 allergic reactions induced in the study, 29 episodes were anaphylaxis (16%). 
These episodes occurred in 13 participants. Two participants were excluded at baseline due to 
severe anaphylaxis. Of the remaining eleven participants who proceeded to the intervention 
stage, 64% developed a repeat episode of anaphylaxis. When examining whether the 
underlying clinical characteristics described above previously were more predictive of 
anaphylaxis compared with non-anaphylaxis a positive correlation with severity of historical 
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reactions (p=0.001) and history of adrenaline use (p=0.001) was seen. Anaphylaxis was less 
likely with higher peanut IgE (p=0.05), higher Arah2 (p=0.005) and less likely with asthma 
(p=0.029). Univariate analyses did not show significant associations of any of the other 
candidate predictors including presence of eczema, age, age of onset of peanut allergy or 
number of adverse reactions on the likelihood of anaphylaxis.   
Frequency of adrenaline use 
The overall rate of adrenaline use in the study was 15%. Three participants required two 
doses of intramuscular adrenaline to stabilise. The most frequent reason for adrenaline 
administration was to correct respiratory symptoms, n=22/28 (79%). 





Table 17: Frequency of intramuscular (IM) and nebulised adrenaline administration. 







10/57 7/44 6/43 5/43 28/187 






3/57 0 0 0 3/187 
% 5    2 
Number of 




3/57 0 0 0  
% 5    2 
 
Participant and investigator perception of severity 
There was a moderate correlation between the investigator and participant scores for both 
Overall Reaction Severity, 0.39 (p=<0.05) and Total VAS score, 0.44 (p=<0.05). A better 
(strong) correlation was observed when within-participant VAS scores were compared: 
Overall Reaction Severity, 0.35 and Total VAS score, 0.62 (p=<0.05). Although there was a 
strong correlation between the investigator VAS score (0.52 p=<0.05) and the overall 





Relationship of dose to severity of symptoms by system   
A summary of the frequency of severe symptoms of each system occurring at each dose is 
shown in Figure 13. Severe cardiovascular symptoms never occurred. The overall frequency 
of severe respiratory symptoms increased as dose increased but remained uncommon. The 
most common severe symptoms were severe cutaneous symptoms and severe rhinitis 
symptoms which occurred at Dose 8. 
 
Figure 13: Percentage of severe symptoms as a % of challenges occurring at that dose 
 
 
Reporting of late symptoms  
Symptoms which developed more than 2 hours after the last dose are shown in Table 18. 
Delayed symptoms occurred in 7/187 (4%) reactions and all occurred between 2-2.5 hours of 
the dose. Cutaneous symptoms were the most common delayed symptom (6/7 reactions, 
86%). However delayed respiratory symptoms also occurred in 1/7 cases (29%). One 




Table 18: Nature of delayed symptoms and treatment administered. Symptoms classed 
as separate resurgence if symptoms appeared after an initial resolution.   
Participant Symptom Time from 
last dose 
(mins) 
Treatment  Protracted or 
separate 
resurgence 
1 Pruritus (gen.) 129 Cetirizine Separate resurgence 
2 Erythema (gen.) 122 Adrenaline 
IM 
Separate resurgence 






4 Abdominal pain 121 Cetirizine Separate resurgence 
5 Urticaria (gen.) 150 Cetirizine  Separate resurgence 
5 Urticaria (gen.) 121 Adrenaline 
IM 
Protracted 
5 Urticaria (gen.) 124 Adrenaline 
IM 
Protracted 
Case summaries of two excluded participants 
Participant 1 
18 year old male diagnosed with peanut allergy aged 2 after eating a bite of peanut butter on 
toast. He had suffered two previous reactions which were mild, developing erythema and 
vomiting only. No co-morbid conditions including asthma present.  
Attended for baseline challenge and was well on the day of challenge. 
During doses 1, 2, 3 and 4, no symptoms 
Following dose 5 he developed mild oropharyngeal symptoms and transient throat tightness 
lasting for 3 minutes only and resolving completely.  
Following dose 6 (cumulative dose 133.3mg peanut protein) participant started developing 
abdominal pain 23 minutes after dose which increased in severity. Seventeen minutes after 
the onset of abdominal pain participant started to feel very lightheaded with worsening 
abdominal pain. Participant became hypotensive BP dropped to 107/65 from a baseline of 
125/71 which had been performed 15 minutes before the onset of symptoms and also 
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mounted a tachycardia (HR106). At this point adrenaline IM (0.5mg) was administered. 
However he then started to become vacant and eyes rolled back. After laying the participant 
down he developed almost immediate profuse projectile vomiting followed by widespread 
generalised erythema (IV hydrocortisone and IV chlorpheniramine given).  Participant started 
to recover but then became aware of his own heart beat beating irregularly. ECG performed 
which showed junctional atrial ectopics. This settled after about 30 minutes- repeat ECG 
showed sinus rhythm but tachycardia still present, probably post adrenaline administration. 
There were delayed symptoms with the participant developing a frequent dry cough (61 
minutes post dose) and worsening erythema (69 minutes post dose). At this point given 
further IM adrenaline 0.5mg IM (with regular monitoring of HR, BP and ECGs), IV fluids, 
salbutamol nebulised (5mg) and high flow oxygen 15L via non-rebreathe bag. Oxygen 
saturations were maintained throughout. Participant was too unwell to provide a peak flow 
but good symptomatic response following second lot of adrenaline. Eventually settled after a 
further hour. Participant felt well enough to go home, was offered admission but declined.  
Using the Visual Analogue Scale the participant graded his overall reaction severity 6/10 
with a total aggregate score of 23/70, compared to my score as the investigator of 9/10 for 
overall reaction severity and a total aggregate score of 53/70. 
The participant was keen to return to continue the study but we decided to exclude him given 
the severity of his reaction.  
Participant 2 
23 year old female diagnosed with peanut allergy at the age of 2 after consuming one peanut 
and developed cutaneous symptoms solely.  She had only suffered 1 adverse reaction 
previously. Participant had a background history of widespread but well controlled eczema 
and no asthma.    
During dose 1,2,3,4 she developed no symptoms. 
Following dose 5 she developed oropharyngeal tingling and started rubbing her hands 
together and scratching the eczema on her hands. Her partner (who was present at the time) 
reported the latter (check) was habitual. 
After dose 6 she developed abdominal pain 11 minutes after dose along with nausea. She then 
started to develop urticaria on her abdomen 18 minutes after dose. At that point she was 
given IV hydrocortisone and chlorpheniramine. However, at 33 minutes post dose the 
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erythema became generalised and IM adrenaline 0.5mg was given. At 50 minutes post dose 
started to develop a frequent dry cough. Further IM adrenaline given 8 minutes later. Also 
given nebulised salbutamol (5mg) at that point. There was a limited response to this and at 78 
minutes post dose she developed generalised polyphonic wheeze. Given nebulised adrenaline 
(1mg/5ml N. saline 0.9%). However, she did not improve and developed recurrent chest 
tightness with use of accessory muscles and began to desaturate on nebuliser (to 92%) so was 
given 2 further lots of nebulised adrenaline interspersed with back to back salbutamol 
nebulisers (5mg). The critical care outreach team was alerted and they reviewed the 
participant, by which point she had started to improve. They did not add further treatment. 
Participant had continuing pruritus and worsening erythema at 88 minutes post dose so was 
given oral cetirizine and prednisolone 30mg.  Participant was maintained on high flow 
oxygen 15L via non-rebreathe bag and IV N saline 1 litre. Her BP was maintained 
throughout. She tolerated IM adrenaline well with max heart rate of 134. Made a good 
recovery after 1-2 hours.  
Using the Visual Analogue Scale the participant graded her overall reaction severity 8/10 
with a total aggregate score of 37/70, compared to my score as the investigator of 9/10 for 





In this study, the effect of repeated challenges within an individual results in reactions of 
increasing severity with each visit. Separately, co-factors such as sleep deprivation and 
exercise can increase the severity of peanut allergic reactions. In particular sleep deprivation 
increased the severity of gastrointestinal symptoms. For the first time, I show that symptom 
patterns during peanut allergic reactions are homogenous within individuals and also that 
commonality exists in symptom patterns across participants in our sample. Limited 
correlations were found between clinical characteristics and severity. Skin prick test size was 
positively correlated with reaction severity but other markers of sensitisation such as peanut 
or Arah2 IgE were not. A history of severe reactions and adrenaline use was correlated with 
the presence of anaphylaxis during challenge. Furthermore the presence of asthma was 
correlated with a significant increase in severity of respiratory symptoms if respiratory 
symptoms were present in the reaction. Lastly using a novel visual analogue scale for 
measuring the participant’s perception of severity, a poor correlation was observed between 
the participant’s perception of the reaction and the overall numerical severity score. 
Assessing the change in severity within an individual as a result of repeated challenges  
In this study, when a linear model was fitted to the reaction severity at each challenge, the 
severity at visit 4 was significantly higher than that at visit 1 by 12 points. There are limited 
data on how reaction severity changes over time within an individual with most information 
coming from patients’ accounts of reaction. Glaumann et al found no association between 
severity scores at two consecutive challenges in 14 peanut allergic patients.126  Separately 
Van der Leek et al followed up children with peanut allergy and compared index reactions 
with subsequent reactions following accidental exposure and found that 44% patients who 
had suffered a non-life threatening reaction initially would subsequently suffer from life 
threatening symptoms.233 However there were no challenge data in this study and community 
reactions will inevitably differ in dose exposure which will endogenously influence severity. 
In our study, even with controlling for dose an effect of increasing severity was still 
observed. Three month intervals were planned in the study to guard against the possibility of 
a desensitisation effect. However, this severity analysis has shown that the opposite effect 
may be happening, that patients may develop increased reactivity at each subsequent 
exposure.  Furthermore caution must be exercised in viewing severity as a linear function of 
visit number given the observed non-linearity of the coefficient on the visit dummies. Such a 
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distinction may prove important medically as a nonlinearly rising effect might imply 
cumulative risk of a very severe reaction following a number of repeated reactions even more 
severe than the proposed linear 4 point increase with each challenge.  
Assessing the change in severity within an individual as a result of interventions (sleep 
deprivation and exercise) 
Both sleep deprivation and exercise increase overall reaction severity with sleep deprivation 
having a greater effect than exercise. As discussed in the previous chapter it is likely that 
exercise may be directly increasing severity by a greater availability of allergen in the 
systemic circulation. Exercise leads to splanchnic hypoperfusion, possibly inducing a relative 
gut ischaemia causing tight junction dysfunction. A possible increased liberation of allergen 
into the blood steam may then ensue through an increase in paracellular transport.137 Another 
possible contributory factor that I noticed during the exercise challenge compared to the other 
challenges, is that often participants did not report many of the early warning signs such as 
oropharyngeal pruritus, altered throat sensation or transient abdominal pain which occurred 
soon after the dose was given. Perhaps this occurred because participants were distracted 
whilst undertaking the exercise period or there may have been a degree of endogenous 
adrenaline release during the exercise period compensating for the early symptoms which 
may have resulted in delayed recognition and symptom reporting by participants. It may be 
that this endogenous adrenaline release and partial compensation is responsible for the 
smaller effect seen during exercise compared to sleep deprivation.  As postulated in the 
previous chapter, it is possible that acute sleep loss, which is a stress-inducing stimulus, leads 
to increased activation of the brain-gut-axis and propagation of mast cell activation and the 
allergic response inducing an increased gut permeability.234 Indeed the results of this study 
indicate that the severity of gastrointestinal symptoms significantly increases during sleep 
deprivation which supports this hypothesis. Brown et al have demonstrated a correlation 
between GI manifestations and the severity of anaphylaxis.235 Furthermore the presence of 
chronic and relapsing GI symptoms and the degree of gastrointestinal permeability positively 
correlated with the severity of anaphylaxis in humans.236 
Frequency of symptoms experienced by participants during challenge and how these 
change with sleep deprivation and exercise. 
Cutaneous and throat symptoms were the most frequently occurring during baseline and no-
intervention challenges (93% and 92% respectively), followed by gastrointestinal symptoms 
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87%. Reassuringly, severe throat symptoms during challenge such as stridor or dysphagia 
were rare and the majority of throat symptoms were due to an altered sensation in the throat 
or persistent throat tightness. These results differ from analyses which examine the frequency 
of anaphylaxis due to all causes. Beyer et al observed in their series looking at anaphylaxis of 
all causes in the community that 86.1% reactions involved symptoms of the cardiovascular 
system, in this study we observed cardiovascular involvement in 17.6% of all challenges.237 
Cianferoni et al’s series of 983 children who underwent OFC to egg, milk and peanut, had a 
lower incidence of cutaneous involvement (56%) and gastrointestinal involvement (59%).238 
When examining changes in system involvement with sleep and exercise, only minor changes 
in symptom frequency were observed during sleep deprivation. However, conversely with 
exercise, there was a notable increase in cardiovascular symptoms (21.4%). Cardiovascular 
symptoms manifested themselves predominantly as dizziness and physical weakness. These 
symptoms were out with the normal physiological responses during exercise. During 
exercise, 80% of cardiac output is diverted to active skeletal muscles at maximal rates of 
work. 239 Furthermore during exercise there is a decrease in total peripheral resistance which 
is balanced by an increased cardiac output and mean arterial pressure. However during an 
allergic reaction, as a result of mast cell mediator release, peripheral vasodilatation may 
occur, exacerbating the already reduced peripheral resistance produced by exercise. This may 
result in an inadequate cardiovascular compensatory response leading to symptoms of 
dizziness, weakness and tachycardia. 
Factors associated with increasing reaction severity 
The only significant positive association found in this study was that of SPT wheal diameter 
to peanut and overall reaction severity score. Other markers of sensitisation including specific 
IgE to peanut and Arah2 could not be correlated. A previous study of community reactions 
based on patient reported symptoms, using a simpler score, found no link between peanut 
SPT size and severity grade.122 The association between higher levels of peanut-specific IgE 
and reaction severity has previously been described in a study by Neumann-Sunshine et al in 
a study of 782 patients with persistent peanut allergy.240  Previously it has been shown in the 
EuroPrevall cohort that although Arah2 confers an extremely high probability of a systemic 
reaction (97%), no significant relationship to reaction severity during food challenge was 
observed, necessitating more prospective research.63 The relationship between IgE binding to 
allergen and reaction severity is likely to be a more complex picture with a more relevant 
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factor being the promiscuity of epitope binding than rather than the recognition of individual 
proteins241 in combination with IgE affinity and avidity. 
Symptom pattern   
Little data exist on the pattern of symptoms and the sequence of symptom progression both 
within and across allergic individuals. Using a sequence alignment technique, homogeneity 
of symptom patterns within an individual could be demonstrated. However, reaction patterns 
across individuals in our sample were almost as similar (78.3% across versus 81.9% within). 
This analysis looked at absolute numbers of all symptoms which appeared over the course a 
reaction however further work is needed on the combinations of symptoms which appear 
during a reaction and whether there are tendencies for certain symptoms to co-appear. 
However the information presented here will allow clinicians to better inform patients about 
the likely nature of further reactions in terms of organ systems involved.  
Adrenaline use 
The overall rate of intramuscular adrenaline use in this study was 15% and nebulised 
adrenaline 2%. This is a fairly comparable rate to other studies examining the frequency of 
adrenaline administration during oral food challenge. Yanagida et al reported a rate of 23% 
for IM administration in patients undergoing oral food challenges prior to the commencement 
of immunotherapy. The rate of use of inhaled adrenaline was 13%.242 In contrast, Noone et al 
reported a much higher rate of adrenaline use in their study, again screening subjects for food 
therapeutic trials.243 In their study, intramuscular adrenaline was administered in 39.2% 
cases, however the higher rate may be accounted for by differences in physician practice for 
example, the use of adrenaline to treat severe abdominal cramping which was not an 
indication in the TRACE study protocol. The incidence of multiple doses of IM adrenaline 
administration was only 2% (3/187 challenges). The first participant requiring two doses was 
one of the first participants to undergo the study and developed a resurgence of cutaneous 
symptoms at a delayed interval. This was the first time that this phenomenon had been 
witnessed and as a result a second dose of adrenaline was administered as a precaution to 
terminate the reaction. The other two participants were poorly responsive to the first dose and 
had protracted reactions (described separately).  In food challenge studies the rate of multiple 
doses ranges from 0.68-6.5%. 242,244 Of course studies focussed on community reactions 




Asthma as a risk factor 
The presence of asthma is considered to be a risk factor for fatal anaphylaxis. Moreover 
Summers et al report a large association between asthma and acute bronchospasm after the 
ingestion of nuts.247 In a European anaphylaxis registry asthma or underlying bronchial 
hyperreactivity was identified as a possible risk factor. 248 In this study the presence of 
asthma was not correlated with a higher overall reaction severity.  However when a different 
question was posed as to whether the presence of asthma increased the severity of established 
respiratory symptoms only then asthma did serve as a risk factor in increasing severity. It is 
possible that this occurs as a result of active inflammatory processes within the airways and 
reduced physiological reserve in patients with asthma who develop respiratory symptoms 
during reaction.235 Less physiological reserve may mean that asthmatics progress to a severe 
state more quickly, particularly if their asthma is less well controlled. In our study all patients 
had well controlled asthma, nonetheless an effect was still observed.   These findings contrast 
with Van Erp’s group who compared asthmatics to non-asthmatics and found that in children 
with a positive food challenge, asthmatics did not report a severe respiratory reaction more 
commonly (29% vs 22% p=0.50). They also found that asthmatics did not have a reaction 
with involvement of the lower airways during challenge more frequently.249 However other 
studies support the importance of asthma as a risk factor with one study reporting that in 
patients with severe asthma the risk of life threatening bronchospasm during nut associated 
anaphylaxis was increased 6.8 fold although this relative risk was only 2.7 times higher for 
the patients with mild asthma.250 Thus when managing patients with food allergy the role of 
asthma in increasing the severity of respiratory symptoms should they develop should not be 
underplayed and patients should be well versed on optimisation of their general asthma 
control. 
Anaphylaxis 
Fifteen percent of reactions met the criteria for anaphylaxis. This is in line with other studies 
which estimate an incidence of anaphylaxis of between 10-15% in patients challenged to 
peanut.249 In our study these reactions frequently occurred repeatedly within one individual, 
64% patients suffered from a repeat episode of anaphylaxis. Reisman analysed the incidence 
of repeat sting induced anaphylaxis in 220 patients who had anaphylaxis at their index sting 
and who did undergo immunotherapy and reported the overall incidence of repeat sting 
anaphylaxis as 56% which was unrelated to the time interval since the initial sting reaction.251 
Spergel et al examined whether the organ system involved in the initial allergic reaction 
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predicted the outcome during subsequent food challenge and found that patients typically 
experienced a similar reaction on re-exposure to the initial reaction.252 In our anaphylaxis 
group a more severe historical reaction or use of adrenaline was associated with the 
development of anaphylaxis compared to no anaphylaxis. The fact that only these risk factors 
have been identified highlight that the severity of a reaction to food is unpredictable and this 
is likely due to the interaction of patient-specific factors ( e.g. degree of sensitisation, target 
organ reactivity, co-morbid diseases) and event specific factors (e.g. amount ingested, 
concomitant illnesses).  An association between asthma and the likelihood of developing 
anaphylaxis was not found but has been reported in another study.253  
Late reactions 
There is limited information on late reactions following double blind placebo controlled food 
challenges. Late symptoms occurred in 4% challenges and were mostly generalised cutaneous 
(86%).   Adrenaline was used to treat late symptoms in this study as a precautionary measure 
but not necessarily because the symptoms were severe or worrying.  One person developed 
respiratory symptoms but this occurred as part of a protracted reaction and was an unusually 
severe case. In a study of children and adolescents undergoing food challenge by Saleh-
Langenberg et al, 20.8% had late reactions however they report a similar frequency of late 
symptoms on the placebo day as on the active day. The majority of late symptoms reported 
were those of restlessness, crying and dizziness and cutaneous symptoms were less frequent 
than our study (33.3%).254 There were no reports in our study of symptoms occurring later 
than 2.5 hours. The recommended period of observation following DBPCFC varies in clinical 
practice between 2-24 hours.255,256 Given that 96% reactions in our study had resolved by 2 
hours, I believe that this is an adequate safety net to ensure that the majority of patients are fit 
for discharge, however this recommendation would come with the caveat that following 
episodes of particularly severe anaphylaxis, a longer period of observation may be required.  
Perception of severity 
The Visual Analogue scores were developed for this study and have never been used 
previously in clinical practice. They proved a useful tool for recording subjective perceptions 
of severity. Results showed that there was only a moderate correlation between the 
investigator’s perception of the reaction and the participant’s, probably due to the fact that 
there are differences in the way each party uses the scale. For example the investigator, based 
on their experience of seeing and treating hundreds of reactions, might believe that only life-
116 
 
threatening reactions should be awarded a score of 9 whereas a highly anxious patient may 
regard the development of throat tightness a worrying enough symptom to grade the reaction 
extremely highly. Thus each party has a different starting point. This explains why looking at 
within-individual comparison of investigator and participant scores with each visit proved to 
be a more sensitive comparison.    When comparing the investigator’s score to the numerical 
overall severity score there was a high correlation. This is to be expected as the investigator 
knows the appropriate weight and gravity to apply to certain symptoms. However the 
investigator VAS, rather than just being a summation of symptoms, can incorporate extra 
dimensions of the reaction for example response to treatment and nature of recovery. In 
addition it can provide a more sensitive evaluation of qualitative severity measures 
particularly in cases where severe and dangerous symptoms were observed, such as the 
acceleration of symptom progression and interaction between symptoms for example scalp 
pruritus and sudden onset rhinitis appearing together is a more ominous sign than each 
symptom appearing separately and transiently during the challenge.  Therefore the 
investigator VAS is a good supplement to the main numerical score. Additional work is 
needed on the correlation of independent investigators scores and ideally the VAS scores of 
two investigators judging the reaction contemporaneously should be compared. It was 
concerning that there was a poor correlation between the participant’s VAS and the numerical 
severity score. This raises the concern that participants are underestimating the severity of 
symptoms. Pumphrey et al noted that severe reactions are frequently not dissimilar from more 
mild reactions at onset, so individuals experiencing life-threatening reactions may not 
initially realize the potential severity.141 This finding is worrying as it may suggest that if 
patients misjudge their reactions in such a way, it may result in a delay to seeking medical 
help and administering life-saving treatment.  
Two severe anaphylaxis cases 
Regarding these participants, there were a few interesting and informative features. In the 
case of Participant 1, following the administration of the first dose of adrenaline the 
participant developed a junctional arrhythmia. Cardiovascular features are reported in 
anaphylaxis including coronary artery spasm and arrhythmias257 as well as the Bezold Jarisch 
reflex causing a paradoxical bradycardia during extreme hypovolaemia in 10% patients with 
anaphylaxis.177 It is difficult to know whether the cardiac arrhythmia occurred as a result of 
the very severe anaphylaxis he was suffering from or as the result of the administration of 
intramuscular adrenaline. Cardona et al examined the safety of adrenaline use in anaphylaxis 
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and found that side effects occurred in 21.64% cases and potentially severe adverse effects 
including ECG alterations occurred only in 2.99% cases.258 In our study adrenaline was very 
well tolerated with few side effects (data not shown), however, it must be noted that the study 
participants were young fit adults and the case may be different in an older age group. 
Participant 2 had significant eczema and it is possible that this played an important role as an 
additional co-factor in worsening the severity of her reaction. Summers et al found that 
severe atopic dermatitis correlated with a 3.1 fold increased risk of severe reactions with 
cardiovascular instability.247 It is possible that the presence of abnormal eczematous skin may 
have masked early symptoms such as urticaria. In addition, the palmar itching, reported as 
‘normal’ for her at Dose 5, could actually have been a herald sign. Previously Van der Zee et 
al reported that children with atopic dermatitis react to higher doses of peanut than patients 
without atopic dermatitis supporting this theory.120    
Limitations 
 The major limitation of this study is that reactions were terminated at the onset of a 
certain number of objective symptoms. Symptoms could therefore not evolve and reactions 
could not progress to their full potential had intervention not occurred making threshold dose 
and reaction severity inextricably linked. Therefore it was necessary to restrict analyses to the 
lowest comparable dose within individuals to circumvent this issue. A better study design is 
indeed required to answer specific questions about severity and this is described in the 
chapter, ‘Further work’. Another important point is that investigator and participant bias is 
unavoidable. Once either party has witnessed the first reaction it is possible that their 
experience of that reaction may influence their actions in the next challenge. From the 
investigator’s point of view this includes lengthening doses intervals knowing how symptoms 
have previously evolved or earlier delivery of treatment. From the participant’s point of view 
they may anticipate certain symptoms or overplay them. The other possibility is that in the 
beginning, as the investigator, I acted in a more cautious way and as the study progressed I 
became more relaxed when managing reactions. By having strict objective criteria for 
threshold estimation and challenge termination these interactions were hopefully minimised. 
Lastly, our proposed severity scale is one of the first of its kind for food allergy. Applying a 
numerical value to a qualitative entity is inevitably subjective. To ensure that the score 
provides accurate assessment of severity in different populations at different time points 






Is mast cell tryptase measurement useful in food allergic reactions? 
Introduction 
Serum tryptase is a marker of mast cell activation and a rise in tryptase is a useful indicator of 
whether an allergic reaction has taken place. Tryptase has been shown to be of value in 
allergic reactions triggered by venom259 and drugs260 however its utility in food allergic 
reactions remains unknown. Some studies report that tryptase does not rise in food induced 
anaphylaxis167 nor in non-hypotensive reactions. These studies are largely based on data 
derived from post mortem samples of patients who died from anaphylaxis 261 or patients 
presenting acutely to emergency departments resulting in varying sample times and a bias 
towards more severe reactions. Experimental evidence of tryptase in food-allergic reactions 
and in particular on its typical time course is lacking.  
We present a large prospective study of the diagnostic utility of serum tryptase in 
experimentally induced peanut allergic reactions of varying severities. Our aim was to 
establish whether tryptase rises in food allergic reactions, the optimal time point for tryptase 
sampling and an optimal diagnostic cut off in serum tryptase rises for determining a reaction 
versus no reaction.  
Methods 
Participants 
Fifty allergic adult participants with a history of systemic reactions (urticaria, angioedema or 
respiratory/gastrointestinal tract symptoms), with acute onset of symptoms after ingestion (up 
to 2hours) of peanut were recruited from 2013 to 2016. Allergic status was determined by 
evidence of sensitisation to peanut demonstrated by positive skin prick tests (SPT) and 
positive serum specific IgE using ImmunoCAP (Thermofisher, Uppsala, Sweden)  to peanut 
and peanut components Arah 2 and/or 1 and 3. A positive test was defined using the criteria 
of ≥3mm for SPT and ≥0.35kUA/L for ImmunoCAP.   Ethical approval was obtained from 
the National Research Ethics Service (NRES) committee East of England. Informed consent 
was obtained from all participants. We carried out a prospective study of mast cell tryptase 
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during reaction. All participants underwent an initial peanut challenge. Participants were 
given incrementally increasing doses of peanut protein until they developed clear objective 
signs of an allergic reaction. Reaction severity was scored according to the Ewan and Clark 
severity scale.152 Anaphylaxis was defined as two or more of the following rapidly occurring 
symptoms (minutes to hours) following exposure to peanut: generalised involvement of the 
skin-mucosal tissue, respiratory compromise (pronounced dyspnoea, wheeze, bronchospasm), 
reduced blood pressure or associated symptoms, severe and persistent abdominal symptoms 
(cramping abdominal pain and vomiting)230 and corresponded to Ewan and Clark severity 
grade 5 reactions. The first peanut challenge was double blind with all patients undertaking a 
placebo arm. The initial challenge was followed by 3 further open challenges.  
Mast cell tryptase- principle and method of the procedure 
Blood samples for mast cell tryptase were taken on each challenge day prior to the 
commencement of peanut doses (pre-challenge sample, at the onset of reaction and at 1 and 2 
hours post reaction). Sampling schedule is shown in Appendix 6. On non-reactive challenge 
days, samples were taken prior to the commencement of doses and at 2 hours post last dose. 
An initial serum tryptase was also taken for each participant on their screening visit. Samples 
were taken in a 2ml clotted blood- brown gel EDTA/Heparin plasma tube. Tryptase was 
measured using UniCAP (Thermo Scientific, Uppsala Sweden) which measures the 
concentration of free tryptase in the human serum. It is intended for use with the Phadia 250 
automated instrument. In this test, the anti-human tryptase is covalently coupled to an 
ImmunoCap and reacts with tryptase in the patient serum. After washing away non-specific 
binding molecules, enzyme labelled antibodies against tryptase (conjugate) are added to form 
a complex. Following incubation, unbound enzyme anti-tryptase is washed away and the 
bound complex is incubated with a developing reagent. The fluorescence of the eluate is 
measured when the reaction is stopped. The higher the response value the more tryptase is 
present in the specimen. To evaluate test results, the responses for the participant samples are 
converted to concentrations with the use of a calibration curve. The lower detection limit of 
the assay is 1 ng/ml and higher detection limit 200 ng/ml.  
In this study the upper limit of normal was taken to be 11.4 ng/ml (95th centile). 
Statistical analysis 
Mean and standard deviations were calculated and because of non-normality, median and a 
non-parametric confidence interval around the median was used. A p value of <0.05 was 
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classed as statistically significant. Peak percentage rise was calculated as (peak tryptase level 
during reaction/same day pre challenge sample) x100. Correlations were calculated with 
linear regression analysis. To investigate the utility of serum tryptase in determining whether 
an allergic reaction has occurred receiver operating characteristic (ROC) curves were used to 
establish the cut off providing the best sensitivity and specificity for the test. Statistical 
analyses were performed with STATA version 12 (StataCorp, College Station, Texas). 
Results 
Participant characteristics 
50 adults aged 18-39 (median age 20.8, M=28, F=22) were included in the study. Tryptase 
readings were measured in 177 reactive peanut and 45 non-reactive challenges. In 17/177 
challenges tryptase levels were <1ng/ml and therefore were unable to be analysed. All 
participants were reactive and developed objective symptoms during the peanut challenges 
and non-reactive during the placebo challenges. Fourteen of the 160 reactions (9%) were 
classed as anaphylaxis. No participants had a raised basal tryptase level.  
Tryptase during placebo challenges 
Tryptase readings were available for 45 placebo challenges. In the placebo challenges, the 
percentage change of the 2 hour reading/baseline was zero in 21 cases, positive in 11 and 
negative in 13. The median peak percentage rise was zero (95% CI  0,0 IQR -1.92, 4.31), the 
arithmetic mean (which gives higher weight to proportional increases than decreases) was 
1.4% and the geometric mean (which gives both equal weight) was -0.1%. Participants with 
higher placebo 2 hour/baseline rises did not exhibit higher reaction peak tryptase/baseline 
rises. 
 Tryptase rise during reactions 
Tryptase was raised above the upper limit of the normal range (11.4 ng/ml) in 4/160 reactions 
and all 4 reactions were severe anaphylaxis. In these reactions the predominant symptom was 
hypotension in 1/4 and profound dyspnoea with no hypotension in 3/4.  Peak levels were 17, 
13, 12.2 and 12 ng/ml respectively.  In 10/14 anaphylactic reactions the peak tryptase 
remained in the normal range. The peak percentage rise was calculated for all reactions. 
Relative to the baseline, a rise was noted in 100 /160 reactions (62.5%); anaphylaxis group 
14/14 (100%) non-anaphylaxis group 86/146 (59%). The average peak percentage rise for all 
reactions was 34.8% (median 25% CI 95% 13.3%-33.3%). In the anaphylaxis group, the 
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average rise was 148.4% (median 70.8% CI 95% 33.3%-300%) and in non-anaphylaxis 
group was 23.9% (median 14.0 % CI 95% 0%-25%).  
Time course of serum tryptase during reactions 
Median percentage change in tryptase over time is shown in Figure 14(a) and (b). Relative to 
a completely flat time course in placebo challenges, tryptase levels rose over time in positive 
challenges. Tryptase followed a steeper time course in anaphylaxis reactions versus non 
anaphylaxis reactions. The commonest time for peak values to occur in both groups was at 2 
hours (57% anaphylaxis group and 36.5% non-anaphylaxis group).  The same peak readings 
at both 1 hour and 2 hours were observed in 35.7% of participants in anaphylaxis group and 
27.1% of participants in the non-anaphylaxis group. No participant experienced a peak level 
independently at 0 hours (onset of reaction) (Table 19).  
 
 
Table 19:  Timing of peak tryptase readings (% participants in each group) 
  








Anaphylaxis 0.0 7.1 57.1 35.7 0.0 0.0 0.0 













Figure 14(a): Tryptase time course during peanut and placebo challenges. Median 
percentage rise in tryptase (peak tryptase/baseline) for each time point is shown.  
 













0 hours 1 hour 2 hours















Tryptase in relation to severity 
Using the Ewan and Clark severity grading system the reactions were graded as shown in 
Table 20.  Peak tryptase correlated with severity with a correlation coefficient of 0.37 (p < 
0.05) (Figure 15).  
Table 20: Frequency and classification of systemic reactions (n=160) during peanut 
challenges according to Ewan and Clark Severity Grade. 
Classification Symptoms Frequency % 
1 localised cutaneous 
erythema/urticaria/angioedema/oral pruritus 
0 
2 Generalised erythema/urticaria/angioedema 3.1 
3 At least grade 1 or 2 and GI symptoms/rhino-
conjunctivitis 
42.5 
4 Mild laryngeal oedema voice change/tightening of 
throat/mild asthma 
46.9 
5 Severe pronounced dyspnoea/hypotensive 
symptoms/collapse/loss of consciousness 
7.5 




Clinical features associated with a rise in tryptase 
Correlations were measured between peak percentage rise in tryptase and binary symptom 
variables (localised cutaneous erythema, generalised erythema, mild respiratory symptoms, 
moderate to severe respiratory symptoms, abdominal pain/nausea, vomiting, throat tightness, 
hypotension and dizziness/tachycardia with no hypotension) based on within-participant 
variation. Statistically significant positive correlations were found with moderate to severe 
respiratory symptoms which were associated with an 84.5% higher peak percentage rise in 
tryptase (CI 95% 1-168% p<0.05) and dizziness associated with 16.7% higher peak 
percentage rise in tryptase (CI 95% 0.4-33% p<0.05). 
Within participant variation in baseline tryptase over time 
Inter-day within-participant variation of baseline was summarised by averaging measures of 
within-participant variation across all participants. Two hundred and fifty nine baseline 
samples were included in the analysis: 50 screening, 160 on the day pre-challenge and 49 
placebo samples. The average participant mean baseline was 3.74ng/ml, based on an average 
of 5 observations. The average participant standard deviation of baseline was 0.46ng/ml, 
giving an average coefficient of variation of baseline of 0.14 corresponding to baseline 
variation of 14%. The average interquartile range of baseline was 0.59 and the average max-
min range was 1.08.  
Relationship of baseline tryptase levels to reaction severity 
No correlation was found between a participant’s median baseline tryptase level and the 
grade of their most severe reaction (correlation coefficient -0.09 p=0.54). No baseline 
tryptase was raised >11.4 ng/ml. 
Clinical utility of serum tryptase as a diagnostic marker 
A ROC analysis was performed to identify the optimal cut off point for percentage rise in 
tryptase above baseline to distinguish between a reaction and no reaction in our population, 
taking into account inter-day within-participant baseline variation. A clinician measuring 
tryptase acutely during a suspected reaction may compare this reading to a baseline taken at 
clinic either on a previous occasion or during subsequent assessment. The diagnostic 
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usefulness of the acute reading depends on whether the difference between reaction and non-
reaction (baseline) readings is large relative to inter-day variation in baseline readings.  
Thus the two following distributions were compared in the ROC analysis: i) peak tryptase 
rise (160 reaction observations) relative to screening baseline and ii) subsequent day 
baselines relative to screening baseline (209 observations)the distributions of which are 
shown in Figure 16. The 209 subsequent baseline observations are clustered around zero and 
symmetric while the reaction observations exhibit far fewer zeros and are markedly skewed 
positive. 
Figure 16: Histogram demonstrating % change relative to initial baseline in reaction 
versus no reaction.  
 
 
Combining these 369 observations, the area under the ROC curve was 0.72 (95 CI 0.67-0.78), 
indicating that percentage tryptase difference relative to a different-day baseline is potentially 
useful as a test to identify the presence of a reaction in a clinical context. The Youden Index, 
which weights the cost of false positives and false negatives equally, identified the optimal 
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cut off to identify a reaction as a 30% rise, which was associated with a sensitivity of 0.53 
and specificity of 0.85. (Figure 17). As an alternative approach to identifying an appropriate 
cut off, taking the two standard deviation within-participant % variation in baseline above the 
participant specific mean baseline (which represents a 95% upper confidence bound on 
percentage baseline variation) yields a cut off of 28%, which is close to the 30% derived from 
the ROC analysis. Taking the median baseline value of tryptase for the median subject (4 
ng/ml), a 30% rise equates to a 1.2ng/ml increase in serum tryptase to 5.2ng/ml. 
Figure 17: Receive operator characteristics (ROC) curve analysis to obtain the best 
value of ratio between peak tryptase during reaction and initial baseline serum tryptase 







We have conducted the largest prospective study on serum mast cell tryptase during 
experimentally induced peanut allergic reactions. We provide new data on tryptase time 
course during peanut allergic reactions and establish a diagnostic cut off to determine 
whether a food allergic reaction has taken place. 
Previous studies have disputed the sensitivity of serum tryptase during a food allergic 
reaction stating that tryptase often fails to rise acutely. Indeed, using only the established 
upper bound (95th centile) of the tryptase assay to denote a rise in tryptase (>11.4ng/ml) this 
statement is correct. Tryptase only rose above this level in 2.5% allergic reactions in our 
study. Previous studies on venom allergy have demonstrated that the sensitivity of the test 
can be improved if acute levels are compared to a baseline tryptase level taken after the 
reaction has resolved.188,262 This method detects rises which may occur within the normal 
range of the assay. When adopting this approach we observed a rise in tryptase compared to 
the baseline in 62.5% all reactions and in 100% of anaphylactic reactions. Reactions in which 
tryptase failed to rise were distributed across all severity grades and were not necessarily the 
least severe reactions.   
The amplitude of the tryptase rise is known to correspond with the allergic trigger. High peak 
tryptase levels are observed in allergic reactions involving anaesthetics, intravenous drugs 
and venom with smaller peaks observed in food allergic reactions.263 This likely due to the 
former being associated with large doses of allergen being rapidly delivered directly into the 
systemic circulation with resultant extensive cutaneous and perivascular mast cell 
degranulation and mediator release. Hypotension is often a presenting feature of these 
reactions. This contrasts with food allergic reactions where allergen absorption occurs at a 
slower rate across the oropharyngeal and gastric mucosa and hypotension is rarely a feature84 
thus the serum rises are likely to be much smaller. Minimal rises in tryptase may also reflect 
the limited extent of mast cell activation for example the gastrointestinal tract versus entire 
skin. Furthermore upon release, mast cell tryptase may be secreted into locally involved 
organs rather than the systemic circulation for example into the gut lumen in predominantly 
gastrointestinal reactions or into laryngeal / bronchial secretions in respiratory reactions. 
Other possible explanations for this could be differences in mediator content of skin versus 
mucosal mast cells. Schwartz et al reported that mucosal mast cells contained less tryptase 
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compared to skin mast cells.264 Lastly it may be that changes in tryptase were too small to be 
detected by the assay, particularly if the participant had low starting levels of serum tryptase 
for example <1ng/ml.  It has previously been postulated that the failure to rise include a 
predominant basophil rather than mast cell involvement in an acute allergic reaction.167 
Basophils are known to contain less than one hundredth of the amount of serum tryptase 
contained by mast cells.178  
Other studies are often based on tryptase levels of participants presenting to emergency 
departments or post mortem samples and are therefore biased towards more severe reactions. 
Our study represents a wider spectrum of reactions including data on reactions of mild to 
moderate severity, 92.5% reactions in our sample.  We have shown, in line with previous 
studies, that tryptase rise correlates with an increasing reaction severity.265 It has been shown 
previously that severe anaphylaxis is more likely to be associated with higher tryptase 
levels192 and peanut anaphylaxis is no exception. In our study the mean rise in tryptase in the 
anaphylaxis group was 148.4% above the baseline level in contrast to 23.9% in the non-
anaphylaxis group.  Previous studies have attempted to relate individual symptoms to 
mediator release. Lin et al showed an association between the presence of tachycardia and 
urticaria and a rise in tryptase.186 Similarly in our study we showed a significant relationship 
between the presence of dizziness and tachycardia and tryptase rise. Both of these are likely 
precursors to hypotension. We are the first to demonstrate that the presence of moderate-
severe respiratory symptoms is associated with a higher tryptase. It follows that tryptase 
release most likely occurs mainly in the airways in respiratory predominant reactions. 
Regarding baseline tryptase as a predictor of reaction severity, Sahiner et al showed that 
serum baseline tryptase levels may predict moderate to severe anaphylaxis in children with 
food allergy.266 We have not been able to prove a correlation between baseline tryptase levels 
and reaction severity.  Our study, however, did not include any participants with raised 
baseline levels of tryptase and other studies in venom allergic adults have established a clear 
relationship between elevated baseline levels of tryptase and severe anaphylaxis.267 
Knowledge of tryptase kinetics is crucial in determining optimal sample timing to capture 
peak levels.  Unlike other mediators such as histamine which are detectable within minutes of 
the onset of allergic symptoms, tryptase may not be detectable during the first 15-30 
minutes.181 In anaphylactic shock the increase in tryptase level in blood occurs later than the 
onset of shock and rash and well after the histamine peak.182 Therefore the appearance of  
tryptase in the blood likely reflects mast cell activation in a variety of tissue locations but is 
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unlikely to be the cause of anaphylactic shock.183 It has been demonstrated that tryptase 
potentiates histamine release.268  Mature tryptase is released in a complex heparin scaffold 
thus slowing its release.184 Once in the circulation, the half-life is about 2 hours and levels are 
thought to diminish after this time. It is recommended therefore that the optimal time for 
sampling is between 30 minutes and 2 hours after the onset of a reaction. This 
recommendation was largely based on a hypothetical time course proposed by Schwartz 
following their observations on 3 patients undergoing bee sting challenges and also 39 
patients who developed anaphylaxis following a yellow jacket or honey bee sting269 In this 
latter study by Van der Linden, however, tryptase measurements were only taken up to 60 
minutes with no further readings.259 Previously we have studied tryptase time course in 
anaphylaxis due to general anaesthesia and found that peak tryptase levels in paired samples 
taken at 0 to 1 hour and 1 to 2 hours were statistically similar.270 In the current study we also 
observed that peak levels did not occur immediately after the onset of reaction. However in 
contrast with other studies where peaks have been observed in the majority of patients within 
30-60 minutes of reaction onset,185 we noted that peak levels occurred later at 2 hours in the 
anaphylaxis group.  One participant with severe anaphylaxis had a further reading taken in 
his recovery period at 3 hours which showed even higher levels compared to 2 hours. 
Unfortunately no data on tryptase readings from 2 hours onwards was available in the 
remaining participants. Furthermore the degradation pathways of tryptase particularly in the 
extracellular environment is not known, it is possible that there is variability in the clearance 
of tryptase between individuals.271 
Limited data exists on the intraindividual variability of baseline tryptase over time. Generally 
it is believed that serum tryptase remains stable. We showed that there was a variation of 
14% in baseline tryptase readings over time within an individual.   Some studies also suggest 
that there may be a diurnal variation in tryptase of up to 15%272 however we saw little 
variation in tryptase measurements taken over the course of the day during placebo 
challenges.   
Having accounted for this inter-day variability we sought to establish a cut off in tryptase rise 
above baseline to signify an allergic reaction. Currently there is no consensus on the optimal 
cut off for diagnosing either mast cell activation or anaphylaxis with different studies quoting 
different values. A cut off point of 11.4ng/ml is recommended by the commercial company 
Thermofisher for the Immunocap assay based on this value being the 95th centile of tryptase 
levels in 129 non allergic control subjects.273 Valent et al state that the acute serum total 
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tryptase level should be an increase 20% plus 2ng/ml over the baseline level of tryptase to be 
indicative of mast cell activation.274 Enrique et al used absolute tryptase levels rather than a 
percentage rise to establish a rise of 8.23ng/ml as a cut off to identify anaphylaxis in 
patients.275 Other studies have defined a threshold difference of 2.0ng/ml or more based on 
sting challenges during venom immunotherapy.185 Egner et al studied tryptase during general 
anaesthesia reactions and established a threshold increment of 20% in tryptase to identify 
mast cell mediator release in an additional 14% of cases with peak tryptase between 5 and 14 
ng/ml and a further 15% with levels below 5ng/ml.276 Data on cut offs specifically for food 
allergy are scarce. One study by Wongkaewpothong identified a delta-tryptase cut-off of >0.8 
μg/L to confirm anaphylaxis in shrimp induced reactions.189 In our study, we identify an 
optimal cut off of a 30% rise in tryptase above baseline to signify an allergic reaction in 
peanut challenges. 
The shortcomings of this test also need to be noted. The result of a serum tryptase sample is 
not immediately available at the time of a reaction and usually takes a few hours to return. 
Thus although this test is extremely useful post reaction to confirm that mast cell activation 
has occurred, contemporaneous diagnosis is still reliant on the attending clinician to identify 
the signs and symptoms of an allergic reaction. Further research is required to develop tests 
for biomarkers which can provide results immediately at the time of reaction.    
Our study has some limitations. Patients were discharged when they had fully recovered and 
this was almost always within 2 hours of the onset of reaction. Therefore we lack tryptase 
data on time points greater than 2 hours post reaction. This is needed for a more complete 
time course and to corroborate exactly where peak levels are occurring. However data on 
general anaesthetic reactions show a substantial fall in tryptase from 2 to 4 hours, with the 
exception of those with extremely elevated peak tryptase levels of greater than 200 ng/ml.270 
Further it would have been useful to measure other allergic mediators such as histamine or 
PAF in order to validate our tryptase findings with regard to mast cell activation. In order to 
further improve diagnostic sensitivity we could consider measuring only β tryptase, as this is 
only released during degranulation and is therefore pathognomonic of this phase. However 
this is not currently available for diagnostic use and validation of sensitivity and specificity is 
needed before it is used routinely.    In conclusion acute tryptase measurement is of value in 
food allergic and normotensive reactions. There is a rise during reactions but this is mostly 
within the normal range. It was raised above the normal range on only 4/160 reactions thus a 
single acute measurement of serum tryptase has poor sensitivity in the diagnosis of peanut 
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allergic reactions. In food allergy, tryptase peaks are relatively low and thus relating reaction 
levels to baseline levels is essential to capture a rise. We show that tryptase peaks may occur 
later at 2 hours in food allergic reactions, therefore readings both at initial and the 2 hour time 
points are important.   We propose a cut off in tryptase rise which may guide clinicians in 
establishing whether mast cell activation and thus an IgE mediated food allergic reaction has 






Conclusions and Future work 
Ongoing work 
Immunological studies 
Allergen immunotherapy to peanut induces immunological changes including suppression of 
effector cells and alterations in the amount of circulating allergen specific antibody.277 Over 
time, during the immunotherapy course, there is an initial rise then a gradual fall in peanut 
specific IgE. Furthermore, with repeated daily oral administration of allergen there is an 
increased production of specific IgG, IgG4 and an inhibitory IgG-dependent serum factor 
which inhibits the allergen/IgE binding response.278 Santos et al noted that patients who had a 
higher ratio of peanut-specific IgG4 to IgE reacted to higher doses of peanut protein during 
challenge suggesting that IgG4 competed with IgE for binding to allergen and blocking its 
effect.123 
 Given the reduction in threshold and rise in severity with successive challenges observed in 
this study, supportive work is being undertaken to examine whether immunological changes 
take place over the course of four oral challenges. The hypothesis is that that specific IgE 
levels rise over time and IgG4 levels may fall. Arah2 specific IgE and IgG4 levels are being 
measured in plasma samples which were taken at each of the four repeat challenges for 30 
participants. 
Future work 
Studying cumulative versus discrete doses 
Food challenges remain the gold –standard outcome for interventional clinical trials in food 
allergy, of e.g. oral immunotherapy. However, uncertainty exists whether cumulative and 
discrete dose thresholds are comparable. Providing clarity on this issue will aid companies 
developing interventional drugs for food allergy where oral challenge is used as a primary 
outcome. Drug regulators in turn required confidence that cumulative dose thresholds 
obtained in drug trials represent discrete exposures in real-life. Eliciting doses are expressed 
differently for different studies. In some studies discrete doses are quoted which is the lowest 
individual dose causing a reaction.119  
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 Other studies, like ours, cite the cumulative dose up to the point where the individual has 
reacted.206 The former approach assumes that the dose is digested and absorbed in a given 
interval and treats each dose as an independent event with each dose having little influence 
subsequent doses whereas the latter approach simply assumes that all exposures in a specific 
time fame are summed. There are currently no data to suggest one approach over another, 
however using a discrete dose over a cumulative one will lead to a more conservative and 
possibly more restrictive approach when attempting to model population thresholds.  
Therefore given that in this study we have data on cumulative doses it would be useful to 
examine whether giving patients a single discrete dose would induce similar symptoms to 
those which occurred following incremental up dosing to a total dose. 
Examining severity across participants 
An approach to managing the endogeneity between dose and severity, would be to give all 
participants the same single dose and measure the effect of that dose on symptoms. For 
example participants who had reacted at a cumulative dose of 133.333mg would be invited 
back and given this quantity as a single dose.  
Sampson has postulated that the longer it takes for anaphylactic symptoms to develop 
the less severe will be the overall reaction.153 This could be formally tested and the time of 
onset of each symptom would be recorded and the time treatment administered will be 
recorded. This will give clearer information on how severity varies across individuals and 
may indicate differences in absorption patterns across individuals. 
It is possible that differences in timing of onset of symptoms and differences in 
symptom pattern occurs as a result of genetically determined differences in mast cell 
activation, mediator release profiles or differences in tissue responses to such mediators. 
Furthermore the distribution of sensitised effector cells will influence organ involvement in 
anaphylaxis and symptom progression.  
Examining the reproducibility of threshold over time 
Given that the first challenge of the study was double-blind placebo controlled and the repeat 
baseline (no intervention) challenge was active arm only, comparison of thresholds between 
the two is problematic as ‘like for like’ challenges are not being compared. In order to answer 
the question as to whether there is consistency in the challenge threshold dose with a repeat 
challenge, a further no-intervention challenge could be repeated under the same conditions as 
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the first. This more accurately determine background variation in threshold over time without 
the application of co-factors. Ideally participants should be challenged at the same time of 
year as their original challenge so that confounding factors such as seasonal rhinitis are 
controlled for. 
Examining physiological changes during sleep and exercise 
Original study participants can be further studied to examine whether gut permeability 
changes during sleep deprivation or exercise.  Markers of intestinal damage and intestinal 
permeability including I-FABP and urinary Lactulose/rhamnose could be assessed whilst the 
participant undergoes challenge with the placebo matrix. 
Comparison of symptoms: adult versus paediatric population 
Summers et al observed in their study that adults were more likely to experience severe 
pharyngeal oedema, bronchospasm and reduced consciousness than children.247  
I will examine data from a study in London where children were given peanut and tree nut 
challenges using the same dosing escalation and similar stopping criteria to our study. I will 
compare symptom frequency, patterns and progression in the two groups examining for 
differences between the two groups.  
Study of further co-factors 
Non-steroidal anti-inflammatory drugs such as aspirin have previously been described as 
cofactors. Proposed mechanisms include tight junction damage, decreased PGE1 and 
augmentation of mast cell degranulation via Syk kinase.132 Peanut challenges could be 
repeated after participants are pre-medicated with a dose of non-steroidal such as aspirin. 
Alternatively the effect of alcohol could be studied and peanut challenges could be 
undertaken following ingestion of a specific volume of alcohol.  
Perception of severity across investigators 
Van Erp et al reported that there is variability in the interpretation of clinical symptoms by 
clinical experts when they asked to retrospectively assess score sheets from challenges.111  
Using the Visual Analogue Scale proposed in our study we could determine prospectively 
whether there is a good intra-observer agreement when scoring food challenges. This would 
require two observers simultaneously and independently scoring a food challenge. 
Further definition of eliciting dose 
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The majority of participants at baseline challenge reacted at doses 5 and 6 (cumulatively 
33.333mg and 133.333mg). This is a relatively large increment from one dose to the next. 
Given that it is likely that the majority of peanut allergic individuals’ thresholds lie in this 
interval, additional increments could be added in this interval (for example 63.333mg and 
93.333mg) for a more definitive determination of the population threshold. 
Severity scoring 
The numerical severity scale proposed in our study requires validation in another larger 
participant cohort. Current scores offer poor discrimination between differing severity grades 
and are not granular enough to capture shifts in severity. A further extension to the severity 
work in this thesis is to demonstrate the unsuitability of existing scores to be used in this 
regard. Another working group (iFAAM) has attempted to model a numerical score 
developed with mathematical modelling (nFASS) which has not yet been published.  It would 





This thesis provides novel data on several important aspects of peanut allergy which will 
influence the care of allergic individuals. 
A clear threshold of peanut has been identified which induces an objective reaction in a 
defined proportion of the peanut allergic population. In other words, a level has been 
identified which is protective for the majority of peanut allergic individuals. Moreover the 
ability of everyday factors such as exercise and sleep deprivation to influence allergic 
reactions both with regards to threshold and severity has been clearly demonstrated. This 
study is the first to establish population eliciting doses for peanut when participants are 
deliberately subjected to the co-factors sleep deprivation and exercise. Further, we are able to 
relate these to a reference threshold when no co-factor (no-intervention) is applied to 
calculate the magnitude of the effect. Thus, compared to a mean ED5 of 11.8mg peanut 
protein when no co-factor is applied we show that exercise lowers the ED5 to 3.8mg and 
sleep to 1.9mg equating to factors of 0.32 and 0.16 respectively. Currently for allergen risk 
assessment, an eliciting dose is chosen (e.g. ED1 or ED5) which is an exposure that is likely to 
be without appreciable risks of deleterious effects for a population. Single dose peanut 
challenges have recently been performed to validate the proposed ED5 for peanut of 1.5mg 
peanut protein. Further studies of this kind are required to validate proposed ED5 and ED1 
doses, particularly in the adult population. Industry can then use these validated reference 
doses to develop guidelines for the use of voluntary precautionary food labelling. Previously 
a reference dose of 0.2mg peanut protein, based on the ED1, has been proposed by the 
VITAL group. However, the group acknowledge in their study that further application of an 
uncertainty or safety factor to this reference dose may be necessary to account for individual 
factors which may potentially affect this dose estimate. Because of a paucity of clinical data, 
the application of safety factors has followed toxicology practice account for (10-fold) inter-
species (for thresholds defined in non-human models) and (10-fold) intra-individual variation 
in response. In practice, such large safety factors result in very low reference doses which, 
being near or below the limit of detection of available assays, are difficult to measure with 
accuracy, rendering them impractical for the food industry to implement. This study, 
commissioned by the UK Food Standards Agency (FSA), through determining the magnitude 
of variability caused by co-factors (accounting for intra-individual variability without co-
factors), showed that the safety factor can be many magnitudes smaller.  Providing thresholds 
which are more feasible to measure should encourage better industry engagement with 
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evidence-based voluntary food labelling reducing excessive, overly cautious precautionary 
allergen labelling. 
By experimentally inducing repeated allergic reactions within and across individuals, I have 
been able to closely observe reaction patterns and severity. I have been able to prove that 
there is an increase in severity with repeated challenges at regular intervals. This will have 
clinical implications when advising patients about frequent accidental exposures. 
Furthermore by demonstrating that there is homogeneity in symptom pattern from one 
reaction to the next, patients may be reassured that subsequent reactions are likely to follow 
the same pattern and progression. It is worrying that a discordance was observed between a 
participant’s perception of their allergic reaction and the overall challenge severity score 
perhaps suggesting that patients misread their symptoms. This emphasises the need for 
clinicians to ensure that patients are well informed about features of severe reactions and the 
indications for adrenaline use.   
Lastly the usefulness of mast cell tryptase has been disputed in food allergy. Previously it has 
been reported that tryptase does not rise in food-induced anaphylaxis and is therefore not 
useful in assisting diagnosis in acute allergic reactions due to food. Through the first 
systematic study of its type, this thesis demonstrates that tryptase does rise, albeit within the 
normal range, necessitating the need for acute levels to be compared to baseline levels. In this 
study a cut off rise has been determined, identifying an acute allergic reaction whilst taking 
into account normal variation in basal tryptase. This has significant implications in helping to 
diagnose whether an acute food allergic reaction has occurred, particularly for physicians 
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